Generation of an HVS-based episomally maintained gene delivery system for reprogramming adult somatic cells by Brown, Hannah Frances
 
 
Generation of an HVS-based Episomally 
Maintained Gene Delivery System for 
Reprogramming Adult Somatic Cells 
 
Hannah Frances Brown 
 
Submitted in accordance with the requirements for the degree of 
PhD 
 
The University of Leeds 
School of Molecular and Cellular Biology 
Faculty of Biological Sciences 
 
September 2012 
 
 
i 
 
The candidate confirms that the work submitted is her own and that 
appropriate credit has been given where reference has been made to the 
work of others. 
 
This copy has been supplied on the understanding that it is copyright 
material and that no quotation from the thesis may be published without 
proper acknowledgement. 
 
The right of Hannah Frances Brown to be identified as Author of this work 
has been asserted by her in accordance with the Copyright, Designs and 
Patents Act 1988. 
 
© 2012 The University of Leeds and Hannah Frances Brown 
  
ii 
 
Acknowledgements 
First and foremost, I would like express my deepest gratitude to my 
supervisor, Professor Adrian Whitehouse. He accepted me on to this project 
and gave me renewed hope and a new direction for my PhD, without which I 
could not have hoped to succeed. Further to this, he has provided immense 
support and guidance throughout my time in this lab, and displayed 
remarkable patience in attempting to shape me into a true scientist. 
Secondly, I would like to thank all the members of the Whitehouse and 
Hewitt labs, both past and present, for all their guidance and support. 
Thanks go to Brian, Dave H, Marko, Dave G, Jen, Laura, Sophie, Chris, 
Suhana, Toral, Andy, Jim, Stu, Susie and Adam. I have truly been very lucky 
in my colleagues, who have provided excellent banter throughout my PhD, 
and made the prospect of work in the morning bearable even when science 
appeared to have other ideas. In addition to my fantastic colleagues, I would 
also like to thank all the friends I have made during my PhD for their support. 
I have come to look upon this excellent bunch of people as an extended 
family, and they will all be truly missed. 
In addition, I would like to thank the other members of the Virology group 
here at Leeds for providing advice and reagents. Thanks also go to Dr. 
Gareth Howell for his time and help with bio-imaging which was always 
given with incredible patience and an infallibly happy demeanour. 
Thanks also go to my external collaborator, Dr. Christian Unger. His valuable 
advice and guidance, in addition to his very generous provision of reagents, 
was unselfishly given, and allowed this work to be possible. For his help, I 
am truly grateful.  
Finally I would like to thank my family, particularly my parents, who have 
always supported and encouraged me in my every endeavour. This has, at 
times, meant bearing the brunt of my frustrations or often lifting my spirits 
when I could see no light at the end of the tunnel. For this, I am truly grateful. 
Financial support for this project was provided by the BBSRC. 
iii 
 
Abstract 
iPSC technology has the potential to generate patient specific pluripotent cells 
for use in stem cell therapies and disease modelling. However, current 
reprogramming methods utilise retroviral vectors, which integrate into the host 
cell genome disrupting normal gene function. Transient gene delivery methods 
have been investigated as safer alternatives but demonstrate poor 
reprogramming efficiency. Therefore, there is a requirement for iPSC gene-
delivery vectors which are capable of providing prolonged transgene delivery 
without integrating into the host cell genome.  
Herpesvirus saimiri (HVS) is a prototype member of the gamma-2 
Herpesviridae, and is capable of persisting as a non-integrated episome in 
dividing and differentiating cell populations, providing sustained transgene 
expression. Therefore, this thesis has explored the potential of HVS-based 
vectors for iPSC generation.  
This thesis focuses on the generation of three HVS-based vectors expressing 
the iPSC reprogramming transgenes, Oct4, Lin28 and Nanog.  
The potential of these HVS-iPSC vectors to reprogram both primary and 
cancerous cells has been investigated. Human primary Neural Stem Cells 
demonstrated cytopathology upon transduction with HVS-based vectors, 
indicating the need for further improvements to the biosafety of these vectors 
before they are suitable for the generation of clinical grade iPSCs. However, 
reprogramming attempts utilising the Ewing‟s sarcoma cell line, A673 cells, 
successfully generated induced pluripotent cancer stem cell (iPC)-like colonies 
upon transduction with all three recombinant vectors. 
Results from detailed analysis of these colonies suggest some form of 
reprogramming has taken place, albeit incomplete, as indicated by elevated 
expression of Oct4, Rex1 and Klf4; in addition to positive alkaline phosphatase 
staining and SSEA4 expression. Furthermore, these iPC-like colonies were 
capable of differentiation down the ectodermal lineage, as evidenced by 
upregulation of MSX1, MAP2, and Nestin. 
In conclusion, this thesis has demonstrated the potential of HVS-based 
reprogramming vectors through the generation of A673-iPCs. 
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2 
 
1  Introduction 
1.1 Stem Cells 
Embryonic stem cells (ESCs) are pluripotent in nature, possessing the ability 
to self-renew, and divide indefinitely. Furthermore, they are capable of 
differentiating into almost any cell type within the adult organism, including 
the extra-embryonic tissues (Macfarlan et al., 2012). 
Evidence for the existence of stem cells was originally identified by 
investigations using teratomas; tumours comprising various different tissue 
types. Experiments demonstrated that a single cell from a teratoma was 
capable of forming new tumours with all the different cell types identified in 
the original teratoma (Kleinsmith & Pierce, 1964). Furthermore, Evans et al 
isolated a subpopulation of cells from these tumours that possessed large 
nuclei and scant cytoplasm and were capable of differentiation in vitro and in 
vivo (Martin & Evans, 1974). These cells, termed Embryonal Carcinoma 
cells, paved the way for the identification of Embryonic Stem Cells (ESCs) 
from mice in 1981 (Evans & Kaufman, 1981; Martin, 1981) and later, from 
humans in 1998 (Thomson et al., 1998). 
ESCs are isolated from the Inner Cell Mass (ICM) of the pre-implantation 
blastocyst. The blastocyst, which forms 3-5 days post-fertilization, consists 
of the ICM in addition to a fluid-filled blastocyst cavity, termed the blastocoel, 
and the trophoblast which comprises a layer of cells surrounding the 
blastocoels and the ICM, which later forms part of the placenta (Figure 1.1). 
ESCs self-renew their populations by asymmetric cell division, whereby a 
stem cell is capable of dividing into a two different daughter cells, one being 
pluripotent and the other differentiated. During differentiation ESCs respond 
to complex interacting signalling cascades which determine the fate of these 
cells, thereby allowing the ordered determination of different cell fates. ESCs 
then differentiate to produce progenitor cells, which produce differentiated 
progeny forming various organ tissues of the ectodermal, endodermal and 
mesodermal lineages. These progenitor cells, or transit-amplifying cells, 
divide more rapidly than ESCs, and proliferate before 
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Figure 1.1: Isolation of ES cells from the Inner Cell Mass of the Blastocyst 
5-8 days post-fertilization, the blastocyst forms. At the blastocyst stage of embryonic development, the embryo 
consists of a fluid-filled blastocoel, and an inner cell mass containing pluripotent stem cells. These are in turn 
surrounded by the trophoblast. Embryonic stem cells are obtained by removing the inner cell mass from the 
blastocyst and culturing these cells on mouse embryonic fibroblast feeder cell layers. 
 
differentiation occurs, thereby amplifying the population of terminally 
differentiated cells  
In addition to ESCs, populations of adult stem cells remain in most tissues. 
These adult stem cells are derived from ESCs, but their differentiation 
potential is limited to producing the various specialised cell types within the 
organ in which they reside, thus making these cells multipotent rather than 
pluripotent.  
1.2 Stem Cell Promise in Therapy and Disease Modelling 
Since their discovery more than 20 years ago, the unique ability of stem cells 
to generate differentiated tissues and whole organs has generated much 
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interest in their potential use in stem cell-based therapies. Indeed, there are 
already a number of adult stem-cell based therapies currently in use, and 
many registered clinical trials based on both adult and embryonic stem cells. 
1.2.1 Adult Stem cell-based therapies 
Most stem cell-based therapies which are currently in use or registered for 
clinical trials are predominantly based on adult stem cells. The first 
successful adult stem cell therapies were bone marrow transplants 
performed in 1968. This is still the most widely used adult stem cell-based 
therapy (Bach et al., 1968; Gatti et al., 1968). Since then, adult stem cells 
have been investigated for their therapeutic potential in a wide variety of 
disorders, and there are currently many adult stem cell-based clinical trials 
registered, including Mesenchymal Stem Cell (MSC)-based therapies for 
Type 1 diabetes, myocardial ischemia, liver cirrhosis and graft-versus-host 
disease (clinicaltrials.gov date accessed 10/08/2012). Bone marrow-derived 
stem cells are also currently being investigated for the treatment of cerebral 
ischemia (Abe et al., 2012; Aurich et al., 2009).  
1.2.2 ESC-based Therapy 
Due to their pluripotent nature, ESCs have an even greater number of 
potential uses in stem cell-based therapies. However, the use of ESCs in 
stem cell-based therapies is tightly regulated due to their highly dynamic 
nature and the ethical issues raised by their derivation from human embryos. 
These issues have limited the progress of ESC-based stem cell therapy 
clinical trials compared with those of adult stem cell-based therapies. 
However, there are many pre-clinical trials which have demonstrated the 
potential of ESCs in the treatment of neurodegenerative disorders. For 
instance, transplantation of ESC-derived dopaminergic neurones 
successfully restored motor function in rats and monkeys (Redmond et al., 
2007; Studer et al., 1998). Further evidence of the potential of ESCs in the 
treatment of neurodegenerative diseases was highlighted in a Phase I/II 
clinical trial of ESC-derived motor neurones for the treatment of spinal 
muscular atrophy (Lunn et al., 2011). 
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1.3 Safety and Ethical Issues with ESC-based therapies. 
Despite the great potential of ESCs in stem cell-based therapies, there are a 
number of issues which currently make ESCs unsuitable for therapeutic use. 
Firstly, there are the ethical and religious implications of using cells derived 
from human embryos. Secondly, due to their highly dynamic nature, there is 
significant variability within and between master banks of stem cell lines, 
including differentiation potential and activity of the cells upon transplantation 
(Carpenter et al., 2009). Thirdly, despite most stem cells being immune-
privileged, there have been certain cases where tissue rejection has been 
reported (Swijnenburg et al., 2008a; Swijnenburg et al., 2008b). Finally, 
there are several issues with the biosafety of transplanted ESCs. Prolonged 
in vitro culture of ESCs results in certain genetic and epigenetic alterations, 
including for example, trisomy of chromosomes 12 and 17 (Buzzard et al., 
2004), and significant variability in the X-inactivation (Dhara & Benvenisty, 
2004; Hoffman et al., 2005). Furthermore, late-passage ESCs have been 
demonstrated to possess many mutations commonly observed in cancers 
(Maitra et al., 2005).  In addition to these acquired mutations, ESCs have the 
ability to form teratoma tumours upon transplantation into a host, and any 
stem cell-based therapy using differentiated cells derived from ESCs may 
contain contamination populations of undifferentiated ESCs which may 
cause tumour formation upon implantation.  
However, despite these issues, there is still a vast amount of interest in the 
eventual use of these cells for both therapeutic uses and as models for 
development processes in health and disease. 
1.4 Induced Pluripotent Stem Cell Technology 
The advent of Induced Pluripotent Stem Cell (iPSC) technology gave 
renewed hope for stem cell-based therapies and disease modelling. This 
technology involves the reprogramming of somatic cells into a pluripotent, 
stem cell-like state. The cells produced from this method are not only 
ethically sourced, but can also be derived from individual patients, thereby 
avoiding tissue rejection upon implantation. 
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iPSCs were first generated in 2006 by Takahashi et al., who detailed in a  
seminal paper the minimal combination of factors required for 
reprogramming somatic mouse embryonic fibroblasts (MEFs) to ESC-like 
cells. Initially, the authors stably transfected MEF cells with a β-geo cassette, 
(a fusion of the β-galactosidase gene and the neomycin resistance gene), 
under the promoter of the Fbx15. Fbx15 is a gene that is expressed in ESCs 
but is dispensable for maintaining pluripotency. These cells were then 
transfected with 24 factors previously identified to be key regulators of 
pluripotency. Leaving out individual genes systematically revealed just four 
factors that were indispensible for reprogramming; namely Oct4, Sox2, Klf4 
and c-Myc (Takahashi & Yamanaka, 2006). After this initial experiment, two 
additional papers were published simultaneously, detailing the 
reprogramming of human somatic fibroblasts to iPSCs using exogenous 
expression of reprogramming factors (Takahashi et al., 2007; Yu et al., 
2007).  
 
 
Figure 1.2: Overview of iPSC technology 
Adult somatic cells are transduced with four reprogramming factors. This eventually reprograms these somatic cells 
to pluipotent, stem cell-like cells, which are capable of indefinite self-renewal, and can differentiate into cells 
comprising all three germlayers.  
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1.5 iPSCs in stem cell-based therapies 
iPSCs are of immense interest for stem cell-based therapies as they provide 
the potential to generate large numbers of ethically sourced, patient specific 
pluripotent cells. This would therefore circumvent the issues of tissue-typing 
and cross-matching donors with recipients, and eliminate the possibility of 
tissue rejection or graft-versus-host disease.  
Although there are significant hurdles to overcome before iPSCs are used in 
clinical therapies, a number of very promising pre-clinical trials have 
demonstrated the potential of these cells. For example, iPSC-derived 
dopaminergic neurones can integrate into the existing host brain neural 
networks and improve the motor function of Parkinson‟s disease model rats 
(Wernig et al., 2008). Moreover iPSCs derived from both murine and human 
cells successfully engrafted and repaired motor function in Spinal Cord Injury 
mice models (Nori et al., 2011; Tsuji et al., 2010). In addition, Terzic et al. 
demonstrated that intramyocardially injected iPSCs were able to functionally 
and structurally repair infarcted hearts in mice (Nelson et al., 2009), and Ma 
and colleagues utilised iPSC-derived endothelial cells expressing Factor VIII 
to rescue the Haemophilia Type A phenotype in mice models of the disease 
(Xu et al., 2009). 
A further potential therapeutic application is to combine iPSCs with gene 
therapy to repair genetic defects in patient-specific iPSCs, and transplant 
these cells back into the donor patient. There are number of ways utilised to 
repair the genomes of these iPSCs, including Zn-finger nucleases to target 
single point mutations, or homologous recombination. Homologous 
recombination can either be mediated by plasmid, virus or bacterial artificial 
chromosome-based vectors to repair homozygous mutations, or 
alternatively, the cells own mitotic-mediated recombination events can be 
used to repair heterozygous genetic disorders (Cheng et al., 2012). This 
type of genetic correction of iPSCs has successfully been demonstrated for 
sickle-cell anaemia, whereby a humanized mouse model of sickle cell 
anaemia was rescued upon transplantation of iPSC-derived haematopoietic 
progenitor cells, previously repaired by homologous recombination (Hanna 
et al., 2007).  
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1.6 Retroviruses and Lentiviruses are the predominant 
iPSC-gene delivery vectors 
Viral vectors are ideal for efficient gene delivery. They are capable of 
receptor binding and internalisation, followed by transfer of transgene-
encoding DNA to the nucleus and regulation of transcription (Wasungu & 
Hoekstra, 2006). Currently, the most commonly utilised gene delivery 
systems for iPSC generation are retrovirus-based vectors. 
Retroviruses contain two copies of their positive sense ssRNA genome 
within enveloped particles, 80-100 nm in diameter (Dimmock et al., 2001). 
There are seven different genera; Alpharetrovirus, Betaretrovirus, 
Gammaretrovirus, Deltaretrovirus, Epsilonretrovirus, Lentivirus and 
Spumavirus, although originally all genera, except Lentivirus and 
Spumavirus, belonged to the oncoretrovirus group due to their oncogenic 
nature. The most common retroviruses utilised for iPSC gene-delivery 
vectors are Murine Leukaemia Virus, (a Gammaretrovirus) and Lentiviruses. 
The defining feature of retroviruses is their method of replication. Uniquely, 
their RNA genome is reverse-transcribed into a DNA pro-virus which then 
integrates into the host cell genome, mediated by the virally encoded 
enzymes, reverse transcriptase and integrase. Both of these are contained 
in the retroviral virions.  
All oncogenic retroviruses comprise three genes, gag, pol and env, flanked 
by long terminal repeats (LTRs). The upstream LTR contains the U3 
promoter, which drives transcription of these genes. Two differentially 
spliced mRNAs are produced, which in turn produce the Gag and Gag-Pol 
poly proteins, and the Env protein. The Gag and Gag-Pol polyproteins are 
self-proteolytically cleaved to produce the capsid proteins (produced by Gag) 
and the non-structural protease, reverse transcriptase and integrase proteins 
(produced by Pol). The env gene encodes the envelope glycoproteins that 
mediate viral entry (Figure 1.3). Lentiviruses and Spumaviruses contain six  
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Figure 1.3: The structure of the retrovirus capsid and genome organisation.  
a) After the retroviral genome has been reverse transcribed, it integrates into the host genome using the virally 
encoded protein, Integrase. This proviral DNA, flanked by the Long Terminal Repeat (LTR) sequences, produces 
two distinct mRNAs by means of alternate splicing events. The gag-pol mRNA produces two poly proteins, the 
Gag-polyprotein, which encoded the capsid proteins, and the Gag-Pol protein. The Gag-Pol protein encoded a viral 
protease, reverse transcriptase and integrase proteins, in addition to the structural proteins encoded by Gag. The 
env mRNA produces two proteins which are both glycoproteins and are expressed on the surface of the viral 
envelope. b) The completed retroviral virion structure. Adapted from  (Dimmock et al., 2006). 
 
additional accessory genes (tat, rev, nef, vif, vpr, vpu) and three extra genes 
(bel-1, bel-2 bel-3) respectively. 
Retroviruses were considered very attractive gene therapy vectors due to 
their ability to integrate into the host genome, thereby enabling long-term 
transgene expression. The most common retroviral vectors are based on the 
Gammaretrovirus, Moloney Murine Leukaemia Virus (MuMLV) or on the 
Lentivirus, Human Immunodeficiency Virus (HIV) (McTaggart & Al-Rubeai, 
2002). Although MuMLV was the first virus to undergo clinical trials (Blaese 
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et al., 1995), these viral vectors had the disadvantage that they, like all 
oncoretroviruses, were only capable of integrating and expressing their 
transgene in dividing cells, thereby making them unsuitable for therapies 
involving certain tissues such as neurones. For this reason, lentiviruses, 
which can infect both dividing and non-dividing cells, may be a more 
practical alternative. 
Retroviral vectors are produced by replacing the genes required for viral 
replication with the transgene of interest. Only the LTR regions and the psi 
(Ψ) packaging sequences remain, as these are essential for virus 
encapsidation. Because these modified viruses are rendered replication 
incompetent, their production requires the use of special packaging cell lines 
which contain the viral structural and functional genes on complementing 
expression cassettes (Figure 1.4). To further improve the biosafety of these 
vectors, the gag-pol and env genes are encoded from separate expression 
cassettes. This reduces the risk of producing replication competent 
retrovirus particles by homologous recombination (McTaggart & Al-Rubeai, 
2002).  
However, viral vectors possess certain drawbacks compared to non-viral 
gene delivery vectors. These include toxicity, immune recognition of virally 
expressed proteins, recombination with wild-type viruses and oncogenicity of 
virally encoded proteins involved in cell cycle regulation. A further 
disadvantage of retroviral vectors is the risk of mutagenesis caused by 
insertion of the viral genome into transcriptionally active areas of the host 
genome (Scherdin et al., 1990). Therefore, a number of alternative methods 
to derived iPSCs have been assessed. 
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Figure 1.4: Production of retroviral gene delivery vectors. 
Packaging cell lines are transfected with expression cassettes containing the gag-pol and env coding sequences, 
in addition to the vector cassette. Vector cassettes contain the transgene of interest, flanked by the LTR regions 
and the Ψ packaging sequences, and are the only cassette to be encapsidated. Viral structural and functional 
proteins required for infectious virus production are therefore provided by the packaging cell. The infectious virus 
particles are capable of infecting target cells, integration and transgene delivery, but are incapable of viral 
replication. Taken from (McTaggart & Al-Rubeai, 2002). 
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1.6.1 Alternative Gene Delivery Approaches 
There have been a number of attempts to generate safer reprogramming 
methods, which are detailed in Table 1.1. Initially, systems were developed 
to excise the retroviral genome using Cre-LoxP recombination, but this 
system left a viral „footprint‟ at the site of integration after excision, which 
could still potentially disrupt normal host gene function (Soldner et al., 2009).  
Reversibly integrating piggy-Bac transposons 
 
  Reprogrammed 
Cells 
Factors 
used 
Efficiency Advantages Disadvantages 
Excisable Transposon Fibroblasts OSKM 0.1 Efficient, no 
integration 
Labour-intensive 
screening of 
colonies 
LoxP-flanked 
lentiviral 
genome 
Fibroblasts OSK 0.1 - 1 Reasonably 
efficient and no 
genomic 
integration 
Labour-intensive 
screening of 
colonies, LoxP 
sites retained in the 
genome 
Non-integrating Adenoviral Fibroblasts, liver 
cells 
OSKM 0.001 no genomic 
integration 
Low efficiency 
Plasmid Fibroblasts OSNL 0.001 Only occasional 
genomic 
integration 
Low efficiency, 
requirement for 
repeated 
transfections, 
occasional 
genomic integration 
Episomal EBV EBNA1 OSKMN 
+ SV40 
LT 
0.000003 no genomic 
integration 
extremely low 
efficiency, EBNA1 
potentially 
oncogenic 
DNA free Sendai Virus Fibroblasts OSKM 1 no genomic 
integration 
sequence sensitive 
RNA-replicase, 
difficulty in 
removing virus 
after 
reprogramming 
Recombinant 
protein 
Fibroblasts OS 0.001  low efficiency, short 
half-life, 
requirement for 
multiple 
applications of the 
proteins 
Modified 
mRNA 
 OSKM or 
OSKML + 
VPA 
1-4.4 No genomic 
integration, 
bypasses innate 
antiviral response, 
faster 
reprogramming 
kinetics, 
controllable and 
high efficiency 
Requirement for 
multiple rounds of 
transfection 
MicroRNA  miR-
200c, 
miR-302s 
or miR-
396 
0.1 Efficient, fast 
reprogramming, no 
exogenous 
transcription 
factors, no 
genomic 
integration 
Low efficiency 
 
 
Table 1.1: Safer gene delivery methods used in iPSC generation.  
Adapted from (Robinton & Daley, 2012). Factors used: O – Oct4; S – Sox2; K – Klf4; M – Myc; N – Nanog; L – 
Lin28; VPA – Valproic Acid. 
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have also been used to deliver iPSC genes. This system can subsequently 
be excised from the genome without leaving any remaining exogenous DNA 
sequences. However, this system requires stringent genome-wide screening 
to ensure all copies of the transposon have been removed upon excision 
(Kaji et al., 2009; Woltjen et al., 2009; Yusa et al., 2009). 
Alternatively, transient methods have also been used, including repeated 
plasmid transfection, (Okita et al., 2008) non-integrating adenoviral vectors, 
(Stadtfeld et al., 2008) cell-permeable recombinant protein transduction, 
(Zhou et al., 2009b) and recently, transfection with mRNAs (Warren et al., 
2010), or mature miRNAs (Miyoshi et al., 2011). 
However, these transient reprogramming methods have poor efficiencies, 
which further highlight the need for prolonged transgene expression in iPSC 
generation. Therefore, the ideal reprogramming vector would be capable of 
providing prolonged expression of the reprogramming transgenes without 
integrating into the host genome. 
To provide sustained transgene expression in a dividing cell population, the 
Epstein-Barr virus latency associated nuclear antigen (EBNA-1) has also 
been used in a plasmid-based episomally maintained system to successfully 
reprogramme  fibroblasts (Yu et al., 2009). However, this study chose to use 
inefficient plasmid transfection to deliver the reprogramming factors rather 
than utilising the natural infectivity of EBV. Furthermore, EBNA-1 has been 
shown to immortalise B cells in vitro, thus questioning the safety of this 
method (Young et al., 1988). However, this study did highlight the 
advantages of episomally maintained reprogramming systems, therefore 
warranting further investigation of such vectors for iPSC generation. 
1.6.2 Replacing the Exogenous Reprogramming Factors 
One of the intrinsic safety issues of iPSC technology is the ectopic 
expression of the specific factors required for reprogramming. All of these 
factors have been identified to be upregulated in a variety of different 
cancers, with Klf4 and c-Myc being well described as potent oncogenes 
(Sun & Liu, 2011). Therefore alternative reprogramming factors to replace 
Klf4 and c-Myc were sought. 
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In 2007, Thompson and colleagues discovered that c-Myc and Klf4 could be 
replaced with the non-oncogenic pluripotency factors, Nanog and Lin28 (Yu 
et al., 2007). However, although this process improved the biosafety of the 
resulting iPSCs, reprogramming efficiency was reduced. Furthermore, this 
method still required transduction of somatic cells with four reprogramming 
factors, which further reduces the efficiency of iPSC generation. Therefore, 
researchers attempted to eliminate the requirement of multiple 
reprogramming factors. Kim and colleagues investigated the reprogramming 
potential of other cell lines. Specifically, they attempted to reprogramme 
Neural Stem Cells (NSCs) using fewer factors. Interestingly, NSCs can be 
reprogrammed to iPSCs using only exogenous Oct4 expression (Kim et al., 
2009b). 
Furthermore, several groups have identified various small molecules 
capable of replacing certain reprogramming factors during iPSC generation. 
For instance, Huangfu and colleagues demonstrated that the histone 
deacetylase inhibitor, Valproic Acid (VPA), enabled the reprogramming of 
human fibroblasts using exogenous expression of only Oct4 and Sox2 
(Huangfu et al., 2008). In addition, iPSCs were successfully generated from 
keratinocytes using exogenous expression of Oct4 and Klf4 in conjunction 
with parnate, (an inhibitor of lysine specific demethylase 1) and an inhibitor 
of GSK3 signalling (Li et al., 2009). Further work detailed the generation of 
human iPSCs from keratinocytes with exogenous Oct4 expression combined 
with a cocktail of small molecule inhibitors (Zhu et al., 2010).  
Interestingly, another small molecule, Nr5a2, has been demonstrated to be 
capable of replacing the activity of Oct4 in the generation of iPSCs (Heng et 
al., 2010). However, the combination of Nr5a2 and the molecules defined by 
Zhu et al. is unable to generate iPSCs. 
1.7 Oct4, Sox2 and Nanog are Key Regulators of 
Pluripotency 
The protein-protein networks and signalling pathways governing pluripotency 
and self-renewal in stem cells are diverse and highly complex. As such, 
these mechanisms are still poorly understood despite their immense 
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importance in the maintenance of stem cells. However, it is clear that there 
are three proteins which are central to the complex interaction networks 
governing pluripotency. These key regulators are the transcription factors, 
Oct4, Sox2 and Nanog, and a simplified diagram of the key protein-protein 
interactions governing pluripotency is shown in Figure 1.5. 
 
 
 
Figure 1.5: The protein-protein networks governing pluripotency. 
The network of protein-protein interactions involved in stem cell self-renewal and pluripotency are governed by 
three proteins, Oct4, Sox2 and Nanog. These proteins are capable of regulating the expression of a myriad of 
different genes involved in differentiation and proliferation. In addition, these factors are capable of regulating their 
own expression to fine tune the mechanisms involved in pluripotency. Oct4 and Nanog also form a histone 
remodelling complex with several members of the NuRD complex.  
 
1.7.1 Oct4 
Oct4 is a homeodomain transcription factor of the POU family of proteins. It 
recognises the consensus octamer binding sequence of 5‟-AGTCAAAT 
(Herr & Cleary, 1995). The role of Oct4 in stem cell biology was highlighted 
using mouse embryos containing Oct4 null mutations which were capable of 
developing into blastocysts, however the cells within the inner cell mass 
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were not pluripotent, and differentiated down the extraembryonic trophoblast 
lineage (Nichols et al., 1998). Oct4 remains the only irreplaceable factor for 
reprogramming, with one exceptional case of its replacement using Nr5a2. 
Nr5a2 is an activator of Oct4 and enhances reprogramming efficiency partly 
through activation of Nanog (Heng et al., 2010). 
There are four Conserved Regions identified in the upstream regulatory 
region of Oct4, CR1 – CR4, which have implications in Oct4 regulation. For 
instance, CR1 has a putative Sp1 binding site which is overlapped by a 
Hormone Responsive Element (HRE), which allows Retinoic Acid to shut off 
transcription of Oct4, and CR4 has a ATTA sequence, which is recognised 
by many transcription factors, including Nanog (Loh et al., 2006; Nordhoff et 
al., 2001).   
1.7.2 Sox2 
Sox2 also plays an important role in reprogramming and regulating 
pluripotency. It is a member of the High Mobility Group (HMG) of protein 
transcription factors. Sox2 null embryos develop an inner cell mass, but fail 
to maintain the epiblast (Avilion et al., 2003), although Sox2 null embryos 
are still capable of maintaining some degree of pluripotency. This may be 
due to residual maternal Sox2 and the partial compensation for Sox2 activity 
by Sox3 (Avilion et al., 2003; Wang et al., 2012). 
Sox2 forms a heterodimer with Oct4 (Ambrosetti et al., 1997), which is then 
capable of synergistically binding to, and regulating transcription from a 
highly conserved Oct-Sox binding element, CTTTTGCATTACAATG. This 
Sox2-Oct4 complex can then upregulate FGF4 and Utf1 expression by 
differential binding to enhancer elements within the promoter regions of 
these genes (Nishimoto et al., 1999; Yuan et al., 1995). In addition, this 
complex can also regulate expression of other genes associated with 
pluripotency, including Nanog (Rodda et al., 2005), and Oct4 and Sox2 
themselves (Okumura-Nakanishi et al., 2005; Tomioka et al., 2002). Sox2 is 
also capable of fine-tuning its own expression via an interaction with the poly 
ADP-ribose polymerase 1 protein (PARP1), which occurs in response to 
signals from FGF4. The PARP1-Sox2 complex prevents binding of Sox2 to 
the Oct-Sox element, thereby repressing Sox2 expression (Lai et al., 2012).  
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1.7.3 Nanog 
The final protein involved in governing the pluripotency networks which will 
be discussed herein is Nanog. Nanog is another homeodomain-containing 
protein which is crucial for maintaining pluripotency. It is capable of 
maintaining stem cell self-renewal even in the absence of Leukaemia 
Inhibitor Factor (Chambers et al., 2003). Nanog null embryos develop an 
inner cell mass but this fails to become an epiblast. Instead, these cells 
differentiate into parietal endoderm-like cells (Mitsui et al., 2003). 
Furthermore, Nanog is responsible for repressing differentiation into 
neuroectoderm and neural crest cells, but has no effect on repressing 
differentiation into other lineages (Wang et al., 2012). 
Like Oct4 and Sox2, Nanog also regulates pluripotency via a number of 
protein-protein interactions. For example, Nanog and Oct4 can recruit other 
proteins to form the Nanog and Oct4-associated Deacetylase (NODE) 
complex. This complex contains certain members of the NuRD and Sin3A 
complexes; Mta1, HDAC1/2 and Sin3a, and is capable of repressing genes 
involved in differentiation, thereby promoting self-renewal and maintaining 
pluripotency (Liang et al., 2008). In addition to the NODE complex, Nanog 
mediates pluripotency by regulating the expression of Oct4 and Sox2 (Loh et 
al., 2006). 
1.7.4  Pluripotency Interactomes 
There have been several studies aimed at identifying the various interaction 
partners for Oct4, Sox2 and Nanog. These methods predominantly rely on 
tagging the protein of interest and affinity purification of any complexes 
formed (Pardo et al., 2010; van den Berg et al., 2010; Wang et al., 2006). 
However, these methods have several drawbacks, including the detection of 
„false-positives‟ caused by optimisation to detect protein-protein interactions 
and certain missing interactions. This is highlighted by Nanog, which is 
frequently not detected in Oct4 interactome lists, but has previously been 
shown to form a complex with Oct4 (Zhang et al., 2007). 
These missing links may be caused by the lower levels of expression of 
certain interaction partners, but as many transcription factors are expressed 
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at low levels, this may cause many of these potential interaction partners to 
be missed.  
1.7.5 Post-translational modifications of Pluripotency Factors 
The complex protein-protein interactions governing pluripotency are made 
even more intricate by post-translational modifications. The master regulator 
of pluripotency, Oct4, is phosphorylated at two residues, T234 and S235. 
Mutational analysis of these residues revealed that these phosphorylation 
sites are important for sequence-specific DNA binding by Oct4 (Brumbaugh 
et al., 2012). Furthermore, O-linked β-D-N-acetylglucoamine modification of 
Oct4 and Sox2 has been shown to be important in maintaining pluripotency, 
and is rapidly lost upon differentiation (Jang et al., 2012).  
1.8 Epigenetic Gene Regulation 
The proteins involved in pluripotency regulation, such as those discussed in 
section 1.8, are all capable of  causing epigenetic alterations in cellular gene 
expression. Gene expression can be regulated by several of epigenetic 
mechanisms which are discussed here. 
1.8.1 Histone Modification 
Within the nucleus, DNA is condensed by through winding around 
nucleosomes; octamer complex of four histone proteins (two H2A-H2B 
heterodimers, and two H3, H4 heterodimers). DNA winds around these 
nucleosomes 1.65 times (147 bps), and a final histone, H1, binds to the 
linking DNA between nucleosomes, thereby allowing higher order chromatin 
structures to form. The histones within the nucleosome have extended N-
terminal tails which can be modified in a number of ways, including 
acetylation, methylation, phosphorylation and ubiquitination. These histone 
tail modifications have varying effects on gene expression, and also depend 
on the specific lysine or arginine they affect. Generally, acetylation of histone 
tails results in disruption of the wound DNA, leading to less-densely packed 
chromatin (euchromatin) and results in gene activation. Acetylation of 
histone tails is performed by Histone Acetyl-Transferases (HATs). 
Conversely, Histone Deacetylase enzymes (HDACs) remove acetyl groups 
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from histone tails, resulting in more densely packed chromatin 
(heterochromatin) and gene repression (Alberts, 2002).  
1.8.2 DNA Methylation 
DNA methylation occurs on cytosine residues located next to G residues 
(CpG sites), forming 5-methylcytosine. CpG sites occur within promoters of 
various genes, and are maintained by maintenance methyltransferases 
which methylate CpG sites on newly synthesised DNA strands according the 
methylation pattern of the parental strand. Shortly after fertilisation, de novo 
DNA-methyltransferases begin to methylate specific CpG sites, and during 
development, increasing numbers of promoter regions become more heavily 
methylated. Proteins containing a Methyl CpG Binding Domain, (such as 
MeCP2), are capable of binding to methylated DNA and recruit histone 
remodelling complexes, thereby resulting in heterochromatin formation and 
gene silencing (Alberts, 2002). 
1.8.3 MicroRNAs (miRNAs) 
The role of microRNAs in gene regulation is widely varied between cell 
types. microRNAs are transcribed by either RNA polymerase II or III and are 
initially formed as large primary miRNA transcripts (pri-miRNAs which 
contain a number of hairpin loops). These hairpin loops of the pri-miRNAs 
are cleaved in the nucleus by Drosha to produce 70 bp pre-miRNAs stem-
loops which are exported by Exportin-5 into the cytoplasm. Within the 
cytoplasm, these pre-miRNAs are then further cleaved by Dicer to produce a 
22bp RNA duplex of which one strand is incorporated into the Argonaut 2 
(Ago2) subunit of the RNA-Induced Silencing Complex (RISC). This single-
stranded miRNA can then base-pair with imperfect complementarity to a 
number of target mRNAs and cause transcriptional repression either by 
mRNA cleavage, mRNA decay by deadenylation, or by transcriptional 
repression caused by interfering with ribosomal binding to target mRNAs 
(Kim, 2005; Winter et al., 2009). An overview of miRNA processing is shown 
in Figure 1.6. 
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Figure 1.6: miRNA processing pathway (taken directly from (Winter et al., 2009)). 
miRNAs are expressed in the nucleus as large pri-miRNAs containing several hairpins. Pri-miRNAs are then 
cleaved in the nucleus by Drosha to produce 70bp hairpin stem-loops termed pre-miRNAs. These pre-miRNAs are 
exported into the cytoplasm by Exportin-5, where they are further cleaved by Dicer to form 22bp RNA duplexes. 
One strand of this RNA duplex is incorporated into the RNA-Induced Silencing complex and can therefore repress 
expression of a number of target mRNAs. 
 
1.9 miRNA profiles in ESCs 
The importance of miRNAs in pluripotency and differentiation regulation was 
demonstrated in Dicer knock-out mice. These mice were embryonically 
lethal yet produced viable ESCs. However, these ESCs possessed limited 
differentiation capabilities, thereby highlighting a role of miRNAs in 
pluripotency and regulation of differentiation (Bernstein et al., 2003; 
Kanellopoulou et al., 2005).  
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Since this initial observation a number of miRNA clusters have been 
identified as being upregulated in ESCs and rapidly downregulated upon 
differentiation. One such cluster is the miR-302-367 cluster. These miRNAs 
are activated by the pluripotency factors, Oct4, Sox2 and Nanog and have 
been shown to promote self-renewal by repressing Cyclin D and promoting 
entry into the S-phase of the cell cycle, causing genome-wide demethylation, 
and maintaining pluripotency (Barroso-del Jesus et al., 2009; Card et al., 
2008; Lin et al., 2008). 
1.10 The Flaws of iPSC Technology 
Initially, iPSC technology held great promise for stem-cell based therapies. 
However, there is increasing evidence to demonstrate that iPSC-based 
therapies are not currently feasible due to the biosafety concerns of iPSCs. 
Aside from the risks associated with insertional mutagenesis from retroviral 
gene delivery vectors and the ectopic expression of the oncogenic 
reprogramming factors,  the reprogramming process itself can be oncogenic, 
inducing small nucleotide polymorphisms and copy number variations in 
resulting iPSCs (Laurent et al., 2011; Pasi et al., 2011). In addition, the 
starting somatic cells used for iPSC generation often have mutations which 
are harmless due to the limited proliferative potential of these differentiated 
cells. However when these cells are reprogrammed to a pluripotent cell with 
unlimited self-renewal, these mutations have the potential to cause abnormal 
gene expression and potentially aberrant proliferation. 
iPSCs are also epigenetically different from ESCs, and possess aberrant 
methylation patterns, indicative of a somatic cell memory. One study 
analysed four iPSC cell lines derived by separate groups using various 
reprogramming protocols. These protocols included the use of either 
inducible or constitutive iPSC transgene expression in addition to utilising 
either permanently integrated, Cre-excisable or episomal reprogramming 
vectors. This study identified 15 genes which all four iPSC lines expressed 
at different levels to ESCs, indicating some functional similarity and 
potentially indicating an iPSC-specific gene expression profile distinct from 
that of ESCs or parental fibroblasts (Chin et al., 2009). Furthermore, 
although comparisons of ESC and iPSC gene expression also revealed that 
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most miRNAs expression levels were identical between these cells, there 
were a number of these non-coding RNAs which were expressed at different 
levels, including miR-302b, which has important implications in the 
regulation of self-renewal and pluripotency (Chin et al., 2009; Wilson et al., 
2009). 
 iPSCs derived from female donors can also retain a partially or completely 
silenced X-chromosome (Lister et al., 2011; Pick et al., 2009; Tchieu et al., 
2010). Interestingly, the aberrant methylation patterns found in iPSCs are 
maintained upon differentiation of these cells (Lister et al., 2011). This may 
add to the oncogenic potential of iPSCs upon implantation, as it is 
speculated that some cancers may be caused by changes at the epigenetic 
level (Feinberg et al., 2006). 
Perhaps the biggest disappointment in iPSC technology was the immune 
rejection observed in a strain of in-bred mice. Specifically, iPSCs derived 
from these mice were transplanted back into the same inbred line, However, 
the iPSCs had very poor engraftment success and tissue rejection was also 
observed (Zhao et al., 2011) 
1.11 Disease-in-a dish models 
Because of the issues detailed above in section 1.9 of iPSCs, their 
application in stem cell-based therapy may be a very distant promise. 
Indeed, it is now unclear whether these cells will ever be suitable for 
therapeutic applications.  However, iPSC technology does provide an 
abundant source of pluripotent cells which can be derived from specific 
patients. These cells are therefore ideal to provide in vitro models for a 
myriad of human genetic disorders which were previously modelled in 
animals. Animal models have many limitations, primarily because of 
interspecies variations which can affect the signalling interactions involved in 
disease progression. Furthermore, many genetic disorders do not naturally 
occur in these animal models, and thus have to be recreated artificially. 
iPSCs have therefore been used to model a wide variety of genetic disorders 
(Table 1.2). This „disease-in-a-dish‟ modelling is perhaps particularly  
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Disease Cell type differentiated from 
iPSCs 
Disease  phenotype 
demonstrated in 
Differentiated cells 
Neurological     
Alzheimer’s disease Heterogeneous population of 
neurones 
Yes 
Amyotrophic lateral 
sclerosis (ALS) 
Motor neurons and glial cells ND 
Spinal muscular 
atrophy (SMA) 
Neurons and astrocytes, and 
mature motor neurons 
Yes 
Parkinson’s disease Dopaminergic neurons No 
Huntington’s disease None NA 
Down's syndrome Teratoma with tissue from each of 
the three germ layers 
Yes 
Familial dysautonomia Central nervous-system lineage, 
peripheral neurons, haematopoietic 
cells, endothelial cells and 
endodermal cells 
Yes 
Schizophrenia Neurons Yes 
Haematological     
ADA SCID None ND 
Sickle-cell anaemia None NA 
Metabolic     
Type 1 diabetes β-Cell-like cells (express 
somatostatin, glucagon and insulin; 
glucose-responsive) 
ND 
Glycogen storage 
disease1a (GSD1a) 
Hepatocyte-like cells (foetal) Yes 
Familial 
hypercholesterolaemia 
Hepatocyte-like cells (foetal) Yes 
Cardiovascular     
LEOPARD syndrome Cardiomyocytes Yes 
Type 1 long QT 
syndrome 
Cardiomyocytes Yes 
Type 2 long QT 
syndrome 
Cardiomyocytes Yes 
Other category     
Duchenne muscular 
dystrophy 
None NA 
Cystic fibrosis None NA 
Retinitis pigmentosa Retinal progenitors, photoreceptor 
precursors, retinal-pigment 
epithelial cells and rod 
photoreceptor cells 
Yes 
Osteogenesis 
imperfect 
None NA 
 
 
Table 1.2: iPSC models of genetic diseases.  
Adapted from (Robinton & Daley, 2012).  
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important for neurodegenerative diseases, where isolating tissue samples 
for research purposes is generally not feasible from living patients, and there 
are limited suitable animal models. Neurological diseases whose 
progression has been modelled with iPSCs include Parkinson‟s disease 
(Nguyen et al., 2011; Soldner et al., 2009), Alzheimer‟s disease (Israel et al., 
2012). Smooth muscle atrophy (Ebert et al., 2009) and familial 
dysautonomia (Lee et al., 2009). Often, the resulting differentiated cells 
produced from these disease-specific iPSCs possess the disease 
phenotype. This therefore gives vital insights into the progression of these 
genetic diseases.  
Furthermore, these „disease-in-a-dish‟ models allow safer drug screening in 
vitro in human models of the genetic disease, rather than less physiologically 
relevant animal models. Indeed, iPSC cardiomyocyte models of the genetic 
heart defect, Type 2 long QT syndrome, demonstrated that certain drugs 
aggravated the condition, highlighting a complex cardiotoxic effect of these 
drugs (Itzhaki et al., 2011). Screening drugs in these functional in vitro 
models could therefore reduce the risk of drugs inducing arrhythmias prior to 
market release. 
1.12 Pluripotency Mechanisms and Cancer 
The pluripotency networks of stem cells enable these cells to maintain their 
undifferentiated state, and allow these cells an unlimited capacity for cellular 
division. As such, many of the pluripotency mechanisms are also found to be 
deregulated in cancers, and the disruption of various tumour suppressor 
genes has also been demonstrated to enhance reprogramming efficiency 
(Bernhardt et al., 2012). An overview of the links between pluripotency and 
cancer are shown in Figure 1.7. 
For example, ectopic expression of Oct4 has been shown to increase the 
malignant phenotype of ESCs. Specifically, mice injected with an ES-cell line 
carrying an inducible Oct4 expression cassette demonstrated that Oct4 had 
the potential to cause a malignant phenotype. Moreover, repression of Oct4 
resulted in a 10-fold decrease in tumour formation of these cells (Gidekel et 
al., 2003). Furthermore, Oct4 and Sox2 have been found to be upregulated 
in a number of cancer tissues, including bladder cancer, prostate cancer, 
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leukaemia, glioblastoma, primary colon cancer, hepatocellular carcinoma, 
bladder carcinoma, pancreatic cancer and breast cancer (Sun & Liu, 2011).  
Signalling pathways which are involved in self-renewal and development are 
often upregulated in many cancers. Sonic Hedgehog, which is involved in 
cortical development, induces basal cell carcinoma of the skin if 
overexpressed (Mullor et al., 2002), and Notch signalling, which controls the 
inhibition of many differentiation pathways, has the potential to immortalise 
haematopoietic cells if constitutively activated (Varnum-Finney et al., 2000) 
and is also often upregulated in adenoma cells (van Es et al., 2005). Wnt 
also plays an important role in cancer progression. This pathway is involved 
in a number of different processes in animal development and controls self-
renewal in a variety of adult stem cells. Wnt signalling is positively regulated 
 
 
 
Figure 1.7: The links between pluripotency and cancer. 
Many of the genes which promote reprogramming also enhance proliferation and are upregulated in many cancers. 
Furthermore, disruption of tumour suppressor pathways can also enhance the efficiency of reprogramming. 
Adapted from (Bernhardt et al., 2012). 
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by Nanog and Oct4, and in turn, the downstream effector protein of the Wnt 
pathway, β-catenin, is capable of upregulating Nanog expression by 
interacting with Oct4 (Knoop & Baker, 2001; Loh et al., 2006). One of the 
downstream affects of Wnt is the stabilisation and subsequent cytoplasmic 
accumulation of β-catenin. After accumulating in the cytoplasm, β-catenin 
can translocate to the nucleus, and regulated target gene expression. 
Therefore, aberrant Wnt signalling can cause deregulation of these target 
genes and as such is involved in the formation of a wide variety of cancers, 
including colorectal cancer and leukaemias (Reya & Clevers, 2005).   
1.13 Tumour Heterogeneity and the Tumour 
Microenvironment 
Cancerous tumours are complex heterogeneous populations of cells, each 
with their own role in cancer formation and progression. This complex 
structure of different cells, and the niche environment created by various 
cytokines and growth factors, is termed the Tumour Microenvironment 
(Figure 1.8). Cells within the Tumour Microenvironment include endothelial 
cells and pericytes which provide the tumour associated vascular structure, 
cancer-associated fibroblasts, which can serve a structural function in the 
tumour, and immune inflammatory cells such as macrophages, neutrophils, 
and T and B lymphocytes. These immune inflammatory cells provide 
cytokines which promote tumour growth, including EGF, VEGF, FGF2 and 
TGF-β (Hanahan & Weinberg, 2011). However, perhaps the most important 
cell type identified in the Tumour Microenvironment is the Tumour-Initiating 
Cancer cell, or Cancer Stem Cell (CSC). These cells are capable of 
differentiating into many of the cells found within tumours and are thought to 
have the ability to seed new tumours. 
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Figure 1.8: The Tumour Microenvironment.  
Tumours are heterogeneous populations of cells, each with their own role in tumour formation. Cancer-associated 
fibroblasts serve a structural function, endothelial and pericytes cells provide the vascular system of the tumour, 
immune inflammatory cells produce cytokines which enhance tumour growth and CSCs are able to self-renew their 
populations and differentiate into many of the tumour stromal cells. Adapted from (Hanahan & Weinberg, 2011). 
 
 
1.14 Cancer Stem Cells 
CSCs are defined by their ability to self-renew and to generate new tumours 
upon transplantation. The first evidence for CSCs was shown in 1994 
(Lapidot et al., 1994). A sub-population of leukaemia cells possessing 
CD34+/CD38- antigenic properties were identified; a phenotype which is 
associated with haematopoietic and pluripotent stem cells. This led to the 
discovery in 1997 by Bonnet and Dick that this population of cells were 
capable of self-renewal, and generated differentiated progeny with aberrant 
phenotypes upon transplantation into mice (Bonnet & Dick, 1997). Since 
their initial discovery, CSCs have been identified in a wide variety of 
tumours, including breast (Al-Hajj et al., 2003), brain (Singh et al., 2004), 
prostate (Collins et al., 2005) and many others (Table 1.3).  
CSCs are identified by their ability to form tumours in mice xenograft models 
and by certain marker proteins which were originally identified in adult stem 
cells such as CD34+/CD38low/- for lymphomas, CD133+ for brain tumours, 
and CD44+/CD24low/- for breast cancers. Other markers include drug 
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Cancers with Identified CSC populations Reference 
Breast Cancer (Al-Hajj et al., 2003) 
CNS (Singh et al., 2004) 
Multiple Myeloma (Matsui et al., 2008) 
Melanoma (Fang et al., 2005) 
Prostate (Collins et al., 2005) 
HNSCC (Prince et al., 2007) 
Colorectal cancer (O'Brien et al., 2007; Ricci-Vitiani et al., 
2007) 
Pancreas (Li et al., 2007) 
Lung (Kim et al., 2005) 
Ovarian Cancer (Zhang et al., 2008) 
Cervical Cancer (Feng et al., 2009) 
Bladder Cancer (Chan et al., 2009) 
Liver Cancer (Yamashita et al., 2009) 
Renal Cancer (Bussolati et al., 2008) 
Gastric Cancer (Wakamatsu et al., 2012; Xue et al., 
2012) 
Osteosarcoma (Tirino et al., 2011) 
Ewings sarcoma (Suvà  et al., 2009) 
Rhabdomyosarcoma (Walter et al., 2011) 
Synovial Sarcoma (Terry & Nielsen, 2010) 
 
 
Table 1.3: Cancer Stem Cell Identification 
 
Marker Cancer Marker Cancer 
CD133 Brain CD90 Leukaemia 
  Prostate   Glioma 
  Pancreas   Liver 
  Melanoma ABCB5 Melanoma 
  Colon ALDH Breast 
  Liver   Lung 
  Lung   Head and 
Neck 
  Ovary   Colon 
  Gastric   Liver 
CD44 Colon   Pancreas 
  Breast   Gastric 
  Prostate   Prostate 
  Pancreatic   Renal 
  Gastric     
CD34 Leukaemia     
 
 
Table 1.4: Markers used to Identify Cancer Stem Cells.  
Adapted from (Hu & Fu, 2012). 
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efflux pumps, such as the ABCG2 multidrug resistance pump and ALDH. A 
full list of the different marker types in various cancers is shown in Table 1.4 
(Hu & Fu, 2012). 
1.15 Roles of CSCs in Tumour Resistance to Anti-cancer 
Therapies 
CSCs have been implicated in the acquisition of drug resistance in many 
tumours. Firstly, like normal stem cells, they have a quiescent or slowly 
proliferating nature. Since most anti-cancer therapies target DNA replication 
or protein synthesis, this makes CSCs more resistant to drug treatments 
than their more proliferative differentiated progeny. As such, CD133+ glioma 
cells have increased resistance to ionizing radiation in comparison to their 
CD133- counterparts (Bao et al., 2006). Similar results have also been 
shown in breast cancer (Diehn et al., 2009). 
A second mechanism of drug resistance which CSCs possess is the ability 
to efflux anti-cancer drugs out of the cell. This is achieved through increased 
expression of ABC transporters, which are membrane proteins involved in 
the transport of various hydrophobic and hydrophilic compounds across cell 
membranes by ATP hydrolysis. ESCs and CSCs possess higher levels of 
ABC transporter protein expression than their differentiated progeny. This 
property confers increased drug resistance to CSCs, by efficiently effluxing 
anti-cancer drugs (Hirschmann-Jax et al., 2004; Scharenberg et al., 2002). 
The primary drug efflux pumps upregulated on CSCs are ABCB1, ABCC1 
and ABCG2, which are all capable of effluxing a wide range of anti-cancer 
agents (Dean et al., 2005).  
Because of their role in resistance of tumours to anti-cancer therapies, there 
have been a number of efforts to develop drugs which specifically target 
CSCs, summarised in Table 1.5. These therapies work by either inhibiting 
the self-renewal signalling pathways which become deregulated in cancers, 
such as Wnt, Notch and Hedgehog, or by using monoclonal antibodies to 
target markers upregulated on CSCs (Hu & Fu, 2012). 
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Target Drug Cancer Method of 
Action 
Phase 
Wnt vitamin D3 Basal Cell 
Carcinoma 
β-catenin  III 
PRI-724 Advanced solid 
tumours 
CBP/β-catenin I 
CWP232291 AML β-catenin I 
Notch MK0752 Advanced Breast 
Cancer 
γ-secretase 
inhibitor 
I 
RO4929097 Lung Cancer γ-secretase 
inhibitor 
II 
PF-03084014 Leukaemia γ-secretase 
inhibitor 
I 
OMP-21M18 Pancreatic Cancer anti-DLL4 
specific mAbs 
I 
Hedgehog GDC-0449 Solid tumours, 
Colorectal 
PTCH and/or 
SMO antagonist 
I 
  SMO antagonist II 
BMS-833923 Basal cell SMO antagonist I 
IPI-926 Primary 
Myelofibrosis, 
Fibrosis, Bone 
Marrow 
SMO antagonist II 
ABCB5 3C2-1D12 Malignant 
Melanoma 
An ABCB5-
specific mAb 
target 
validation 
CD44 H90 AML A CD44-specific 
mAb 
pre-clinical 
p245 Breast Cancer A CD44-specific 
mAb 
pre-clinical 
EPCAM Adecatumumab Metastatic Breast 
Cancer 
an EPCAM-
specific mAb 
II 
Edrecolomab Colon Cancer an EPCAM-
specific mAb 
II-III 
Catumaxomab Ovarian and 
Gastric Cancer 
Ab against 
EPCAM and 
CD3 
II-III 
MT110 Lung and 
Gastrointestinal 
Cancer 
Ab against 
EPCAM and 
CD3 
I 
 
 
Table 1.5: Cancer stem cell specific drugs and their targets.  
Adapted from (Hu & Fu, 2012; Zhou et al., 2009a). 
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1.16 The Role of the Epithelial – Mesenchymal Transition in 
Cancer 
The Epithelial – Mesenchymal Transition (EMT) is an evolutionarily 
conserved process which occurs both in normal development and during 
tissue injury (Thiery, 2003). However, there is increasing evidence to 
suggest that this developmental process is involved in tumour formation and 
metastasis. 
EMT is primarily initiated by transforming growth factor-β (TGF-β), which is 
also associated with cancer formation and progression. TGF-β receptors 
phosphorylate SMAD 2 and 3, which in turn form a heterodimer with SMAD 
4 (Comijn et al., 2001; Postigo et al., 2003; Verschueren et al., 1999). These 
SMAD complexes associate with transcription factors and upregulate 
expression of various EMT associated genes, including C2H2-type zinc 
finger proteins, Snail, Slug and Zeb; and the bHLH factor, Twist. Expression 
of these EMT-related proteins results in the repression of the cell-adhesion 
molecule, E-cadherin, by the recruitment of histone deacetylases. This 
increases cell motility (Peinado et al., 2007), and as such, the EMT is 
implicated in cancer metastasis (Figure 1.9). 
Interestingly, in addition to TGF-β, there are a number of pathways involved 
in EMT induction which are deregulated in cancer, including Wnt signalling, 
Notch signalling and NF-κB (Chua et al., 2007; Kim et al., 2002; Min et al., 
2008; Noseda et al., 2004; Sahlgren et al., 2008). Furthermore, during EMT 
the normally pro-apoptotic signalling protein, TGF-β, can become anti-
apoptotic through TGFβ-mediated induction of the PI3K signalling pathway. 
This TGF-β initiation of PIK/AKT signalling has been shown to block 
apoptosis in mammary epithelial cells (Gal et al., 2008). 
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Figure 1.9: The Epithelial-to-Mesenchymal Transition 
TGFβ signalling causes SMADs 2 and 3 to become phosphorylated. SMADs2 or 3 can then form a heterodimer 
with SMAD4 which then translocates to the nucleus and activates transcription of the EMT-associated genes, 
Twist, Zeb1, Slug and Snail. These proteins repress expression of the cell-adhesion molecule, E-cadherin, 
resulting in reduced cell-cell adhesion and increased cellular motility.  
 
1.16.1 The EMT can generate Cancer Stem Cells 
Recently, the EMT has been shown to be capable of generating populations 
of CSCs. This was initially highlighted by the observation that disseminated 
secondary breast cancer possesses a high percentage of CD44high/CD24low 
cells (Al-Hajj et al., 2003). From this observation, Mani and colleagues 
provided the first evidence for the role of EMT in the generation of CSCs. 
They induced EMT in both primary mammary carcinoma samples and non-
tumorigenic immortalized human mammary epithelial cells, either by ectopic 
expression of Snail or Twist, or by treatment with TGF-β. These cells 
possessed a CD44high/CD24low antigenic phenotype, an increased ability to 
form mammospheres, and were capable of self-renewal and forming 
differentiated progeny (Mani et al., 2008). Further evidence supporting this 
hypothesis has been demonstrated by showing that several of the EMT-
associated proteins promote cell de-differentiation. These include Zeb-1 
which modulates KLF4 and Sox2 directly, Snail cooperating with SOX9 in 
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forming the mammary stem cell state and Twist acting downstream of BMI-1 
to silence target genes involved in differentiation (Ansieau, 2012). 
1.16.2   EMT-mediated Cancer Cell drug resistance 
In addition to roles in metastasis and the enrichment of CSC populations in 
tumours, the EMT has also been implicated in cancer drug-resistance. 
Indeed, many of the epigenetic changes observed in cancer cells which 
have acquired drug resistance are associated with EMT, such as the 
increased expression of the EMT-associated protein Zeb-1, which protects 
cells from damaged induced apoptosis of cancers (Sayan et al., 2009). 
Moreover, the resulting cells produced after EMT possess phenotypes and 
gene expression profiles which more closely resemble MSCs. MSCs are 
capable of enhancing anti-cancer drug resistance of a number of cancer 
cells in co-culture experiments (Houthuijzen et al., 2012; Singh & Settleman, 
2010). 
Importantly, the ability of EMT to promote cell de-differentiation and generate 
new populations of CSCs from differentiated progeny complicates the design 
of new anti-cancer therapies. If therapies target the more proliferative 
differentiated cells within a tumour, the tumour-initiated CSCs are likely to 
remain, thereby seeding new tumours. However, if CSCs alone are targeted, 
the process of EMT could cause the dedifferentiation of other tumour stromal 
cells to form new CSCs, once again enabling the formation of new tumours. 
One possible solution to this paradox could be to identify anti-cancer drugs 
which selectively target cells which have undergone EMT. Gupta and 
colleagues successfully identified four such compounds from an initial 
screen of 16,000. These compounds were capable of selectively targeting 
cells in which EMT had been induced by shRNA knockdown of E-cadherin 
with IC50 values around 7-10 fold lower than for control cells. Further 
investigation of one of these drugs, salinomycin, demonstrated it was 
capable of reducing CD44+/CD24- CSC populations in breast cancer cells 
by 20-fold and selected for cells with morphological features which more 
closely resembled epithelial cells. This was in contrast to the 
chemotherapeutic drug, paclitaxel, which selected for cells exhibiting a 
mesenchymal and migratory phenotype. Finally, salinomycin pre-treatment 
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of breast cancer cells prior to implantation into mice resulted in a >100 fold 
reduction in tumour seeding capacity relative to paclitaxel treated cells 
(Gupta et al., 2009b). 
1.17 Controversy surrounding the existence of CSCs 
CSCs, like other cancer cells, contain a number of genetic and epigenetic 
abnormalities which give these cells a highly dynamic and unstable nature, 
thereby complicating their detection and isolation. Therefore, the presence of 
CSCs has been extremely difficult to prove. This has resulted in a great deal 
of controversy surrounding whether these cells actually exist. Some of the 
difficulties in identifying and isolating these cells are discussed herein.  
One of the „gold-standard‟ detection methods for CSCs is their ability to form 
new tumours upon transplantation into mice. However, these tumour 
xenograft models are less than ideal as there is significant variation in the 
physiology of the various different animal host models. These differences in 
physiology present several problems, including the potential lack of cross-
species functionality of the growth factors and cytokines, which provide the 
CSC niche, thereby promoting tumourigenesis. Indeed, to prevent immune 
rejection of human tumour cells in mice models, immunocompromised mice 
are often used for tumour xenograft experiments. However, these mice are 
unable to produce many of the cytokines which promote tumour growth. The 
importance of a cytokine-rich environment in CSC tumour formation was first 
demonstrated by Kelly and colleagues in 2007. Transgenic mice were used 
which contained the N-ras or Myc/immunoglobulin chromosomal 
translocations used to model lymphomas. Experiments with these transgenic 
mice demonstrated that as many as 10% of cells from primary lymphomas 
were capable of initiating lymphomas in this histocompatible xenograft 
animal model (Kelly et al., 2007). This contradicted the earlier belief that 
CSCs represent a very small population within cancers.  
A further issue complicating the identification of CSCs is the current lack of 
stringent CSC markers which are consistently present in tumour-initiating 
cells, but absent in the remaining cells of the tumour stroma. For example, 
cells isolated from Acute Myeloid Leukaemia (AML) in patients possessing a 
mutation in the nucleophosmin gene were CD34-, but were still capable of 
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generating malignant progeny (Taussig et al., 2010).  This may lead to false 
identification of CSCs due to the isolated populations of CSCs being impure. 
Solid tumours present a further hurdle to the isolation of CSCs. During CSC 
isolation from solid tumours, the tumours must first be dissociated into single 
cells before fluorescence activated cellular sorting of cells expressing certain 
markers, and seeding into artificial niches in immunocompromised mice. The 
mechanical stresses of disseminating the cells may select for cells that are 
more capable of surviving the various insults of the isolation process rather 
than CSCs.  
The EMT also adds further complexity to the CSC hypothesis, as it is 
capable of generating CSC populations from differentiated progeny (Mani et 
al., 2008). This de novo generation of CSCs adds to the already highly 
dynamic nature of these cells, further complicating any attempts to isolate 
these cells.  
1.18 Tracking CSC differentiation provides strong evidence 
for their existence 
The controversy surrounding the existence of CSCs may have finally been 
put to rest after the recent publication of three reports which, for the first 
time, provide strong evidence for the presence of CSCs. The first of these 
reports, by Parada et al., utilised a nestin-responsive reporter gene 
expressing GFP to specifically label neural stem cells. They demonstrated 
the presence of GFP positive „stem-like cells‟ within glioblastoma, which 
when ablated, significantly arrested tumour growth (Chen et al., 2012). 
Secondly, Blanplain and colleagues non-specifically labelled cells within 
squamous skin tumours, and identified two distinct proliferative cell 
compartments within the tumour; one which had limited potential to divide 
and produced terminally differentiated cells, and another which was capable 
of unlimited cell divisions and possessed stem-like characteristics. In 
addition, more aggressive tumours were shown to possess a higher 
proportion of these stem-like cells (Driessens et al., 2012). Finally, and 
perhaps in the most elegant of these studies, Clevers et al. used a dual 
labelling strategy to track a population of gut cancer stem cells throughout 
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their differentiation. Firstly, they utilised a GFP reporter gene under the 
control of the Lgr5 promoter. Lgr5 is expressed in pluripotent cells from both 
healthy crypt stem cells, and intestinal adenocarcinoma CSCs (Barker et al., 
2009). This therefore enabled the identification of undifferentiated CSCs 
within adenocarcinoma samples, but GFP expression was lost upon 
differentiation of these cells. Lgr5 labelling was then combined with stable 
transfection of these cells with a fluorescent protein expression cassette. 
Expression from this cassette was induced by addition of the drug tamoxifen, 
and constitutive expression of the fluorescent marker protein was maintained 
throughout differentiation. Furthermore, a second treatment with tamoxifen 
induced a colour switch in the fluorescent marker expression cassette. This 
allowed the investigators to trace the differentiation and expansion of 
individual CSCs. The results of this dual labelling system,  
 
Figure 1.10: Tracing CSCs within an adenocarcinoma segment.  
Differential Interference Contrast (DIC) is shown in grey, Lgr+ CSCs express EGFP. The cells which were originally 
labelled and produced from Lgr+ cells are displayed in red (RFP). A second addition of tamoxifen induced a colour 
change to blue (CFP) in one CSCs. This CSC could be traced as it expanded and produced differentiated progeny 
which subsequently lost GFP expression. Scale bars indicate 50 µm. Taken from (Schepers et al., 2012). 
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demonstrated in Figure 1.10, showed that the Lgr5+ CSCs were not only 
capable of self-renewing, but they could form Lgr5- differentiated progeny in 
a hierarchical manner closely resembling normal intestinal development 
(Schepers et al., 2012). Together, these reports demonstrate that cancers 
possess a subpopulation of cells which are undifferentiated and are capable 
of self-renewing their populations, in addition to producing differentiated 
progeny which form the bulk of the tumour. 
1.19 Reprogramming Cancer Cells 
Tumour-initiating CSCs have been identified in a number of cancers. These 
cells are capable of differentiating into various cells within tumours, and are 
believed to be the main cause of metastasis and secondary cancers. 
However, CSCs are difficult to isolate from primary tumour samples due to 
their rarity and highly dynamic nature. Therefore, utilising iPSC technology to 
reprogramme somatic cancer cells to these tumour-initiating CSCs would 
provide an abundant source of these cells for studying their role in cancer 
progression. To date, there have been a number of attempts to generate 
induced Pluripotent Cancer Stem Cells (iPCs) which are detailed in Table 
1.6. 
 
 Reprogramming 
Factors 
Vector Delivery Reference 
Colorectal cancer, pancreatic cancer, 
hepatocellular carcinoma (cell lines) 
OSKM Retroviral 
/lentiviral 
(Miyoshi et 
al., 2010) 
Chronic Myeloid Leukaemia (cell line) OSKM retroviral (Carette et 
al., 2010) 
Melanoma, pancreatic cancer (cell 
lines) 
miRNA-302 retroviral (Lin et al., 
2008) 
Melanoma (cell line) OKM lentiviral (Utikal et 
al., 2009) 
Polycythemia vera, primary 
myelofibrosis (primary samples) 
OSKM retroviral (Hu et al., 
2011) 
Chronic Myeloid Leukaemia (primary 
samples) 
OSKM retroviral (Kumano et 
al., 2012) 
EBV-immortalised B-cells OSKM episomal 
EBNA1/OriP 
based 
(Choi et al., 
2011) 
 
 
Table 1.6: Generation of Induced Pluripotent Cancer Stem Cells from somatic cancer cells.  
Adapted from (Sun & Liu, 2011). O – Oct4, S – Sox2, K – Klf4, M – Myc. 
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Perhaps the most interesting of these studies was performed by Hu and 
colleagues, whereby primary human lymphoblasts from a patient with 
Chronic Myeloid Leukaemia containing the JAK2-V617F mutation (+) 
polycythemia vera (PV) mutation were successfully reprogrammed to iPC 
cells (Hu et al., 2011). This study demonstrated it was possible to 
reprogramme leukemic cells containing a complex genetic mutation which, 
as yet, cannot be recreated in experimental models by genetic engineering. 
Furthermore, a non-integrating, episomally maintained reprogramming 
vector based on the Epstein-Barr virus nuclear protein, EBNA1, was used for 
this study. The episomal nature of the reprogramming vector would prevent 
any perturbations to the gene expression profiles of these cells which could 
occur with integrating retroviral gene delivery vectors. Therefore, iPCs 
generated by this method would represent a more accurate model of 
leukemic stem cells. Although, as previously mentioned, EBV EBNA-1 is 
capable of immortalising B-cells in vitro (Young et al., 1988). 
1.20  Ewings Sarcoma Family Tumours 
First identified in 1921 by Professor James Ewing (Ewing, 1921), Ewings 
sarcoma is the second most common bone malignancy after osteosarcoma. 
It predominantly affects children and young adults, with a peak incidence at 
the age of 15, and most tumours found in the long bones of the arms and 
legs or in the ribs (Riggi & Stamenkovic, 2007). However, Ewings sarcoma is 
only part of a larger family, termed the Ewing‟s Sarcoma Family of Tumours 
(ESFTs). These incorporate a family of morphologically similar cancers, 
including the „classic‟ Ewing‟s sarcoma of bone, extraskeletal Ewing‟s 
sarcoma (Angervall & Enzinger, 1975), small cell tumours of the 
thoracopulmonary region (Askin et al., 1979), and soft tissue-based primitive 
neuroectodermal tumours (PNET) (Jaffe et al., 1984).  
ESFTs are treated with a combination of surgery, radiation, and 
chemotherapy. However the survival rates remain poor, with 50% survival 
after 5 years, and less than 30% after 10 years. Survival rates can even be 
as little as 25% if metastases are present at diagnosis (Riggi & Stamenkovic, 
2007). 
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1.21 ESFTs are caused by a chromosomal translocation 
ESFTs are caused by a chromosomal translocation which fuses the N-
terminal transactivation domain of the Ewing‟s Sarcoma (EWS) gene with 
the C-terminal DNA-binding domains of various ETS family transcription 
factors. The most commonly occurring chromosomal translocation in ESFTs 
is t(11;22)(q24:q12) (Figure 1.11a), present in 85% of ESFTs. This 
translocation causes a fusion of the EWS gene with the Friend Leukaemia 
Integration 1 transcription factor (FLI1) gene (Delattre et al., 1992). Other, 
less common translocations produce different oncogenic fusion proteins, 
including the EWS-ERG fusion protein which occurs in 10% of ESFTs, and 
various other EWS-ETS protein fusions account for the remaining cases. 
1.21.1  The EWS gene 
EWS is a member of the TET family of proteins, which also include the 
Translocated in Liposarcoma (TLS), and TATA-binding protein-associated 
factor 15 (TAF15). These proteins are believed to have a role in RNA 
transcription and processing. EWS contains an N-terminal transcriptional 
activation domain and a C-terminal RNA-binding domain. The N-terminal 
domain is capable of interacting with RNA pol II and TFIID (Bertolotti et al., 
1998) and thus is implicated as a transcriptional co-activator (Law et al., 
2006; Lee et al., 2005; Thomas et al., 2004). The C-terminal domain of EWS 
contains an 86-amino acid RNA Recognition Motif (RRM) implicated in RNA 
binding (Ohno et al., 1994), and has three RGG boxes, which repress the 
activity of the N-terminus (Alex & Lee, 2005).  
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Figure 1.11 The EWS-FLI1 fusion protein 
A) A chromosomal translocation occurs between chromosome 22 and chromosome 11. This fuses the N-terminal 
transactivation domain of the EWS gene to the DNA-binding domain (DBD) located at the C-terminus of the FLI1 
gene. B) The EWS-FLI1 gene product is a potent oncoprotein, capable of interacting with various proteins involved 
in transcription, thereby regulating the expression of a number genes involved in cell cycle regulation and 
proliferation. 
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1.21.2  The FLI1 gene 
The FLI1 gene was first identified as a proto-oncogene which is a preferred 
site of entry for the Friend Murine Leukaemia Virus (Ben-David et al., 1991). 
It is a member of the ETS family of transcription factor proteins, classified as 
such due to a characteristic Helix-Loop-Helix N-terminal activation domain 
(ATA) (Rao et al., 1993).  The FLI1 C-terminus possesses an ETS-DNA 
Binding Domain, containing a Helix-Turn-Helix motif capable of binding to 
the consensus sequence, GAAA/T. Additional adjacent sequences 
determine the specificity of FLI1 recognition (Liang et al., 1994; Mao et al., 
1994).  
1.21.3  The EWS-FLI1 fusion protein 
The EWS-FLI1 fusion protein is therefore a potent oncoprotein capable of 
recognising the same specific DNA motifs as the wild-type FLI1 protein (Mao 
et al., 1994), but possessing enhanced transcription activation capabilities, 
due to the EWS N-terminal domain and the loss of the regulatory EWS C-
terminus.  
The disordered nature of the EWS-FLI1 protein also enables it to interact 
with multiple proteins to initiate oncogenesis. As such, it is capable of 
interacting with proteins involved in transcriptional regulation, such as the 
Fos-Jun dimer, RNA pol II, TFIID, and CBP (Figure 1.11b). An excellent 
review of these protein interactions is provided in (Erkizan et al., 2010).  
EWS-FLI1 can also affect pre-mRNA processing. Specifically, it can alter 
splice site selection by counteracting heterogeneous nuclear ribonuclear 
protein A1 (hnRNPA1). It interacts with Splicing Factor 2 (SF2) and the U1 
small nuclear ribonuclear protein U1C to redirect the splicing machinery to 
more proximal 5′ splicing sites (Knoop & Baker, 2000; Knoop & Baker, 
2001). This alternative splicing can lead to oncogenesis by altering the 
relative expressions of Cyclin D splice variants. Cyclin D has 2 possible 
splice variants; Cyclin Da and Cyclin Db. Of these, Cyclin Db is more 
oncogenic and usually expressed at lower levels. However, EWS-FLI1-
mediated alternative splicing causes upregulation of Cyclin Db, thereby  
Chapter 1: Introduction 
42 
 
 
Figure 1.12: EWS-FLI1 represses p53 activation of p21 
A) EWS-FLI1 binds to p53 and represses p300-mediated acetylation. This inhibits the binding of p53 to its target 
sequences. B) Phosphorylated and acetylated p53 is capable of promoting p21 transcription. However, in the 
presence of EWS-FLI1, p21 transcription is repressed. This is caused by EWS-FLI1 repressing p53 acetylation, 
and by recruiting HDAC1 into a complex with p53, thereby further repressing p21 transcription. 
 
enhancing the G1-S phase progression of the cell cycle (Sanchez et al., 
2008). 
In addition, EWS-FLI1 can deregulate the activities of the tumour suppressor 
protein, p53 (Figure 1.12). EWS-FLI1 is capable of forming a complex with 
p53 via its N-terminus, at residues 65-109. This interaction represses p53 
activity in two ways. Firstly, it represses p300-mediated acetylation of p53, 
reducing the ability of p53 to bind to its target promoter sequences. 
Secondly, the EWS-FLI1 protein recruits HDAC1 to the EWS-FLI1/p53 
complex, which further represses the transcription of p53 target genes, such 
as p21. p21 prevents cell cycle progression from G1-S phase by binding to 
cyclin dependent kinase 4. Therefore, by repressing expression of p21, 
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EWS-FLI1 drives cell cycle progression, enhancing proliferation (Li et al., 
2012; Li et al., 2010). 
1.22 ESFTs Originate from Mesenchymal Cells 
Although ESFT cells express various genes found in neural differentiation 
and ectodermal lineages (Hu-Lieskovan et al., 2005), there is evidence to 
suggest they may originate from Mesenchymal Stem Cells (MSCs). This is 
exemplified by results showing that the ectopic expression of the EWS-FLI1 
protein in fibroblast cells results in growth arrest and cell death; whereas in 
contrast, ectopic expression of the EWS-FLI1 protein in both murine and 
human MSCs produced cells with ESFT-like characteristics (Lessnick et al., 
2002). These include the expression of the ESFT-associated marker CD99, 
morphological changes from elongated spindle shaped cells to small, 
rounded cells with scant cytoplasm, and the upregulation of genes 
implicated in neural differentiation (Riggi et al., 2005; Riggi et al., 2008). 
Further evidence for MSCs being the cells of origin for ESFTs is the ability of 
ESFT CSCs to differentiate down mesenchymal lineages, suggesting these 
cells have maintained some of their parental MSC characteristics (Suvà  et 
al., 2009). 
1.23 ESFT CSCs 
Recently a small subpopulation of ESFT cancer stem cells has been 
identified which are CD133+. These CSCs account for between 4% - 8% of 
ESFT cell populations in primary tumours and are capable of forming 
multicellular spheroids in vitro. Moreover, only 2,300 of these CSCs were 
required to form tumours in mice. Interestingly, these cells were also capable 
of differentiating down three mesenchymal lineages, namely adipogenic, 
chondrogenic and osteogenic. This further indicates these cells may have 
been derived from mesenchymal stem cell precursors (Suvà  et al., 2009). 
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1.24 Herpesviruses  
Herpesviruses are large DNA viruses that are prevalent throughout the 
animal kingdom, spanning both vertebrates and invertebrates. These viruses 
belong to the order herpesvirales, which contains three families; 
Alloherpesviridae, which infect fish and amphibians, Malacoherpesviridae, 
which infect molluscs, and Herpesviridae which infects mammals, birds and 
reptiles. The Herpesviridae encompasses 90% of herpesviruses (McGeoch 
et al., 2006) and contains 3 sub-families; α, β, and γ, which are grouped on 
their genome sequence and organization.   
Alphaherpesvirinae primarily form latent infections in the host sensory 
ganglia. This subfamily includes the two mammalian genera (Simplexvirus 
and Varicellovirus), two avian genera (Mardivirus and Iltovirus), and several 
reptilian viruses which remain unclassified. The human herpesviruses, 
Herpes simplex virus type-1 and 2, (HSV-1 and -2), which form cold sores 
and genital herpes respectively, and Varicella Zoster virus (VSV), which 
causes chicken pox and shingles, belong to this sub-family. 
The Betaherpesvirinae typically has a restricted host range and a long 
reproductive cycle. This family consists of four genera; Cytomegalovirus, 
Muromegalovirus, Roseolovirus and Provoscivirus. The most notable of 
human viruses in this family is human Cytomegalovirus (HCMV), which 
typically causes mild diseases or asymptomatic infections in up to 90% of 
the population worldwide. However, HCMV can cause serious pneumonia-
like symptoms in immune-suppressed patients. 
Gammaherpesvirinae contains four genera; Lymphocryptovirus (gamma-1), 
Rhadinovirus (gamma-2), Macavirus and Percavirus. Viruses within this 
family typically replicate in T- and B-lymphocytes, with gamma-1 
herpesviruses typically infecting B-cells, and gamma-2 herpesviruses 
persistently infecting T-cells. 
Herpesvirinae possess ds DNA genomes of 124-241kb in size (Davison et 
al., 2003; Gray et al., 2001), which are packaged within an icosohedral 
(T=16) capsid composed of 162 capsomeres (McGeoch et al., 2006). 150 of 
these capsomeres are homo-hexamers, 11 are homo-pentameric multimers, 
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and the final pentameric position is occupied by a portal complex which 
allows DNA entry into the completed capsid. Surrounding the capsid is the 
tegument layer which contains a number of pre-synthesised viral and cellular 
proteins required for infection and initiation of replication (Varnum et al., 
2004; Zhu et al., 2005). Finally, the entire virus particle is enveloped by a 
lipid bi-layer membrane which contains virally encoded glycoproteins 
required for viral attachment and entry into infected cells. The size of these 
entire herpesvirus particles varies between 120-260 nm, depending on the 
size of the tegument layer (Dimmock et al., 2001). The typical structure of a 
herpesvirus virion is shown in Figure 1.13. 
 
Figure 1.13: The Herpesvirus capsid structure.  
Herpesvisues possess a dsDNA genome which is encased within a T=16 icosohedral nucleocapsid. This capsid 
contains a portal complex which enables the dsDNA genome to be inserted into the completed capsid after its 
assembly. Surrounding the nucleocapsid is the protein-filled Tegument layer, which is in turn surrounded by a lipid-
bilayer envelope. Adapted from abcam.com, date accessed 04/09/2012. 
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1.25 Gammaherpesviruses 
Like all herpesviruses, the Gammaherpesvirinae are able to form latently 
persistent infections in their host. Moreover, unlike the alpha- and 
betaherpesviruses, gammaherpesviruses can replicate their genome in 
dividing cell populations due to the presence of a virally encoded latent 
origin of replication (OriP). These viruses are lymphotrophic and 
predominantly infect T- and B-lymphocytes. However, they have been 
shown to infect a number of other cell types, to form latent infections or 
undergo lytic replication.  
Gammaherpesviruses show remarkable similarity within their genomes, with 
more shared genes compared to members of the alpha- or 
betaherpesviruses. Furthermore, their genomes are highly co-linear, 
containing conserved blocks of highly similar genes with only a few genes 
unique to each virus. These coding regions are, in turn, flanked by terminal 
repeat regions (Pellet & Roizman, 2007). Figure 1.14 demonstrates the co-
linearity of three gammaherpesviruses, Herpesvirus saimiri (HVS), Epstein - 
Barr virus (EBV), and Kaposi‟s Sarcoma-associated Herpesvirus (KSHV).   
A further property of the gammaherpesviruses is their ability to induce 
neoplastic disease, either in their natural host, in the case of EBV or KSHV, 
or in a foreign host, as is observed for HVS. All three of these viruses are 
associated with lymphoproliferative disorders. However, EBV has also been 
linked with the formation of nasopharyngeal carcinomas, and KSHV linked 
with endotheliosarcomas, such as Kaposi‟s sarcoma (Damania, 2004). This 
oncogenic potential is due to virally encoded genes involved in lytic and 
latent stages of the virus life cycle. These genes subvert the host immune 
response, regulate the cell cycle and inhibit apoptosis. The two 
gammaherpesviruses which will be discussed in further detail here are EBV 
and HVS. 
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Figure 1.14: The genome structures of HVS and related gamma-herpesviruses.  
A) Herpesvirus saimiri (HVS) genome arrangement, B) Kaposi‟s Sarcoma-associated Herpesvirus (KSHV) genome 
structure, C) The genome structure of Epstein-Barr Virus (EBV). There is significant co-linearity between the 
gammaherpesvirus genomes, with four conserved gene blocks (shown here in different colours). These gene 
blocks contain proteins with conserved functions between gammaherpesviruses, with unique proteins found 
between these conserved blocks. Adapted from (Pedro Simas & Efstathiou, 1998). 
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1.26 Epstein - Barr virus 
EBV is the prototype member of the type-1 gammaherpesviruses, and can 
be found in over 95% of the world‟s population. It forms asymptomatic 
infections in children, but can cause infectious mononucleosis if acquired 
during adolescence (Henle et al., 1968). Following initial infection, EBV 
develops life-long asymptomatic latent infections in the host. Typically, EBV 
infections are non-carcinogenic; however, it has been associated with a 
number of malignancies, including Hodgkin‟s lymphoma, nasopharyngeal 
carcinoma and T-cell lymphomas (Jones et al., 1988; Levine et al., 1971; 
Pathmanathan et al., 1995). 
EBV primarily infects B-lymphocytes via an interaction with the viral 
glycoprotein, gp350/220, and the cellular complement receptor, CD21 
(Fingeroth et al., 1984; Kawaguchi et al., 2009). Upon initial infection, a short 
lytic reproductive cycle occurs, activating the naïve infected B-cells, causing 
them to proliferate. These activated B-cells then further differentiate into 
long-lived memory B-cells in which the EBV can reside in a latent state 
(Babcock et al., 1998).  
Only a limited number of genes are transcribed in the latent phase of the 
EBV lifecycle. These comprise of six EBV nuclear antigens (EBNAs 1-6), 
three latent membrane proteins, (LMP-1, LMP-2A and LMP-2B), and two 
small RNAs (EBERs 1 and 2). There are three distinct forms of EBV latency 
described, each possessing different expression patterns of the latency-
associated genes. During Type I latency, only the EBERs and the episomal 
maintenance protein, EBNA-1, are expressed. Type I latency is frequently 
associated with Burkitt‟s Lymphoma, but the expression of these genes 
alone is not sufficient for transformation (Klein et al., 2007). Type II latency 
involves the expression of the LMPs in addition to the genes transcribed 
during Type I latency. Once again, this expression profile is not capable of 
inducing cell proliferation, but is, however, associated with Hodgkin‟s 
lymphoma and nasopharyngeal carcinoma (Chiang et al., 1996; Deacon et 
al., 1993). Finally, Type III latency involves the expression of the complete 
set of latency-associated genes, and this expression profile is capable of 
inducing autonomous proliferation. 
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Although EBV usually remains latent, it can reactivate, initiating lytic gene 
expression in a temporal cascade. Like other herpesviruses, the genes 
involved in lytic replication are expressed in a temporal cascade, with the 
Immediate Early (IE) genes being primarily expressed. This in turn enables 
the expression of the Delayed Early (DE) genes, and the structural late (L) 
genes. EBV has two IE genes which control the lytic replication cascade, 
termed BRLF1 and BZLF1, which produce the transcription factors Rta and 
Zta, respectively (Countryman et al., 1987; Countryman & Miller, 1985; 
Hardwick et al., 1988). These proteins activate transcription of the other 
genes involved in the lytic cascade by binding directly to the viral promoters 
(Liu & Speck, 2003; Ragoczy & Miller, 1999). Consequently, lytic replication 
leads to the production of infectious virions. 
1.27 Herpesvirus saimiri (HVS) 
Herpesvirus saimiri (HVS) is a member of the Rhadinovirus genera of 
Gammaherpesvirinae, first identified in 1968. HVS establishes a persistent 
asymptomatic infection in T-lymphocytes of their natural host, the squirrel 
monkey (Saimiri sciureus) (Falk et al., 1972; Melendez et al., 1968). 
However, HVS is capable of forming acute malignant T-cell lymphomas 
upon experimental infection of New World primates, including owl monkeys, 
common marmosets, and cottontop tamarins (Fleckenstein & Desrosiers, 
1982). Moreover, HVS can transform a variety of simian and human cells to 
continuous growth in vitro (Desrosiers et al., 1985a; Schirm et al., 1984). 
HVS also shares considerable sequence homology with the human 
herpesvirus, Kaposi‟s sarcoma-associated Herpesvirus (KSHV), and is used 
as a model to study the KSHV lytic lifecycle. 
1.28 Genome Structure 
The HVS ds DNA genome consists of a central region, 112,930 bp in length, 
which has a low G+C content (36%) termed L-DNA, flanked by a variable 
number of G+C rich (71%) H-DNA repeats, 1,444bp in length (Albrecht et al., 
1992; Murthy et al., 1986). The L-DNA region contains the unique region of 
the genome, and encodes all 75 open reading frames (ORFs). In addition, 
the L-DNA also contains several virally encoded small nuclear viral RNAs; 5 
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in HVS strain C288, and 7 in HVS strain A11 (Albrecht et al., 1992; Biesinger 
et al., 1990).  Among the 75 ORFs in HVS, there are 15 cellular 
homologues, including ORF4 and ORF15, which encode glycoproteins 
related to complement control proteins (Albrecht et al., 1992), and ORF74, a 
G-protein coupled receptor homologue (Nicholas et al., 1992). It is believed 
these cellular homologues enhance immune evasion, transformation and 
pathogenesis. 
1.29 Viral Entry 
HVS entry has not been extensively studied. However, HVS possesses 
many of the envelope glycoproteins conserved in other herpesviruses; 
namely gB, gD, gH, gL, gM and gN (Ensser et al., 2003; Neipel et al., 1997). 
Therefore the entry mechanisms of HVS can be elucidated by studying the 
mechanisms of other herpesviruses. For example, the viral entry 
mechanisms of Herpes Simplex Virus Type-1 (HVS-1) have been 
extensively studied, and will therefore be discussed here. 
HSV-1 primary attachment occurs by binding of the viral gB and gC 
glycoproteins to heparan sulphate-containing proteoglycans on the cell 
surface (Herold et al., 1994; Laquerre et al., 1998; Shieh et al., 1992). 
Following this binding, gD interacts with either Herpes Virus Mediator of 
Entry (HVEM) (Whitbeck et al., 1997), nectin-1 (Richart et al., 2003), or 3-O-
Sulphate (Shukla et al., 1999), which causes a conformational change in the 
C-terminal domain of gD. This conformational change has been implicated in 
transmitting a signal to the gB and gH/gL glycoproteins which subsequently 
mediate viral entry (Reske et al., 2007). Because the glycoproteins, gB, gH 
and gL, are highly conserved, a similar mechanism for viral entry is believed 
to occur upon HVS infection. However, the exact mechanism involving these 
proteins is, as yet, unknown (Reske et al., 2007). 
Although gB, gM and gL are conserved, there is some variation between 
species. The HVS glycoprotein, ORF51, has also been implicated in viral 
entry into host cells, as it is present in the HVS virion and is capable of 
binding to heparan sulphate. Furthermore, ORF51 also shares significant 
homology to the KSHV protein, K8.1, which has also been shown to bind to 
heparan sulphate glycosaminoglycans and is believed to be involved in initial 
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binding in a similar way to gC of HSV-1 (Birkmann et al., 2001; Means, 
2004; Wang et al., 2001).  
1.30 HVS lifecycle 
Upon viral entry, the linear HVS genome is transported to the nucleus. This 
process is believed to be similar to that of KSHV, whereby genome transport 
is mediated through dynein motors processing along microtubules (Naranatt 
et al., 2005). Like other herpesviruses HVS is then capable of undergoing 
two distinct phases of infection; lytic replication, or a latent state. During 
latent infections many of the viral genes are repressed. In contrast, during 
lytic infections the virus is capable of replicating its genome and forming new 
infectious virions. 
1.30.1  Lytic replication 
Lytic infection allows HVS to reproduce its genome and eventually produce 
viral progeny within the host cell. Like all Herpesviruses, HVS genes are 
categorised into three distinct groups based on their temporal expression. 
These categories are Immediate Early (IE), Delayed Early (DE), and Late 
(L). IE genes are expressed first, and some are even present in the HVS 
virions. These proteins are responsible for initiation of DE gene expression. 
DE proteins are involved in DNA replication and L gene products encode the 
structural proteins involved in capsid formation and the envelope 
glycoproteins. 
The exact mechanisms of HVS DNA replication and assembly are yet to be 
fully elucidated. However, in HSV-1 it is believed that once the viral genome 
has entered the cell, it is ligated into a circular genome, initiating rolling circle 
replication (Muylaert & Elias, 2007). Once DNA concatemers have been 
produced and Late structural proteins have formed capsids in the nucleus, 
DNA is incorporated into the capsids via a capsid pore complex. The exact 
packaging mechanism of HVS is again unknown, but the putative packaging 
protein encoded by ORF29 is believed to be involved in this process (Ensser 
et al., 2003).  
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1.30.2 HVS Lytic replication is mediated by the IE genes, ORF50 
and ORF57 
Two IE genes regulate expression during HVS lytic replication, termed 
ORF50, (also known as the replication and transcription activator), and 
ORF57. ORF50 is the first protein to be expressed in the lytic gene temporal 
cascade. This transcriptional activator gene, encodes two transcripts, 
ORF50a and ORF50b. ORF50a is a spliced transcript containing a single 
intron, 960bp in length, and is detected early in viral replication. ORF50a is 
the major transcriptional activator, whereas ORF50b is expressed later in 
replication from a promoter that lies within the second exon (Nicholas et al., 
1991; Whitehouse et al., 1997). ORF50a upregulates expression of many 
HVS genes, including ORF57, via ORF50 response elements which have 
the consensus sequence, CCN9GG (Walters et al., 2004). ORF50 is 
capable of enhancing transcription by interacting with cellular proteins, such 
as the TATA-binding protein and components of the TFIID complex (Hall et 
al., 1999; Smale & Kadonaga, 2003). 
The second IE gene crucial for HVS replication is the multifunction protein, 
ORF57. ORF57 enhances the translation of viral intron-less mRNAs by 
transporting them out of the nucleus (Goodwin et al., 1999). During normal 
cellular mRNA processing, unspliced pre-mRNA transcripts acquire distinct 
protein complexes required for their nuclear export during splicing. However, 
as most of the transcripts produced by HVS are intron-less, they require 
recruitment of these protein complexes to enable efficient transport of these 
mRNAs out of the nucleus and their subsequent translation. ORF57 has 
been shown to bind these intronless viral RNAs and recruit cellular export 
proteins to enhance translocation through the nuclear pore, thereby allowing 
subsequent translation (Jackson et al., 2012). Specifically, the C-terminus 
binds to the consensus binding motif GAAGRG, which is found in the 
majority of HVS viral mRNAs (Colgan et al., 2009a). ORF57 then shuttles 
these viral mRNAs out of the nucleus by forming an export-competent 
ribonucleoprotein particle by binding to the human TREX component, Aly, at 
residues 103-120 of ORF57 (Tunnicliffe et al., 2011). This interaction then 
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mediates HVS mRNA nuclear export by the TAP-mediated pathway (Colgan 
et al., 2009b).  
In addition to exporting viral mRNAs, ORF57 is also capable of 
downregulating expression of genes containing at least 1 intron. This is 
achieved through interactions with the host cell splicing machinery, including 
SC-35 (a member of the spliceosome complex), thereby causing these 
proteins to aggregate in nuclear bodies (Cooper et al., 1999; Fu & Maniatis, 
1990). This disrupts the splicing and export of cellular mRNAs, a process 
which is intrinsically linked to nuclear export of these mRNAs. Furthermore, 
this function of ORF57 allows it to regulate the activity of ORF50, whereby 
the more potent transactivator of expression, ORF50a, is repressed by 
ORF57 later in infection as ORF50a is spliced. In contrast, the unspliced 
ORF50b is upregulated by ORF57 later in infection (Whitehouse et al., 1998; 
Williams et al., 2005). 
1.30.3  Latency 
One of the unique features of gammaherpesvirinae is their ability to persist 
as a high-copy number episome without viral integration in a dividing cell 
population during the latent phase of their infection. To this end, the viral 
genome is replicated during host cell mitosis and segregated to daughter 
cells (Fickenscher & Fleckenstein, 2001). During latency, only three genes 
are expressed from one polycistronic mRNA; ORF71, ORF72 and ORF73. 
ORF71 encodes an anti-apoptotic gene, termed viral FLICE protein (vFLIP), 
and ORF72 encodes a cyclin D homologue (Chang et al., 1996; Thome et 
al., 1997). These proteins protect latently infected cells from apoptosis 
induced by the extrinsic death receptor associated pathway, and promote 
progression from G1 to S phase of the cell cycle, respectively.  
ORF73 however, is responsible for HVS episomal maintenance by attaching 
the HVS episome to the host mitotic chromosome through its C-terminal 
region. The C-terminus of ORF73 possesses 2 chromosome association 
sites, termed CAS1 and CAS2, at amino acid positions 285-303 and 396-
407, respectively (Calderwood et al., 2004). ORF73 is also capable of 
interacting with the abundant cellular chromosome-associated protein, 
MeCP2, independently of these two CAS sites (a.a. 324-396), and Histone 
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H1 at a similar site (a.a. 342-379) (Griffiths et al., 2008; Griffiths & 
Whitehouse, 2007). Furthermore, the cellular insulator protein (CTCF) is also 
capable of binding the HVS-episome at one of two CTCF Binding Sites 
(CBS) within the orf73 promoter region (Zielke et al., 2012). The features of 
the ORF73 protein product are demonstrated in Figure 1.15. 
ORF73 tethering of the HVS episome is mediated by its interaction with TR 
domains within the H-DNA at two sites termed 73 binding region (BR)-1 and 
73BR2 (Verma & Robertson, 2003). These regions are therefore essential 
for HVS latent persistence, as demonstrated by White et al. whereby, upon 
removal of the TR regions by RecA mediated recombination, viral genomes 
were produced which were incapable of latent persistence (White et al., 
2003).  
 
 
 
Figure 1.15: Features of the HVS ORF73 protein.  
The ORF73 protein of HVS consists of an N-terminus which contains 2 nuclear localisation signals, a central acidic 
repeat domain, and the C-terminus, which is responsible for tethering the viral genome to host cell chromosomes. 
The C-terminus is capable of binding to the chromosomes either directly through two chromosome association 
sites (CAS 1 and 2), or indirectly through interactions with the chromosome associated proteins, MeCP2 and 
Histone H1. This region is also capable of binding the Terminal Repeat (TR) regions within the HVS genome, 
thereby allowing HVS to persist as a non-integrated episome. Adapted from (Turrell, 2010). 
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In addition to maintaining the HVS episome during latent infections, ORF73 
negatively regulates the transactivator protein gene product of ORF50, 
thereby suppressing the lytic gene cascade (Schafer et al., 2003). 
1.31 Strain Variation and Oncogenicity 
There are three HVS subgroups, termed A, B and C. These are classified on 
their ability to transform a variety of cells and on their homology within a 
highly variable 7kb region at the left-most region of the L-DNA (Medveczky 
et al., 1984). These subgroups vary in their transforming capability, with 
strains A and C being capable of transforming common marmoset T-
lymphocytes, and strain B being non-oncogenic (Brinkmann & Schulz, 
2006).   
1.31.1  STP 
The transforming capabilities of HVS are associated with the product of the 
ORF1 gene which encodes the Saimiri Transformation-Associated Protein 
(STP). Both STP-A and STP-C contain a 17 a.a. cytoplasmic acidic N-
terminus, 18 collagen-like repeats in the central region and a 16 a.a. 
hydrophobic, plasma spanning C-terminal domain. STP-B however, is a 
truncated version of the protein and does not possess the acidic N-terminal 
region or the collagen-like repeats (Choi et al., 2000).  
The collagen-like repeats appear to be essential for the transforming 
capabilities of STP, as insertion of this domain into the non-transforming stp 
gene of strain B confers transforming ability (Choi et al., 2000). STP-C can 
associate with cellular Ras which stimulates the MAPK pathway (Jung & 
Desrosiers, 1995), whereas STP-A interacts with the SH2 motif of Src kinase 
and Stat3 (Chung et al., 2004; Lee et al., 1997). Furthermore, all STP 
genotypes are capable of interacting with the Tumour Necrosis Factor 
Receptor-Associated Factors (TRAFs), with STP-A and STP-C being 
capable of activating NF-κB via these interactions (Brinkmann & Schulz, 
2006; Garcia et al., 2007).  
1.31.2  Tip 
HVS strain C viruses encode a further protein with transforming potential 
adjacent to ORF1, termed the Tyrosine kinase Interacting protein (Tip). This 
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protein is membrane located and is largely unstructured, possessing a single 
C-terminal transmembrane domain, an N-terminal glutamate-rich region, 
serine-rich regions and three conserved tyrosine residues (Fickenscher & 
Fleckenstein, 2001; Mitchell et al., 2007). Tip-mediated transformation is 
mediated through a strong interaction with the Src family protein tyrosine 
kinase, Lck, which is a key regulator of T-cell activation (Isakov & Biesinger, 
2000). This interaction is mediated by the Lck Binding Domain of Tip, which 
consists of a 9 aa motif with homology to the C-termini of various Src family 
kinase domains (CSKH), a 20 aa linker and a 9 aa proline-rich consensus 
sequence for SH3 domain binding (Biesinger et al., 1995; Jung et al., 
1995a). These domains work cooperatively to bind Lck, enabling 
transformation of T-lymphocytes by the T-cell receptor (TCR) signalling 
pathway (Heck et al., 2006). However, there have been conflicting reports on 
this activation mechanism, as Tip-C488 overexpression in T-cells partially 
reversed the activities of constitutive Lck expression (Jung et al., 1995b), 
making the activity of Tip in HVS-infection unclear. One explanation for this 
downregulation could be to evade host cell immune control. Furthermore, 
Tip has been shown to interact with the lysosomal protein, p80, enhancing 
lysosome formation and subsequently recruiting Lck into the lysosome for 
degradation (Park et al., 2003). This in turn disrupts cellular trafficking by 
interacting with the Vps35 subunit of the retromer complex, leading to the 
downregulation of CD4 expression on the cell surface, thereby further 
reducing TCR signalling (Kingston et al., 2011). 
Tip also associates with the SH2 domains of STAT1 and 3 via a 
phosphotyrosine residue at position Y114 in Tip-C488, or Y72 in Tip-C484, 
which is also believed to mediate T-cell transformation (Hartley & Cooper, 
2000; Lund et al., 1997).  
1.32 HVS miRNAs  
Upon infection, viruses are able to exploit host cell miRNAs to achieve 
regulation of a number of viral constructs and to redirect host cellular 
machinery. This can either enable virus replication or shut off virally encoded 
proteins during latent infection (Ghosh et al., 2009).  
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Several dsDNA viruses, including Herpesviruses, also encode their own set 
of miRNAs which allow the virus to regulate viral and host cell transcripts, 
thereby controlling latency or lytic replication. For instance, EBV encodes 25 
miRNAs, some of which regulate latent infection of the virus. Firstly, miR-
BART2 represses lytic infection through downregulation of the EBV 
transcription factor BALF5 (Barth et al., 2008). Secondly, three EBV-
encoded miRNAs tightly regulate expression of LMP1, which promotes cell 
proliferation during latent infection, but can result in cell cycle arrest and 
apoptosis if overexpressed (Lo et al., 2007). 
Additionally, Herpesvirus miRNAs can bear homology to cellular miRNAs, as 
observed for the miR-K12-11 of KSHV. This miRNA shares the same first 8 
nucleotides as the cellular miRNA, miR-155, an miRNA involved in cell-
growth regulation. Overexpression of miR-155 in B-cells is associated with 
lymphomas, thereby highlighting a role of virally encoded miRNAs in cancer 
progression (Eis et al., 2005; Skalsky et al., 2007). 
Herpesvirus saimiri also encodes its own microRNAs, termed Herpesvirus 
saimiri U-rich RNAs (HSURs); 5 in HVS strain C288, and 7 in HVS strain 
A11 (Albrecht et al., 1992; Biesinger et al., 1990). Two of these virally 
encoded miRNAs (HSUR 1 and 2) have been shown to rapidly degrade the 
host cell miRNA, miR-27, which is an activator of Wnt and promotes 
proliferation (Cazalla et al., 2010). The rapid degradation of miR-27 has also 
been observed upon murine CMV infection and, interestingly, appeared to 
be important for viral replication (Marcinowski et al., 2012). 
1.33 HVS as a Gene Therapy Vector 
HVS possesses many features which make it attractive as a gene therapy 
vector. Firstly, like all herpesviruses, HVS possesses a large dsDNA 
genome (150kb), which gives it a large packaging capacity for heterologous 
DNA. Secondly, HVS is capable of forming a persistent latent infection, 
maintaining its genome as a non-integrated circular episome in host cells for 
up to 150 cell doublings (Grassmann & Fleckenstein, 1989; Simmer et al., 
1991). This allows prolonged transgene expression without the risk of 
insertional mutagenesis. Finally, HVS has a broad tropism and can infect a 
variety of cell types. 
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1.33.1  Tropism 
HVS is capable of forming persistent latent infections in a wide variety of 
primary and cancerous cell lines. Indeed, intravenous and intraperitoneal 
injection of HVS expressing luciferase demonstrated, using non-invasive 
optical imaging, that HVS has a broad biodistribution. Viral DNA was 
detected in a number of organs, including the liver, spleen, lung, kidney, 
heart and brain. HVS infection was well tolerated in this mouse model, with 
predominantly ORF73 transcripts observed in infected organs, indicating the 
establishment of latent infection. In addition, no toxicity was observed in the 
liver, where the highest levels of infection were seen (Smith et al., 2005).  
HVS has a natural tropism for cells of the haematopoietic lineage, including 
T, B, Pre-B, myeloid and monocytoid cell lines and bone marrow stromal 
cells (Frolova-Jones et al., 2000; Stevenson et al., 1999; Stevenson et al., 
2000b). In addition to terminally differentiated cells, HVS is capable of 
infecting more primitive cells, as demonstrated by Doody and colleagues, 
who showed that HVS could infect CD34+ haematopoietic progenitor cells 
isolated from human umbilical cord blood and persist as a non-integrated 
episome through differentiation into erythroid cells (Doody et al., 2005). 
In addition to infecting primary pluripotent and haematopoietic cells, HVS is 
also capable of stably infecting a wide variety of cancer cell lines, including 
pancreatic, lung, and colorectal cells (Griffiths et al., 2006), and is capable of 
infecting ESFT cell lines in multicellular spheroidal cultures (Smith et al., 
2004). HVS is also capable of maintaining latent infections in tumours in 
vivo, as demonstrated with MiaPaCa and SW480 tumour xenografts in 
Balb/C nude mice, without infecting surrounding tissues (Smith et al., 2001) . 
A complete list of cell lines demonstrated to be stably infected with HVS is 
shown in Table 1.7.  The ability of HVS to infect a broad range of cancer 
cells demonstrates its potential as a gene delivery vector for reprogramming 
cancer cells to their tumour-initiating stem cell-like state. 
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Cell Line Status of DNA Virus 
Production 
Carcinoma Cells   
Lung- A549 Episomal yes 
Colorectal- SW480, HCT116 Episomal no 
Pancreatic- MiaPaCa, Panc1 Episomal/Linear yes 
Breast- MCF7 Episomal no 
Gastric- MKN45 Episomal no 
Oesophageal- Kyse 30, Oe19 Episomal no 
Ewings Family Tumours- A673, SK-ES Episomal yes 
Hepatocellular Carcinoma- Huh7, Huh7.5, 
HepG2 
Episomal no 
Human Haematopoietic Cells   
T cells- Jurkat, Molt 4 Episomal no 
Pre-B cell- LAS-221 Episomal no 
B Cells- Raji, Daudi Episomal yes 
Myeloid- K56, HEL 92 Episomal no 
Monocytoid- THP-1, U937 Episomal no 
Pluripotent Cells   
Mouse Embryonic Fibroblasts- CCE Episomal no 
 
 
Table 1.7: HVS infections and episomal persistence in various cell types. 
Adapted from (Griffiths et al., 2006). 
 
1.33.2  Engineering HVS-based Gene Delivery Vectors 
Traditionally, modifying the HVS genome was very technically demanding 
due to its large size and fragility, a typical feature of all gamma-2 
herpesviruses (Longnecker & Neipel, 2007). Initially, one approach was to 
clone the HVS C488 strain into an overlapping cosmid library and co-
transfect these cosmids into the permissive owl monkey kidney cells. This 
resulted in reconstitution of recombinant HVS-based viruses, but was very 
time consuming, and required replication competent viruses (Ensser et al., 
1999; Wieser et al., 2005). 
Engineering HVS-based vectors was made easier upon the use of the 
bacterial F-factor-based bacterial artificial chromosome (BAC) system. This 
system can stably maintain DNA fragments of up to 300 kb in length and can 
be easily genetically manipulated in E.coli (Shizuya et al., 1992). The first 
HVS-BAC was based on the HVS-C484-77 strain, but was incapable of 
forming persistent latent infections, as the bacterial replication elements 
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disrupted the TR regions of the virus. However, episomal maintenance could 
be restored by incorporation of four copies of the TR unit into the construct 
(Collins et al., 2002). The second HVS-BAC was created by White et al. in 
2003 and was based on the non-transforming HVS strain A11. Here, the 
bacterial replication elements were inserted in ORF15 of the HVS genome to 
prevent disruption of the TR regions and episomal maintenance. ORF15 
encodes a viral homologue of the complement control protein, CD59, and is 
not required for HVS lytic or latent infections. The BAC element also 
contains an I-PpoI restriction site, enabling simple and fast cloning of desired 
genes into the HVS genome. I-PpoI is an extremely rare cutting enzyme, 
with only three restriction sites in the entire human genome, so there is little 
chance of a suitable restriction site being present in any transgenes cloned 
into the HVS-BAC. Genes can therefore be quickly cloned into the HVS-BAC 
by I-PpoI restriction digestion of the pShuttle Link1 construct containing the 
desired transgene, and subsequent ligation of the excised fragment into the 
HVS-BAC. The BAC element also contains the chloramphenicol resistance 
marker for easy selection of successful clones and either a GFP or RFP 
mammalian expression cassette, enabling quick identification of cells 
successfully infected with recombinant HVS virus. The features of the HVS-
BAC cloning system are detailed in Figure 1.16. 
The generation of the HVS-BAC allowed for improvement of the biosafety of 
HVS-based vectors by creating the HVS-based amplicon system (Macnab et 
al., 2008). An amplicon is specifically a defective vector derived from a viral 
genome. It contains a therapeutic transgene expression cassette and the 
cis-acting sequences required for replication, cleavage and packaging into 
the Virus-Like Particle (VLP). Amplicons carry no, or few, trans-acting viral 
genes, and do not induce synthesis of viral proteins. Therefore, these 
vectors are non-toxic and non-pathogenic to the transduced cell or tissue. 
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Figure 1.16: Features of the HVS-BAC system 
The BAC elements were inserted within ORF15 of the HVS strain A11 genome via RecA mediated recombination, 
in addition to three selective marker genes. These genes comprised of a GFP or RFP fluorescent marker, and the 
hygromycin and chloramphenicol resistance genes. Transgenes of interest can be cloned into the BAC by utilising 
the pShuttle Linker plasmid which contains a multiple cloning site and a kanamycin selection marker, flanked by 
two I-PpoI restriction sites. 
 
 
The amplicon-like system which has been generated for HVS was 
developed by digesting a 50kb fragment of HVS genomic DNA spanning 
ORFs 19-62. Although this is not a true amplicon as it still contains some 
viral gene sequences, it did remove the two genes essential for controlling 
lytic replication; namely ORF50 and ORF57. Furthermore, this HVS 
amplicon still contained ORF73, and was therefore capable of persisting as 
a non-integrated episome through repeated cellular divisions (Macnab et al., 
2008).  
Further engineering of HVS-based vectors for gene therapy applications has 
involved re-targeting the virus to preferentially infect hepatocellular 
carcinoma cell lines. The naturally broad tropism of HVS is useful in gene 
therapy applications; however, there are certain cases where a more 
targeted delivery of the vector into specific diseased cells is required. To this 
end, HVS was genetically altered by RecA mediated recombination to 
modify the ORF51 glycoprotein; replacing the heparan sulphate binding 
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domain with a somatostatin receptor binding motif (Turrell & Whitehouse, 
2011). Hepatocellular carcinoma cell lines often have increased levels of 
somatostatin receptor expressed on their cell surface. Therefore, this 
recombination aimed to re-target these modified HVS vectors to 
preferentially infect hepatocellular carcinoma. This recombination step 
swapped only 15 a.a. in the ORF51 region at positions 214-228 with 17 a.a. 
from the somatostatin binding motif. Interestingly, the resulting virus, termed 
HVSmORF51, did not display improved binding to somatostatin receptors. 
Perhaps this is not so surprising, as there is no way of ensuring the 17 a.a. 
somatostatin binding motif will be in the correct conformation or even 
exposed when it is translated as part of the ORF51 gene product. However, 
its binding to non-hepatocellular carcinoma human cell lines was perturbed, 
whereas binding to hepatocellular carcinoma lines remained high. Therefore, 
the HVSmORF51 virus was successfully engineered to possess enhanced 
specificity for hepatocellular carcinoma cell lines (Turrell & Whitehouse, 
2011).  
1.33.3  HVS-based therapies 
The potential of HVS as a gene-delivery vector was first realised in 1985. 
Recombinant HVS expressing the bovine growth hormone gene was able to 
successfully produce circulating bovine growth hormone upon infection of 
new world primates (Desrosiers et al., 1985b).  
Since this initial pre-clinical trial, HVS has been investigated as a gene 
therapy vector for the treatment of rheumatoid arthritis. HVS vectors 
encoding a combination of the anti-inflammatory cytokines IL-1RA and IL-10 
were demonstrated capable infecting rheumatoid arthritis fibroblasts-like 
cells. Furthermore, these vectors conferred a „protective‟ effect on cells 
treated with pro-inflammatory cytokines (Wieser et al., 2005).  
In addition to these initial studies, HVS has since been successfully 
engineered as an anti-cancer gene therapy vector. The potential of HVS as 
an oncolytic virus was first suggested by infection of the pancreatic cancer 
cell lines, MiaPaCa and Panc-1. HVS infection of these cells resulted in 
extensive cell death. In contrast, infection of all other carcinoma cell lines 
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tested showed no cytopathic effect, wherein the virus established a latent 
persistent infection (Stevenson et al., 2000c). 
The first HVS-based anti-cancer gene delivery vector generated expressed a 
64 nt synthetic shRNA against the Endothelin-Converting Enzyme-1. 
Infection of prostate cancer cells with this vector resulted in a 32% reduction 
in endogenous expression of the mitogenic protein Endothelin-1. Moreover, 
this vector significantly reduced prostate cancer cell invasion in scratch 
assays and Matrigel invasion assays (Hong et al., 2011). A further anti-
cancer HVS-based therapy involved generating a recombinant HVS-based 
vector expressing a negative regulator of Wnt signalling, the Adenomatous 
Polyposis Coli (APC) protein. Upon infection of two colorectal cancer cell 
lines, SW480 and SW620, these cells displayed reduced proliferation and 
migration in scratch assays (Macnab et al., 2011). 
 Most recently, HVS has been engineered to express the anti-cancer gene, 
TNF-Related Apoptosis Inducing Ligand (TRAIL). Here, the TRAIL gene was 
inserted under the control of the α-survivin promoter into a deletion mutant 
version of the HVS-BAC, HVSΔ71-73, as ORF71 of HVS encodes vFLIP 
(Thome et al., 1997). The HVSΔ71-73-TRAIL virus was capable of inducing 
apoptosis in a number of human cancer cell lines, including colorectal 
(SW480), Hepatocellular (Huh7, Huh7.5, HepG2), Prostate (PC3), ESFTs 
(TC32), and lung (A549), among others. In addition to inducing apoptosis in 
these monolayer cultures, HVSΔ71-73-TRAIL infection was used in 
conjunction with a JAK-inhibitor to successfully disrupt spheroid cultures of 
the melanoma cancer cell line, Mel888, after 4 days post-infection (Turrell et 
al., 2012). 
1.34 HVS as a potential iPSC gene-delivery vector 
As previously stated, there is great potential for episomally maintained viral 
vectors in iPSC generation. Episomally maintained reprogramming vectors 
would be able to provide prolonged expression of the reprogramming factors 
without the risks associated with retroviral insertional mutagenesis. Indeed, 
episomal persistence has already been utilised in a plasmid-based 
reprogramming method which utilised the EBV episomal maintenance 
protein EBNA1 and OriP origin of replication (Yu et al., 2009). This system, 
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however, was highly inefficient, likely due to the lack of virus-mediated entry. 
Nevertheless, this study demonstrated the potential of a non-integrating, 
episomally maintained system in iPSC generation. Moreover, an additional 
advantage is that episomal vectors could be removed from the 
reprogrammed cell populations by repeated cellular division without 
selection. This is an extremely desirable trait in any vector used for iPSC 
technology, as withdrawal of transgene expression upon successful 
reprogramming of cells has been demonstrated to produce iPSCs which 
more closely resemble ESCs in their gene expression profiles (Soldner et 
al., 2009; Sommer et al., 2010). Because HVS episomal persistence is 
reliant on a single protein, ORF73, HVS-based iPSC reprogramming vectors 
could, in theory, be removed from reprogrammed cells by regulating 
expression of this viral gene. 
Perhaps the most interesting feature of HVS as a potential gene delivery 
vector for iPSC reprogramming is the ability of HVS to infect undifferentiated 
ESCs and persist through their differentiation. This was demonstrated by 
Stevenson et al. whereby Mouse Embryonic Stem Cells (mESCs) were 
infected with HVS carrying a neomycin resistance gene and a GFP reporter 
gene. The initial infection rate in these cells was 20%, but infected cell 
populations were enriched by G418 selection. The virus remained as a non-
integrated episome in these cells. Infected mESCs appeared to have no 
morphological changes, and no infectious virus was produced. Moreover, 
the episome was maintained in these cells during differentiation into 
macrophages, and was capable of maintaining GFP expression in these 
cells (Figure 1.17). Similar studies were performed in human CD34+ 
haematopoietic progenitors selected from cord blood. HVS-delivered 
expression of GFP was readily detected in cells of the erythroid lineage upon 
differentiation (Doody et al., 2005). 
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Figure 1.17: HVS episomal persistence in differentiating cells. 
Mouse Embryonic Stem Cells (mESCs) were infected with HVS-GFP (Day 1), with an efficiency of 20%. After G418 
selection to enrich the infected cell population, the mESCs were differentiated for a period of 14 days to terminally 
differentiated macrophages (Day 14). These cells displayed expression of the GFP reporter transgene from the 
HVS-GFP genome, demonstrating the ability of HVS-GFP to persist and maintain transgene expression within a 
differentiating cell population. These images were taken at 100x magnification. Adapted from (Stevenson et al., 
2000a). 
 
These results indicate that HVS may be a suitable viral vector for iPSC 
generation, and is not subject to the same positional effect silencing which is 
observed in retroviral vectors (Hotta & Ellis, 2008). Moreover, A549 lung 
carcinoma cells infected with HVS carrying a GFP reporter gene 
demonstrated GFP transgene expression up to 12 months post-infection, 
indicating HVS is capable of prolonged transgene expression. This would be 
a valuable trait in iPSC reprogramming where prolonged expression of the 
reprogramming factors enhances the efficiency of iPSC generation (Hanna 
et al., 2009). 
Therefore, HVS possesses many desirable traits of an episomally 
maintained iPSC reprogramming vector, which could be used for safer iPSC 
generation. Furthermore, HVS-based vectors would not perturb the host cell 
gene functions through insertion of its genome, unlike their retroviral 
counterparts. Therefore, this virus presents a useful tool to reprogramme 
somatic cancer cells to tumour-initiating iPCs, which can then be used as an 
accurate model for studying tumour formation and progression. 
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1.35 Thesis Aims 
This thesis will explore the potential of HVS-based reprogramming vectors to 
generate iPSCs and iPCs in a proof-of-principle study. 
Firstly, HVS-based recombinant vectors will be produced expressing the 
iPSC transgenes, Oct4, Sox2, Lin28 and Nanog under the control of the 
immediate early CMV promoter. 
Secondly, the potential of these vectors to reprogramme primary cells and 
cancerous cell lines will be investigated 
Finally, resulting iPSC and iPC colonies will be characterised to determine 
the extent of reprogramming achieved within these cells. Furthermore, the 
potential of resulting iPCs to differentiate into various cell types will be 
determined. 
. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and reagents 
All chemicals and reagents were purchased from Sigma-Aldrich and Melford 
unless otherwise stated. Primers, T4 DNA ligase, DNA ladders and protein 
ladders were supplied by Invitrogen. Restriction enzymes were purchased 
from New England Biolabs or Promega. Gel extraction and Maxi-prep kits 
were obtained from QIAGEN. Reagents for qRT-PCR were supplied by 
Bioline. 
2.1.2 Plasmid constructs 
Lentiviral constructs containing cDNAs of each iPSC gene, pSin-E2F-Oct4-
Pur, pSin-E2F-Sox2-Pur, pSin-E2F-Lin28-Pur and pSin-E2F-Nanog-Pur, 
were obtained from Addgene. pEGFP-C1 was purchased from Clontech. 
The pShuttle Link 1 vector and the HVS-BAC construct were created by Dr. 
Robert White (White et al., 2003). 
2.1.3 Oligonucleotides 
Oligonucleotide primers used for sequencing and Polymerase Chain 
Amplification Reactions (PCR) were purchased from Sigma-Aldrich. A full list 
of these primers is given in Table 2.1. The Oligo(dT) primer used for 
Reverse Transcription reactions was purchased from Promega.  
2.1.4  Antibodies 
Primary antibodies were supplied from a range of companies, or provided by 
Dr. Christian Unger (Centre for Stem Cell Biology, University of Sheffield), 
and are detailed in Table 2.2. Horseradish peroxidise (HRP) conjugated 
secondary antibodies were supplied by Dako and used for western blotting. 
Alexa-fluor conjugated anti-mouse Immunoglobulin G (IgG) antibodies, used 
for immunofluorescence microscopy, were purchased from Invitrogen. 
  
Chapter 2: Materials and Methods 
 
69 
 
Primer Use  Sequence 
AgeI/EcoRI Oct4 PCR, Cloning, RT-PCR FWD GCGACCGGTATGGCGGGACACCTGGCTTCGGAT 
    REV GCGGAATTCTCAGTTTGAATGCATGGGAGAGCC  
AgeI/EcoRI Sox2 PCR, Cloning, RT-PCR FWD GCGACCGGTATGTACAACATGATGGAGACGGAG 
    REV GCGGAATTCTCACATGTGTGAGAGGGGCAGTGT 
AgeI/EcoRI Lin28 PCR, Cloning, RT-PCR FWD GCGACCGGTATGGGCTCCGTGTCCAACCAGCAG 
    REV GCGGAATTCTCAATTCTGTGCCTCCGGGAGCAG 
AgeI/EcoRI Nanog PCR, Cloning, RT-PCR FWD GCGACCGGTATGAGTGTGGATCCAGCTTGTCCC 
    REV GCGGAATTCTCACACGTCTTCAGGTTGCATGTT 
pEGFP NotI/MluI PCR of expression cassette FWD ATAAGAATGCGGCCGCAACCGTATTACCGCCATGCAT 
    REV GCG ACGCGT GGACAAACCACAACTAGAATGC 
qPCR Oct4 qRT-PCR FWD AAGCTGGAGAAGGAGAAGCTG 
    REV TCAAAGCGGCAGATGGTCGTT 
qPCR Sox2 qRT-PCR FWD TGAACCAGCGCATGGACAGTT 
    REV GTTCATGTAGGTCTGCGAGCT 
qPCR Lin28 qRT-PCR FWD AAGTGGTTCAACGTGCGCATG 
    REV GTGACACGGATGGATTCCAGA 
qPCR Nanog qRT-PCR FWD TGAGATGCCTCACACGGAGACT 
    REV TACACACAGCTGGGTGGAAGA 
qPCR GFP qRT-PCR FWD GCTGACCCTGAAGTTCATC 
    REV GATGCGGTTCACCAGGGTG 
pShuttle REV Sequencing FWD - 
    REV CTTGTGCAATGTAACATCAGAG 
Endogenous Oct 4 qRT-PCR ESC marker FWD CGCAAGCCCTCATTTCACC 
    REV CACAGAACTCATACGGCGG 
hTERT qRT-PCR ESC marker FWD CCTGCTCAAGCTGACTCGACACCGTG 
    REV GGAAAAGCTGGCCCTGGGGTGGAGC 
Klf4 qRT-PCR ESC marker FWD GCTGCTGAGTGGAAGAGAG 
    REV GAGAAAGATGGGAGCAGCG 
Rex1 qRT-PCR ESC marker FWD CAGATCCTAAACAGCTCGCAGAAT 
    REV GCGTACGCAAATTAAAGTCCAGA 
FLK1 qRT-PCR Differentiation marker FWD TGATCGGAAATGACACTGGA 
    REV CACGACTCCATGTTGGTCAC 
MAP2 qRT-PCR Differentiation marker FWD CAGGAGACAGAGATGAGAATTCCTT 
    REV GTAGTGGGTGTTGAGGTACCACTCTT 
Sox17 qRT-PCR Differentiation marker FWD CTCTGCCTCCTCCACGAA 
    REV CAGAATCCAGACCTGCACAA 
MSX 1 qRT-PCR Differentiation marker FWD CGAGAGGACCCCGTGGATGCAGAG 
    REV GGCGGCCATCTTCAGCTTCTCCAG 
Nestin qRT-PCR Differentiation marker FWD CCGGGTCAAGACGCTAGAAGA 
    REV CTCCAGCTCTTCCGCAAGGTTGT 
β-Tubulin III qRT-PCR Differentiation marker FWD GTCCGCCTGCCTCTTCGTCTCTA 
   REV GGCCCCTATCTGGTTGCCGCACT 
 
 
Table 2.1: Primer sequences and their applications 
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Target Cat. No. Working Dilution Type Provider 
Oct4 SC-5279 1:200 Mouse 
Monoclonal 
Santa Cruz 
Sox2 Ab75485 1:200 Mouse 
Monoclonal 
Abcam 
Nanog Ab76586 1:500 Mouse 
Monoclonal 
Abcam 
Lin28 Ab76369 1:500 Mouse 
Monoclonal 
Abcam 
GAPDH Ab8245 1:5000 Mouse 
Monoclonal 
Abcam 
SSEA4  1:10 Mouse Serum Dr. Christian 
Unger 
 
 
Table 2.2: Primary Antibodies used for various applications 
 
2.1.5 Bacterial Growth Media 
LB medium (Luria Bertani) – Tryptone (1% w/v), yeast extract (0.5% w/v), 
NaCl (1% w/v). For LB agar plates, agar (1.5% w/v) was added to LB 
medium. Media was autoclaved at 15 lb/sq. Inch on a liquid cycle. For 
selective media, antibiotic was added at either 50 µg/ml or 12.5 µg/ml once 
the media had cooled to 50°C. 
SOC medium (Super optimal broth with catabolite repression) – Tryptone 
(2% w/v), yeast extract (0.5% w/v), NaCl (0.05% w/v), 2.5 mM KCl. Media 
was autoclaved and, once cooled, sterile glucose and sterile MgCl2 were 
added to a final concentration of 20 mM and 10 mM respectively. 
2.1.6 Mammalian culture reagents 
Media and supplements were supplied by Invitrogen, Lonza and Stem Cell 
Technologies. A full list of cell culture reagents and their suppliers is given in 
Table 2.3. 
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Medium Supplements and Coating Agents Provider 
DMEM  Lonza 
RPMI  Invitrogen 
Knock-Out DMEM  Invitrogen 
Neural Stem Cell Media 
Kit 
 Invitrogen 
mTeSR  Stem Cell 
Technologies 
 FCS Invitrogen 
 Knock-Out Serum Replacement Invitrogen 
 mTeSR Supplement Stem Cell 
Technologies 
 Penicillin/Streptomycin Invitrogen 
 hygromycin Invitrogen 
 β-mercaptoethanol Sigma-Aldrich 
 Non-Essential Amino Acids Invitrogen 
 Glutamax Invitrogen 
 Matrigel BD Biosciences 
 Gelatin Sigma-Aldrich 
 
 
Table 2.3: Mammalian cell culture media and supplements 
2.2 Cloning 
2.2.1 Restriction Enzyme Digest 
Restriction enzymes were obtained from New England Biolabs. I-PpoI was 
purchased from Promega. Typically, restriction digests were performed in a 
20 µl reaction, with 2 µl of the appropriate 10x buffer, 1 µl enzyme, 0.1-2 µg 
DNA, 17 µl ddH2O, and were incubated for 1-16 hours at 37°C. Digested 
fragments were purified by agarose gel electrophoresis and extracted as 
described in section 2.2.6. For I-PpoI digests, 0.1 µl of enzyme was used 
and reactions incubated at 37°C for 50 minutes before heat inactivating the 
enzyme at 65°C for 20 minutes to prevent over-digestion. 
2.2.2 Cloning Strategies 
Restricted DNA fragments were separated by agarose gel electrophoresis 
and the bands visualised and excised using a UV transilluminator. DNA was 
extracted using the QIAquick Gel Extraction Kits as described in section 
2.2.6. DNA was eluted off the columns in 30-50µl of elution buffer (10 mM 
Tris-HCl, pH 8.5).  
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Purified products were ligated into pre-digested parent vectors in a 3:1 molar 
ration of insert: vector. The ligation reaction consisted of 0.5 µl (200 Units) of 
T4 DNA ligase and 2 µl of 10x ligase buffer (50mM Tris-HCl pH 7.5, 10 mM 
MgCl2, 1 mM ATP, 10 mM DTT) made to a total volume of 20 µl with ddH20 
and samples incubated for 16 hours at 16ºC prior to transformation of 
chemically competent cells (section 2.2.7). A list of the recombinant plasmid 
constructs generated and their parent vectors is given in Table 2.4. 
 
Recombinant 
Vector 
Parent Vector Primers Used Restriction Enzymes 
Used For Cloning 
pCMV-Oct4 pEGFP-C1 Age/EcoRI Oct4 FWD and REV AgeI/EcoRI 
pCMV-Sox2 pEGFP-C1 Age/EcoRI Sox2 FWD and REV AgeI/EcoRI 
pCMV-Lin28 pEGFP-C1 Age/EcoRI Lin28 FWD and REV AgeI/EcoRI 
pCMV-Nanog pEGFP-C1 Age/EcoRI Nanog FWD and REV AgeI/EcoRI 
pShuttle-Oct4 pShuttle Link 1 pEGFP NotI/MluI NotI/MluI 
pShuttle-Sox2 pShuttle Link 1 pEGFP NotI/MluI NotI/MluI 
pShuttle-Lin28 pShuttle Link 1 pEGFP NotI/MluI NotI/MluI 
pShuttle-Nanog pShuttle Link 1 pEGFP NotI/MluI NotI/MluI 
HVS-BAC-Oct4 HVS-BAC-GFP - I-PpoI 
HVS-BAC-Sox2 HVS-BAC-GFP - I-PpoI 
HVS-BAC-Lin28 HVS-BAC-GFP - I-PpoI 
HVS-BAC-Nanog HVS-BAC-GFP - I-PpoI 
 
 
Table 2.4: List of recombinant vectors produced and their parental plasmids. 
 
2.2.3 Polymerase Chain Reaction 
Polymerase Chain Reaction (PCR) was performed with Platinum Pfx DNA 
Polymerase or Taq polymerase. Conditions for Pfx reactions consisted of 
denaturation for 5 min at 95°C followed by 25 cycles of 95°C for 1 minute, an 
annealing step of 55°C for 1 minute, and an extension step for 1 
minute/1000 bp at 68°C. A final extension of 68°C for 10 minutes was used 
to ensure full extension of any remaining incomplete fragments. For 
reactions using Taq polymerase, a 5 minute incubation at 95°C was followed 
by 25-35 cycles of denaturation at 95°C for 1 minute, annealing of primers at 
55°C, and extension at 72°C for 1 minute/1000 bp. Annealing temperatures 
were optimised for each primer pair. A list of all the primers used is given in 
Table 2.1. 
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2.2.4 Agarose Gel Electrophoresis 
1% w/v agarose gels were prepared using electrophoresis grade agarose 
and 1x TBE buffer (0.045 M TRIS-borate, 0.002 M EDTA) and 0.1 µg/ml 
ethidium bromide was added prior to setting the gel. 5-10 µl of DNA loading 
buffer (1 mg/ml Orange G, 30% glycerol) was added to each sample before 
loading, along with either 1 kb or 100 bp DNA ladders. Electrophoresis was 
performed in 1x TBE buffer at 90 V or 120 V for typically 1 hour. 
2.2.5 Pulsed Field Gel Electrophoresis 
1.2% pulsed-field grade agarose gels were made 0.5x TBE buffer. Midrange 
I PFG Marker (New England Biolabs) was used along with λ DNA HindIII 
Digest (New England Biolabs) and 1 kb DNA ladder (Invitrogen) as size 
comparisons, and 10 µl of loading dye was mixed with DNA samples prior to 
loading. Electrophoresis was performed at 6 V for 9-16 hours, with an initial 
switch of 2 seconds and a final switch of 16 seconds, and the buffer chilled 
to 15.5°C using a Bio-Rad Model 1000 Mini chiller. Bands were visualised by 
staining the gels for 1 hour using 200 ml of 0.5x TBE containing 0.1 µg/ml of 
Ethidium Bromide. 
2.2.6 Gel Purification of DNA 
Following agarose gel electrophoresis, DNA bands were excised and 
purified using the QIAquick gel extraction kit according to the manufacturer‟s 
protocol. The gel slice was weighed and incubated with 3 times the gel 
volume of QG buffer (patented by manufacturer) at 50°C for 10 minutes to 
melt the agarose. Once melted, 1 volume of isopropanol was added and the 
sample was mixed before applying to a QIAquick column. The samples were 
centrifuged for 1 minute at 13,000 r.p.m and the flow-through discarded. The 
DNA bound to the column was washed once with 750 μl of buffer PE prior to 
centrifugation at 13,000 r.p.m for 1 minute to remove impurities. The flow-
through was once more discarded and a further centrifugation step of 13,000 
r.p.m for 1 minute was performed to remove the remaining PE buffer from 
the column. Finally, the DNA was eluted using 30-50 μl of ddH2O, by 
centrifuging the sample at 13,000 r.p.m for 1 minute. Pure DNA was stored 
at -20°C until use. 
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2.2.7 Transformation 
Chemically competent DH5α E.coli cells (kindly provided by Dr. Brian 
Jackson) were thawed on ice for 10 minutes prior to use.  1-5 µl of plasmid 
DNA was added to 50 µl aliquots of cells, and incubated on ice for 15-30 
minutes before heat shock treatment in a 42°C water bath for 30 seconds. 
Cells were chilled on ice for 2 minutes prior to addition of 250 µl of LB, and 
incubated at 37°C at 200 r.p.m for 1 hour before plating on selective LB 
agar. 
The HVS BAC DNA required the use of the E-Shot Electromax DH10β T1R 
Electrocompetent cells (Invitrogen) which are RecA- and more efficient at 
taking up large DNA fragments. 5-10 µl of HVS-BAC DNA was prepared by 
drop dialysis on 0.025 µm nitrocellulose membrane filters (Millipore) for 2 
hours. Electroporation was performed as detailed in the product protocols. 
Briefly, cells were thawed for 10 minutes on ice before adding the dialysed 
viral DNA. Electroporation was performed using the following conditions: 2.0 
kV, 200 Ω and 25 µF. Immediately after electroporation, 250 µl of SOC 
medium was added to the cuvettes and cells were incubated at 37°C, with 
shaking at 200 r.p.m for 1 hour before plating onto selective LB agar plates. 
2.3 Purification of plasmid DNA and BAC DNA 
2.3.1 Small scale plasmid purification (mini-preps) 
The protocol was adapted from „Molecular Cloning – A Laboratory Manual‟ 
(Sambrook et al., 1989). Colonies were picked into 2 ml of selective LB 
medium and incubated overnight at 37°C, 200 r.p.m. 1ml of each culture was 
centrifuged for 1 min at 13,000 r.p.m in a bench-top centrifuge and the 
bacterial cell pellets resuspended in 100 µl of Solution 1 (50 mM glucose, 25 
mM TRIS-HCl (pH 8.0), 100 mM EDTA (pH 8.0)). To lyse the cells, 200 µl of 
Solution 2 (0.2 M NaOH, 1% SDS) was added and samples mixed by 
inverting 4-6 times before incubating at room temperature for 5 minutes. 
Following lysis, 150 µl of ice-cold Solution 3 (60 ml 5 M potassium acetate, 
11.5 ml glacial acetic acid, 28.5 ml dH2O) was added to each sample to 
neutralise the pH and precipitate cellular protein and chromosomal DNA. 
Samples were mixed by inverting 4-6 times and incubated on ice for 10 
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minutes prior to centrifugation at 13,000 r.p.m for 10 minutes to pellet the 
cellular debris. The supernatant was transferred to a fresh eppendorf 
containing 450 µl phenol:chlorophorm (1:1, pH 8.0), mixed by vortexing, and 
centrifuged for 3 minutes at 13,000 r.p.m. The aqueous top fraction was 
collected and mixed with 1 ml of 100% ice-cold ethanol to precipitate 
plasmid DNA. Samples were centrifuged at 13,000 r.p.m for 10 minutes to 
pellet the DNA and washed with 1 ml 70% ethanol. DNA pellets were 
allowed to air dry for 5 minutes before resuspension in 50 µl ddH2O with 0.2 
µl RNAse A. 
2.3.2 Large Scale plasmid purification (maxi-preps) 
The QIAGEN Plasmid Purification Maxi Kit was used according to the 
manufacturer‟s protocols. 50 ml selective LB was inoculated with a 2 ml 
starter culture, and cells incubated at 37°C shaking at 200 r.p.m. Cells were 
pelleted by centrifugation at 5,000 r.p.m for 15 minutes at 4°C, and 
resuspended in 10 ml of resuspension buffer P1 (50 mM Tris-HCl (pH 8.0), 
10 mM EDTA, 100 µg/ml RNAse A). Lyseblue was also added to buffer P1 
to allow visualisation of complete lysis and neutralization in subsequent 
stages of the protocol. 10 ml of lysis buffer P2 (200 mM NaOH, 1% SDS) 
was added and samples inverted 4-6 times before incubating for 5 minutes 
at room temperature. Following lysis, the pH was neutralised using 10 ml of 
neutralisation buffer (3M potassium acetate pH 5.5, pre-chilled to 4°C), and 
samples were incubated on ice for 20 minutes to ensure complete 
precipitation of genomic DNA and protein. Cellular debris was removed by 
centrifugation at 5,000 r.p.m for 30 minutes, during which time a QIAGEN-tip 
500 column was prepared using 10 ml of buffer QBT, (750 mM NaCl, 50 mM 
MOPS (pH 7.0), 15% (v/v) isopropanol, 0.15% (v/v) Triton X-100). The 
supernatant was added to the equilibrated column and passed through the 
resin by gravity flow. Once all the supernatant had passed through the 
column, it was washed twice with 30 ml of wash buffer QC (1 M NaCl, 50 
mM MOPS (pH 7.0), 15% (v/v) isopropanol), and plasmid DNA eluted with 
15 ml of elution buffer QF (1.25 M NaCl, 50 mM Tris-HCl (pH 8.5), 15% (v/v) 
isopropanol). DNA was precipitated by mixing the eluate with 10.5 ml of 
100% isopropanol, and centrifugation at 5,000 r.p.m for 45 minutes at 4°C. 
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The supernatant was discarded and the DNA pellet washed with 70% 
ethanol and air dried for 5-10 minutes. Purified plasmid DNA pellets were 
resuspended in 400 µl of ddH2O and quantified by nanodrop. 
2.3.3 Small scale purification of low copy number plasmids and 
BACs ………………………………………. 
All solutions used for this method are described in section 2.3.1. Successful 
colonies were picked to 15 ml LB cultures containing appropriate antibiotic 
and cultured for 16 hours at 37°C, shaking at 200 r.p.m. Following 
centrifugation at 5,000 r.p.m for 10 minutes, the cell pellets were 
resuspended in 600 µl of Solution 1. 1.2 ml of lysis buffer (Solution 2) was 
added to the resuspended cells and the samples mixed by inverting 4-6 
times before incubating at 18-25°C for 5 minutes. Lysis of the cells was 
stopped and by using 1 ml of ice cold neutralization buffer (Solution 3). 
Subsequently, the samples were centrifuged at 5,000 r.p.m for 20 minutes at 
4°C to pellet the cellular debris. The samples were mixed with 2 ml of ice 
cold isopropanol and incubated on ice for 15 minutes prior to centrifugation 
at 5,000 r.p.m for 30 minutes to pellet the precipitated DNA, and the pellet 
washed in 70% ethanol. Pellets were air dried for 5-10 minutes before 
resuspension in 50 µl ddH2O containing 0.2 µl RNAse A. 
2.3.4 Large scale purification of low copy number plasmids and 
BACs ………………………………………. 
This protocol is modified from the large scale plasmid purification QIAGEN 
protocol, and all solutions are described in section 2.3.2. A 1 litre culture of 
LB containing appropriate antibiotic was inoculated with 2 ml of starter 
culture and incubated for 16 hours at 37°C, shaking at 200 r.p.m. The culture 
was centrifuged at 6,000 r.p.m for 15 minutes at 4°C using a Sorvall 
ultracentrifuge, SLA 1500 rotor using 4 x 250 ml containers. Cell pellets were 
resuspended in 5 ml of buffer P1 before combining the pellets to give 2 x 10 
ml samples. 10 ml of buffer P2 was added to each of these and samples 
incubated for 20 minutes at 4°C on a rotating wheel to lyse samples without 
shearing the larger BAC DNA. Samples were then neutralized by addition of 
10 ml of ice cold buffer P3 before incubating for a further 20 minutes on a 
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rotator wheel at 4°C. Cellular debris was removed by firstly centrifuging the 
samples at 12,000 r.p.m for 30 minutes before filtering the supernatant 
through sterile gauze to a fresh polypropylene tube and a further 
centrifugation at 5,000 for 15 minutes. Subsequently, 20 ml of 100% 
isopropanol was added to each of the two samples, and mixed gently by 
inversion. Following this, the samples were incubated on ice for 30 minutes 
and centrifuged at 5,000 r.p.m for 30 minutes for the first precipitation of the 
DNA. 
The resulting pellet was resuspended in 500 µl of TE buffer by gently 
pipetting up and down with a p1000, cut-off tip and agitation in a 37°C water 
bath. 4.5 ml of QBT buffer was added and the two samples combined. A 
QIAGEN-tip 500 column was prepared using 10 ml of QBT buffer before 
adding the suspension and allowing this to enter the column by gravity flow. 
The column was then washed once using 20 ml of QC buffer, and DNA 
eluted using 20 ml of buffer QF. 30 ml of isopropanol was mixed with the 
eluate and incubated on ice for 30 minutes, prior to centrifugation at 5,000 
r.p.m for 30 minutes. The resulting pellet was washed in 70% ethanol, 
resuspended in 100 µl TE buffer, and stored at 4°C to prevent repeated 
freeze-thaw which could compromise the stability of the fragile HVS-BAC 
DNA. 
2.4 Cell Culture 
2.4.1 Cell Maintenance 
Foreskin Fibroblasts, Human Embryo Kidney 293T, , Owl Monkey Kidney 
and Huh7 cells were all maintained in DMEM containing 10% heat-
inactivated Foetal Calf Serum (FCS), and 1% penicillin/streptomycin, on 
Corning tissue culture-grade plastic. 
The murine mESC-derived Neural Stem Cell NS5 adherent cell line was 
kindly provided by Dr. Ian Wood (School of Biomedical Sciences, University 
of Leeds).  
The Ewings sarcoma cell lines, TC32 and TTC466, were cultured in RPMI 
containing 10% FCS and 1% penicillin/streptomycin. A673 cells were grown 
in DMEM with 10% FCS and 1% penicillin/streptomycin. All Ewings cell lines 
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were cultured on Primaria tissue culture-grade plastic (BD biosciences).  
Induced pluripotent stem cell line (iPSC), ShiPS-FF5 was kindly provided by 
Dr. Christian Unger (Centre for Stem Cell Biology, University of Sheffield).   
They were reprogrammed through lentiviral overexpression of Oct4, Sox2, 
Nanog and Lin28 in human foreskin fibroblasts. ShiPSFF5 cells are 
karyotpically normal, have typical embryonic stem cell morphology, and 
express pluripotency markers SSEA4, Tra1-81, Oct4 and Nanog. iPSCs and 
induced pluripotent cancer stem cells (iPCs) were cultured on Matrigel ESC 
qualified extracellular matrix (BD Biosciences) coated tissue cultured plates, 
in mTeSR 1 complete medium. The cells were split 1 in 6, once every 5-7 
days by treating with 1 mg/ml collagenase type IV (Stem Cell Technologies) 
for 5 minutes at 37°C. The collagenase was removed and cells were washed 
twice with 2 ml of pre-warmed serum-free DMEM-F12 and 1 ml of fresh 
mTeSR added to the well. The colonies were scored by scraping with a blue 
tip and pipetted up and down with a P1000 pipette 2-3 times to break up the 
colonies, prior to centrifuging the cells at 400 r.p.m to replace the mTeSR. 
Cells were split 1 in 6 or 1 in 10 to pre-coated 12 well or 6 well dishes. 
Cells were stored in a humid atmosphere with 5% CO2 at 37°C. All cells 
were tested monthly for mycoplasma and they genotype was confirmed by 
suppliers. 
2.4.2 Reprogramming A673 cells 
1 day prior to infection, 2 x 104 A673 cells were plated per 6 well dish. 
Reprogramming was initiated by infecting cells with an MOI of 0.5 of HVS-
based vectors per well. Viral supernatants were added to 2 ml of DMEM 
containing 5% FCS. If multiple viruses were used, the total MOI of virus was 
maintained using HVS-GFP. After day 1 post-infection (p.i.), the medium 
was removed, the cells washed twice with 2 ml of 1x DPBS, and fresh 10% 
DMEM added to the cells. On day 2 p.i., cells were dissociated using 0.05% 
trypsin-EDTA and plated onto 10 cm Primaria dishes in 10% DMEM. Day 3 
p.i., cells were treated with 100 µg/ml of hygromycin B and maintained in 
selective medium. Medium was replaced every 2-3 days until the emergence 
of colonies (around day 19 p.i.). Colonies were collected by washing them 
off the 10 cm plates in DPBS by gentle agitation. Subsequently, colonies 
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were centrifuged at 400 r.p.m for 3 minutes and resuspended in medium 
comprising ½ DMEM 10%, and ½ mTeSR complete medium, and plated into 
2-4 wells of a 24 well dish, which had been pre-coated in Matrigel ESC 
qualified extracellular matrix.  Alternatively, colonies were picked directly 
from the 10 cm dishes using a P20 pipette, and each colony transferred to a 
24 well dish. The following day, the medium was replaced with mTeSR 
complete medium. The colonies were maintained for a further 1-2 weeks in 
24 well dishes until large enough to split (usually 1-2 mm in size). To split 
colonies the medium was firstly replaced with fresh mTeSR and each colony 
scored with a yellow tip 4-6 times and pipetted up and down twice to break 
up clumps. No cell dissociation reagents were used in the first split. The cells 
were transferred to a 6 well dish in 2 ml mTeSR.  
2.4.3 Freezing and Thawing of cells 
Cells were dissociated from tissue culture plastics using 0.05% trypsin-
EDTA and washed with medium containing 10% FCS. Following 
centrifugation at 1500 r.p.m for 3 minutes, the medium was removed and 
cells resuspended in freezing medium, (DMEM or RPMI with 20% FCS and 
10% Dimethyl Sulphoxide (DMSO)).  Cells were frozen in 1.8 ml cryovials 
(Nunc) in a Mr. Frosty at -80°C overnight before transferring to liquid 
nitrogen for long term storage. Frozen cells were recovered by rapid thawing 
in a 37°C water bath, washing in 10 mls of growth medium and 
resuspending in fresh growth medium. For iPSCs and iPCs the same 
procedure was followed with the substitution of freezing medium with 
mFreSR stem cell freezing medium (Stem Cell Technologies). 
2.4.4 Transfection 
Cells were cultured in Corning 6-well tissue culture dishes until 50-70% 
confluency. Transfections were performed in 2 ml serum free medium 
without antibiotics. 3 µl Lipofectamine 2000 (Invitrogen) was used per 1 μg 
of DNA transfected into cells, and transfections were performed in a final 
volume of 200 µl. 4-6 hours post-transfection, the medium was replaced with 
medium containing 10% FCS, 1% penicillin/streptomycin. 
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2.4.5 Transducing cells 
Cells were transduced with an MOI of 0.5-1 of each virus in DMEM with 5% 
FCS for 24 hrs. Cells were washed twice with 2 ml of DPBS and 10% 
medium added to the cells. If multiple viruses were used, an MOI of 0.5 of 
each virus was used and total MOI of virus maintained using HVS-GFP. 
2.5 Virus Generation and Characterisation 
2.5.1 Generation of Viral Stocks 
The HVS-BAC-iPSC constructs were each transfected into the permissive 
cell line, Owl Monkey Kidney (OMK) cells. 6-12 µl of BAC DNA was mixed 
with 10 µl of Lipofectamine 2000 in serum free medium, according to the 
manufacturer‟s protocols, and 200 µl of this mixture was added to 2 ml total 
volume of serum free medium per 3.5 cm dish. After 6 hours, the medium 
was replaced with DMEM containing 5% FCS, and cells were cultured for 2-
3 weeks until the cell sheet was lysed. Virus containing supernatant was 
subsequently used to infect 1x107 OMK cells to produce higher titre viral 
stocks. These higher titre viral supernatants were harvested when the cell 
sheet was lysed (typically 3-7 days p.i.). 
2.5.2 Titration of Viral supernatants 
Upon production of fresh viral supernatants, titres were performed in OMK 
and A673 cells. Serial 1 in 10 dilutions were made in 5% DMEM and 1 ml of 
these dilutions was added to each 6 well dish of cells. 24 hours post-
infection, cells were analysed for GFP expression from the virus by flow 
cytometry 
The GFP expressing Units/ml of each viral supernatant was calculated using 
the following equation: 
  
                 
                                      
                   
 
2.5.3 Flow Cytometry 
Cells were prepared for flow cytometry using 0.05% trypsin-EDTA per 6 well 
dish, and washed in 1 ml DMEM 10% FCS to inactivate the trypsin. Cells 
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were centrifuged at 1,500 r.p.m for 3 minutes before washing once in 1 ml of 
1x DPBS. Subsequently, cells were pelleted by centrifugation at 1,500 r.p.m 
for 3 minutes, resuspended in 0.5 ml of 1x DPBS, and stored on ice prior to 
flow cytometry analysis. Cells were live sorted using a Becton Dickinson BD-
LSRFortessa and results were analysed using the FACS DiVa6 software 
(BD Biosciences). 
2.6 Electrophoretic analysis of proteins 
2.6.1 Tris-glycine SDS-PAGE 
1x106 cells were washed once in 1x DPBS before lysing with 100-250 µl 
RIPA (50 mM Tris base, 150 mM NaCl, 1% NP40, pH 7.6) containing 2% 
EDTA-free protease inhibitor (Roche) for 20-30 minutes on ice. Samples 
were centrifuged at 13,000 r.p.m to pellet cellular debris, and the 
supernatants harvested. Protein concentration was determined with the DC 
assay (BioRad) as directed by the manufacturer‟s protocol. Samples were 
mixed with an equal volume of 2x Laemmli buffer (50 mM Tris-HCl (pH 6.8), 
2% (w/v) SDS, 20% (v/v) glycerol, 50 μg/ml bromophenol blue, 10 mM DTT), 
and incubated at 95°C for 5 minutes. All SDS-PAGE was performed using a 
BioRad mini-PROTEAN 3 cell, set up according to the manufacturer‟s 
instructions. Samples were loaded onto 10% or 12% polyacrylamide Tris-
glycine gels, overlaid with 5% polyacrylamide Tris-glycine stacking gel. 10-
20 μg of protein was loaded onto the gels before running at 180 V for 
typically 45 minutes, until the bromophenol blue had reached the bottom of 
the gel. SeeBlue Plus 2 (Invitrogen) or Colourplus (New England Biolabs) 
pre-stained protein standard markers were run alongside samples to indicate 
molecular weight. 
2.6.2 Western Blotting 
10-20 µg of protein was separated by SDS-PAGE as described in section 
2.6.1, prior to transferring the proteins onto Hybond C extra nitrocellulose 
(Amersham biosciences), using the BioRad Mini Trans-Blot Electrophoretic 
Transfer Cell, as stated in the manufacturer‟s instructions. The gel, four 
pieces of Whatman 3 mm filter paper, and one piece of Hybond C were 
arranged in a specific order and soaked in transfer buffer (25 mM Tris-base, 
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190 mM Glycine, 20% (v/v) methanol), before being secured in the Mini 
Trans-Blot, according to the manufacturer‟s instructions. Proteins were 
transferred at 100 V for 1 hr. Subsequently, membranes were blocked for 1 
hr at 18-25°C in 5% non-fat milk (Marvel) dissolved in 1 x TBS (Tris-base, 
500 mM NaCl) containing 0.1% TWEEN (TBST), before incubating with 
primary antibody diluted to the appropriate concentration (see Table 2.2) in 
5% milk/TBST for 16 hr at 4°C. Membranes were washed three times for 10 
minutes in 1x TBST before incubating with HRP-conjugated secondary 
antibody (Dako) diluted in 5% milk/TBST for 1 hour. Three further washes of 
10 minutes in 1 x TBST were performed, and membranes incubated with the 
EZ-ECL kit (Geneflow) prior to exposure on ECL hyperfilm (Amersham). 
2.7 Characterisation of iPC cells 
2.7.1 Alkaline Phosphatase staining of cells 
The Alkaline Phosphatase staining kit II from Stemgent was used to stain 
cells as described in the manufacturer‟s protocols. Briefly, the cells were 
washed with 2 ml 1x DPBS fixed for 2 minutes with Fix Solution (4% w/v 
paraformaldehyde) and washed using 1x DPBS containing 0.05% v/v 
Tween-20. The staining solution was prepared by mixing 1.5 ml of Solution A 
(<1% w/v Fast Red Violet solution) with 1.5 ml of Solution B (<1% w/v 
Napthol AS-BI Phosphate solution) and incubating at room temperature for 2 
minutes before finally adding 2 ml of Solution C (<1% w/v Sodium Nitrate 
solution). The prepared staining solution was immediately added to the fixed 
cells and incubated at room temperature in the dark for 15 minutes. 
Following this, the staining solution was removed and the cells washed 3 
times using 2 ml of 1x DPBS. 
2.7.2 Reverse-Transcription Polymerase Chain Reaction 
2.7.2.1 RNA extraction 
Cells were harvested using 1 ml of Trizol per 6 well dish. 200 µl of 
chloroform was added, and the samples were mixed by vigorous shaking for 
15 seconds before incubating at 18-25°C for 2-3 minutes. Samples were 
then centrifuged at 13,000 r.p.m, 4°C for 15 minutes and the top layer of the 
supernatant collected and transferred to a fresh 1.5 ml eppendorf containing 
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0.5 ml of 100% isopropanol. The samples were mixed and incubated at 18 - 
25°C for 10 minutes to precipitate the RNA. RNA was then pelleted by 
centrifugation at 13,000 r.p.m for 10 minutes at 4°C, and the pellet washed 
in 1 ml 70% ethanol before a further centrifugation at 9,000 r.p.m for 5 
minutes. The ethanol was removed and pellets allowed to air dry for 5 - 10 
minutes before resuspending them in 20 µl of RNAse-free ddH20 at 18-25°C 
for 30 minutes. RNA was stored at -80°C and repeated freeze-thawing 
avoided. 
2.7.2.2 Generation of cDNA 
Total cellular RNA was extracted as described in section 2.7.2.1. The 
concentration of each sample was determined by nanodrop and 10 µg of 
RNA was treated with 1 µl of 2 Units/µl DNA-free DNAse (Ambion) in a 50 µl 
reaction containing 5 µl of 10x DNAse buffer (100 mM Tris-HCl pH 7.5, 25 
mM MgCl2, 5 mM CaCl2) for 30 minutes at 37°C, according to the 
manufacturer‟s protocol. The reaction was stopped using 5 µl of DNAse 
Inactivation Reagent, and samples centrifuged for 2 minutes at 13,000 r.p.m. 
The supernatant, containing DNAse-treated RNA, was transferred to a fresh 
eppendorf and 5 µl of treated RNA was used to produce cDNA using M-
MuLV Reverse Transcriptase (New England Biolabs) according to the 
manufacturer‟s protocol. This required incubating the RNA with 1 µl of 
Oligo(dT) primer and 1 µl of 10 mM dNTP mix in a total reaction volume of 
13 µl before incubating at 65°C for 5 minutes. The samples were chilled on 
ice for 1 minute before adding 1 µl M-MuLV reverse transcriptase, 2 µl of M-
MuLV buffer, and 1 µl of RNAse OUT (Invitrogen), with the total volume of 
the reaction mix made up to 20 µl with ddH2O. Reverse transcription 
reactions were performed at 42°C for 1 hour, prior to enzyme inactivation at 
80°C for 5 minutes. Negative controls containing no reverse transcriptase 
enzyme were also prepared to demonstrate the samples were free from 
DNA contamination. cDNA samples were stored at -20°C. 
2.7.2.3 Reverse Transcription Polymerase Chain reaction (RT-PCR) 
Total RNA was extracted as described in section 2.7.2.1, and cDNA 
produced (section 2.7.2.2). 2.5 µl of cDNA was subsequently PCR amplified 
as described in section 2.2.3. A typical reaction cycle for RT-PCR involved 
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an initial denaturation step of 95°C for 5 minutes before 35 cycles of 
denaturation at 95°C for 30 seconds, primer annealing at 55°C for 30 
seconds, and extension for 30 seconds at 72°C. Samples were analysed 
using agarose gel electrophoresis as described in section 2.2.4. 
2.7.2.4 Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) 
Samples were set up in triplicate for each condition and total RNA harvested 
as described in section 2.7.2.1. cDNA was generated, as described in 
section 2.7.2.2, and diluted to a final concentration of 2 ng/µl. 10 ng of cDNA 
(5 µl) was mixed with 5.5 µl ddH20, 2 µl of 10 mM primer mix and 12.5 µl of 
2x SensiMix SYBR Green (Bioline), and qPCR performed using a Rotor-
Gene Q 2-plex Thermocycle (Qiagen). Typical reaction conditions for a 
qPCR run involved a denaturation of 10 minutes at 95°C followed by 45 
cycles of 95°C for 15 seconds, primer binding at 55°C for 30 seconds and 
extension with acquisition of fluorescence levels at 72°C for 20 seconds. 
Rotor-Gene 2000 software was used to analyse results. 
2.7.3 Immunofluorescence 
Cells were grown in 24 well dishes pre-coated in Matrigel and fixed after 3 
days in culture using 0.5 ml of 4% Paraformaldehyde in PBS per 24 well for 
15 minutes. Cells were washed 3 times using 2 ml 1 x DPBS and blocked for 
non-specific antibody binding using 1 x DPBS containing 1% Bovine Serum 
Albumin for 1 hour at 37°C. Primary antibody was diluted to the appropriate 
concentration in 1 x DPBS containing 1% Bovine Serum Albumin, and 
samples incubated with 200 µl of primary antibody at 37°C for 1 hour. Five 
washes in 1 x DPBS were performed to remove the primary antibody, before 
incubating samples with 200 µl of fluorescently-tagged secondary antibody 
diluted to the appropriate concentration at 37°C for 1 hour. Secondary 
antibody was removed and the cells washed 5 times in 1 x DPBS before 
staining the DNA with 5 µg/ml Hoechst stain in 1 x DPBS for 15 minutes. 
Hoechst was then removed and the cells washed a further 3 times using 2 
ml of 1 x DBPS. 
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2.7.4 Microscopy 
Images of colonies were taken using a DM1L fluorescent microscope 
attached to a Leica DC 300 camera, or Zeiss AxioVert 200 inverted 
microscope with images captured using a Hamamatsu CCD camera 
controlled by Openlab software using 10x or 20x magnification. 
Immunofluorescence analysis was performed on an inverted Zeiss AxioVert 
135 TV microscope using a Zeiss AxioVertCam HRC camera under 20x 
magnification. Images were analysed using ImageJ software. 
2.8 Differentiation of Induced Pluripotent Stem Cells and 
Induced Pluripotent Cancer Stem Cells 
2.8.1 Embryoid Body Formation 
Cells were split, as described in section 2.4.1, and colonies centrifuged at 
400 r.p.m for 3 minutes before resuspending in 6 ml of differentiation 
medium (Knock-out DMEM, 20% Knock-out Serum Replacement,1% Non-
essential amino acids, 1mM Glutamax, and 0.1mM β-mercaptoethanol), or 6 
ml of DMEM containing 10% FCS, and plated out onto low-adherent tissue 
culture dishes in a total volume of 2 ml of the chosen differentiation medium. 
The Embryoid Bodies (EBs) were cultured for 6-8 days as suspension 
cultures, with medium exchanged every 2-3 days, before transferring half of 
the cells onto 6 well dishes pre-coated in 2 ml of 0.1% gelatin.  The 
remaining cells were harvested in Trizol for later analysis. EBs were further 
cultured on gelatin coated plates for 6-8 days and cells imaged using DM1L 
fluorescent microscope before being harvested in Trizol. 
2.8.2 Directed Neural Differentiation 
Colonies were split and EBs formed as described in section 2.8.1. The EBs 
were then cultured in low-adherent dishes in 2 ml of EB medium containing 1 
μM All-Trans retinoic acid. Cells were cultured in this medium in suspension 
cultures for 2 days before transferring the EBs to gelatin coated 6 well 
dishes. These EBs were allowed to attach to the gelatin-coated plates, and 
cultured for a further 8 days in EB medium without All-Trans retinoic acid.  
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Alternatively, the EB were cultured in Neural Stem Cell (NSC) Medium for 2 
days in suspension culture before transferring to gelatin coated dishes. 
These EBs were then cultured for a further 8 days in NSC medium. 
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3  Generation of HVS-based iPSC-gene Delivery Vectors  
3.1  Introduction 
Induced pluripotent stem cell (iPSC) technology involves generating stem-
cell like cells from adult somatic cells by exogenous expression of certain 
reprogramming factors such as Oct4, Sox2, Klf4 and Myc (Takahashi & 
Yamanaka, 2006). This technology therefore has the potential to generate 
stem cells which are patient-specific and ethically sourced, and is of great 
interest in stem cell-based therapies. However, initially there were certain 
problems with the biosafety of iPSCs. Firstly, two of the original 
reprogramming factors used, Myc and Klf4, are oncogenic and lead to cell 
proliferation; although this issue was partially solved by the discovery that 
these factors could be replaced with Lin28 and Nanog, thereby making the 
reprogramming process safer (Yu et al., 2007).  
A further issue with iPSCs was the requirement of integrating retroviral 
vectors for delivery of the reprogramming factors. Retroviral vectors have the 
advantage of providing prolonged expression of the reprogramming factor 
transgenes which is essential for efficient reprogramming. However, 
retroviruses preferentially integrate into highly expressed regions of the 
genome and can disrupt normal gene function by causing overexpression of 
genes related to proliferation or, alternatively, silence regulatory genes. 
There have been many attempts to develop safer reprogramming vectors 
including generating excisable retroviral vectors using Cre/LoxP 
recombination (Kaji et al., 2009) or piggyBac transposons (Woltjen et al., 
2009). However, both these systems still leave behind a “footprint” after 
excision which can still disrupt normal gene function and require very 
stringent screening processes to ensure all viral DNA is excised. Alternative 
gene delivery methods have been assessed, including adenoviral infection 
(Stadtfeld et al., 2008), repeated plasmid transfection (Okita et al., 2008), 
mRNA transfection, (Warren et al., 2010) and cell permeable recombinant 
reprogramming factor proteins (Kim et al., 2009a). While these transient 
delivery methods have had some success, their efficiencies are poor when 
compared to the retroviral vectors. For example, the Epstein-Barr virus 
latency associated nuclear antigen (EBNA-1) has previously been used in a 
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plasmid-based episomal system to successfully reprogramme fibroblasts. 
However, this study chose to use inefficient plasmid transfection to deliver 
the reprogramming factors rather than utilising the natural infectivity of the 
virus. Furthermore, EBNA-1 has been shown to immortalise B cells in vitro, 
thus questioning the safety of this method (Young et al., 1988). 
Recently, certain small molecules have been identified which are capable of 
replacing the activities of the reprogramming factors. Successful 
reprogramming of keratinocytes has been achieved with a cocktail of small 
molecule inhibitors and Oct4 expression (Zhu et al., 2010). As yet however, 
iPSCs have not been generated using small molecules alone; therefore 
there is still the requirement for the delivery of exogenous Oct4.   
The aim of this chapter was to generate reprogramming vectors capable of 
efficient delivery and prolonged transgene expression without integration 
and disruption of normal host cell gene function using Herpesvirus saimiri 
(HVS) based viral vectors. HVS is a prototype member of the gamma type II 
herpesvirinae and is capable of maintaining its genome as a non-integrated 
episome in host cells. This episome is tethered to host cell chromosomes by 
the virally encoded protein ORF73, which interacts with the abundant 
chromosome associated protein, MeCP2 (Calderwood et al., 2004; Griffiths 
& Whitehouse, 2007), thus allowing long term persistence in a dividing cell 
population. 
All HVS-based vectors are based on the HVS-A11 strain, which contains a 
natural deletion removing the transforming gene Tyrosine Kinase Interacting 
Protein (Tip) (Biesinger et al., 1990). The biosafety of these viral vectors is 
further improved by deleting the STP coding region (Griffiths et al., 2006). 
Perhaps of particular interest in iPSC technology is the ability of HVS to 
persist and provide prolonged transgene expression in differentiating cell 
populations. This was demonstrated by Stevenson and colleagues, whereby 
Mouse Embryonic Stem Cells (mESCs) were infected with a HVS-based 
vector encoding a GFP reporter gene. These mESCs were then 
differentiated to terminally differentiated macrophages which remained GFP 
positive (Stevenson et al., 2000a). Therefore, HVS could potentially be 
capable of maintaining its episome in reprogramming cells without transgene 
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silencing occurring. Furthermore, HVS has a naturally broad tropism and has 
been demonstrated to be capable of infecting both a wide variety of primary 
tissues and cultures (Doody et al., 2005; Simmer et al., 1991; Smith et al., 
2005; Stevenson et al., 1999) and also cancer cells (Smith et al., 2004; 
Smith et al., 2001). These properties make HVS an attractive viral vector for 
use in reprogramming both primary and cancer cells to a stem cell-like state.  
In order to produce HVS-based vectors expressing Oct4, Sox2, Lin28 and 
Nanog, a multistep cloning strategy was performed as detailed in Figure 3.1. 
This chapter details each stage of this cloning procedure and the generation 
of infectious HVS-iPSC virus particles. 
 
Figure 3.1: Overview of the Generation of the HVS-based iPSC vector constructs 
The iPSC coding sequences were firstly PCR amplified to incorporate AgeI/EcoRI restriction sites, enabling the 
fragments to be cloned into the empty pEGFP-C1 vectors to create the pCMV-iPSC constructs. These constructs 
contain a specific iPSC gene under the control of the CMV promoter. Each CMV-iPSC expression cassette was 
then PCR amplified to incorporate NotI/MluI restriction sites, allowing them to be cloned into the pShuttle Link 1 
vector. Finally each expression cassette was cloned into the HVS-BAC-GFP at the I-PpoI sites. 
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3.2  Stage 2: Construction of pCMV-iPSC constructs 
To provide strong expression of each of the transgenes, the first stage of the 
cloning strategy involved placing each gene under the control of the human 
Cytomegalovirus (CMV) promoter.  To achieve this, the EGFP cloning 
vector, pEGFP-C1 was utilised. This plasmid contains the EGFP coding 
sequence under the control of a CMV promoter and SV40 polyadenylation 
signal. The cloning strategy devised removed the EGFP coding region by 
AgeI/EcoRI restriction digestion and replaced this with the coding region of 
the iPSC genes, yielding the expression constructs, pCMV-iPSC.  As no 
suitable restriction sites were present flanking the coding sequences for the 
reprogramming genes in their parent vectors, PCR amplification of the genes 
was required to incorporate AgeI/EcoRI restriction sites flanking the gene of 
interest from the parental plasmid, pSin-E2F-iPSC-Pur. 
 
Figure 3.2: PCR amplification of iPSC genes.  
Sox2, Oct4, Lin28 and Nanog coding sequences were PCR amplified from each of parent vectors, pSin-E2F-iPSC-
Pur. AgeI and EcoRI restriction sites were incorporated at the 5‟ and 3‟ termini of the amplified fragments, 
respectively. Fragments of sizes 950 bp, 1,000 bp, 650 bp and 900 bp were produced for Sox2, Oct4, Lin28 and 
Nanog respectively. 
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Figure 3.2 shows PCR fragments were amplified comprising 950 bp, 1,000 
bp, 650 bp and 900 bp for Sox2, Oct4, Lin28 and Nanog, respectively. This 
indicated the successful amplification of the full length coding sequences for 
each gene. These PCR fragments were then sub-cloned into the pre-
digested pEGFP-C1 vector via the PCR cloning vector, pCR®-Blunt TOPO II, 
by AgeI/EcoRI restriction digestion. Figure 3.3 shows restriction digestion 
with AgeI/EcoRI to screen for the presence of the iPSC coding sequence 
inserts in picked colonies. Results are shown for pCMV-Oct4 as an example 
and similar results were produced for Sox2, Lin28 and Nanog (data not 
shown). 
Inserts of 1 kb were produced after AgeI/EcoRI restriction digestion, 
indicating the presence of the Oct4 insert. Sequencing analysis was 
performed to confirm the integrity of the cloned inserts in successful colonies 
(data not shown). 
 
 
 
 
 
 
 
 
Figure 3.3: AgeI/EcoRI 
restriction digestion of 
pCMV-Oct4 colonies 
DNA was extracted from 
surviving colonies and 
screened by AgeI/EcoRI 
restriction digestion. The 
presence of a 1 kb fragment 
demonstrates the presence of 
the Oct4 coding sequence has 
been successfully cloned into 
the empty pEGFP-C1 vector. 
Similar screening was 
performed for each of the 
pCMV-iPSC constructs. 
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3.3  Expression of iPSC transgenes from pCMV-iPSC 
constructs 
Prior to producing recombinant HVS-based vectors, it was first necessary to 
confirm each pCMV-iPSC expression construct was capable of expressing 
their relative reprogramming factors. Transgene expression analysis was 
performed using RT-PCR and western blot analysis.  
HEK 293T cells were transfected with the control pEFGP-C1 or each pCMV-
iPSC construct. After 24 hours, RNA was isolated and reverse transcribed. 
Semi-quantitative RT-PCR was then performed and results showed the 
successful amplification of iPSC gene expression compared to the controls 
(Figure 3.4). Samples incubated without reverse transcriptase (-ve RT) were 
used to demonstrate no DNA contamination was present.  
Further confirmation that the pCMV-iPSC constructs were able to express 
their respective transgenes was provided by western blot analysis. Again, 
293T cells were transfected with each pCMV-iPSC construct, or the pEGFP-
C1 construct as a negative control. Cell lysates were then analysed by 
immunoblotting with specific antibodies to each iPSC protein. Figure 3.5 
shows expression of each iPSC protein, with bands detected at 
approximately 39 kDa, 34 kDa, 23 kDa, and 35 kDa for Oct4, Sox2, Lin28 
and Nanog respectively. These data therefore demonstrate that the pCMV-
iPSC constructs are capable of producing full length iPSC proteins.  
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Figure 3.4: RT-PCR Analysis of pCMV-iPSC gene expression in 293T cells 
Total RNA from transfected cells was extracted and reverse transcribed with Oligo(dT) primers. PCR was 
performed on the cDNA produced using primers specific for each iPSC transgene. Cells transfected with each 
pCMV-iPSC construct express their respective transgenes. Samples incubated without Reverse Transcriptase (-ve 
RT) controls were used to demonstrate the absence of DNA contamination. 
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Figure 3.5: Western Blot Analysis of pCMV-iPSC expression in 293T cells 
Whole cell lysates were extracted from transfected 293T cells and separated by SDS-PAGE followed by western 
blotting. Antibodies specific for each iPSC gene were used to detect protein expression. Expression of each iPSC 
gene is detected in transfected 293T cells, and is absent in cells transfected with the negative control plasmid 
(pEGFP-C1). 
 
3.4  Stage 3: pShuttle-iPSC construct generation 
Cloning of the CMV-iPSC expression cassettes into the HVS-BAC genome 
firstly required each iPSC factor to be sub-cloned into the shuttle vector, 
pShuttle Link1 (White et al., 2003). This construct contains a multiple cloning 
site and kanamycin resistance gene flanked by two I-PpoI sites. I-PpoI is an 
extremely infrequent restriction site, with no naturally occurring restriction 
sites in the HVS genome. Firstly, the CMV-iPSC cassette, incorporating the 
CMV promoter, iPSC coding region and SV40 poly adenylation signal were 
PCR amplified to incorporate NotI and MluI restriction sites at the 5‟ and 3‟ 
ends of the expression cassette, respectively. The PCR fragments 
generated were 2 kb for CMV-Oct4, 1.85 kb for CMV-Sox2, 1.5 kb for CMV-
Lin28 and 1.8 kb for CMV-Nanog (Figure 3.6). These sizes indicate 
successful amplification of each transgene expression cassette, with the 500 
bp CMV promoter and the 50 bp SV40 poly adenylation signal. Each 
amplified PCR fragment was then cloned into pCR®-Blunt TOPO II prior to 
cloning into pShuttle Link1 via NotI/MluI restriction digest. Colonies were 
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then screened for the presence of the CMV-iPSC inserts by NotI/MluI 
restriction digestion. As an example, Figure 3.7 shows pShuttle-Oct4 
colonies digested with NotI/MluI with the 2 kb CMV-Oct4 insert in all colonies 
except colony 6. Sequencing analysis was performed on successful clones 
to confirm the integrity of the cloned insert (data not shown). Similar results 
were observed for Sox2, Lin28 and Nanog (data not shown). 
 
 
 
Figure 3.6: PCR amplification of the CMV-iPSC expression cassettes 
The iPSC expression cassettes were PCR amplified using 1 μg of each pCMV-iPSC template. Clean PCR 
fragments were produced of sizes 2 kb, 1.85 kb, 1.5 kb and 1.8 kb for the CMV-Oct4, CMV-Sox2, CMV-Lin28 and 
CMV-Nanog expression cassettes, respectively. 
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Figure 3.7: NotI/MluI restriction digestion of pShuttle-iPSC colonies 
DNA was extracted from picked colonies and screened for correct inserts by NotI/MluI restriction digestion. 
Successful colonies were identified by presence of the CMV-Oct4 insert, shown by a 2 kb band. 
 
3.5  Stage 4: Generation of HVS-BAC-iPSC recombinant 
virus 
To insert the iPSC expression cassettes into the HVS genome, the HVS-
BAC system was utilised (White et al., 2003). The HVS-BAC has been 
engineered to contain a single I-PpoI restriction site, which enables simple 
and fast cloning of desired genes into the HVS genome. The presence of a 
chloramphenicol resistance marker allows for easy selection of successful 
clones and either a GFP or RFP mammalian expression cassette enables 
quick identification of cells which have successfully been infected with HVS-
BAC recombinant virus. 
To insert the iPSC expression construct, the HVS-BAC-GFP was linearised 
with I-PpoI followed by drop dialysis to purify the BAC DNA. pShuttle-iPSC 
constructs were also digested with I-PpoI which produced a fragment 
containing the expression cassette containing the iPSC gene of interest 
along with the kanamycin resistance marker of the pShuttle-Link 1 plasmid. 
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This kanamycin resistance gene allows selection of successful HVS-BAC-
iPSC colonies under dual selection with kanamycin and chloramphenicol. 
DNA was extracted from successful colonies by low-copy number mini-
preparations prior to screening by I-PpoI restriction digest and Pulsed-Field 
Gel Electrophoresis for the presence of the CMV-iPSC insert. Figure 3.8 
shows mini-prepped analysis of putative HVS-Oct4 recombinants, with 
similar results obtained for Sox2, Lin28 and Nanog (data not shown). This 
analysis yielded fragments of sizes 3.3 kb, 3.15 kb, 2.85 kb and 3.1 kb for 
HVS-Oct4, HVS-Sox2, HVS-Lin28 and HVS-Nanog, respectively. These 
fragment sizes correspond to the size of the CMV-iPSC fragments and the 
remaining pShuttle Link 1 backbone containing the kanamycin resistance 
gene and indicate the successful cloning of each CMV-iPSC cassette into 
the HVS-BAC-GFP genome. The integrity of each insert was confirmed by 
sequencing analysis (data not shown).  
After confirming the integrity of the cloned inserts, each HVS-BAC-iPSC 
construct was isolated by low-copy number maxi-preparations of the DNA, 
and their purity confirmed by Pulsed-Field Gel Electrophoresis (Figure 3.9).  
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Figure 3.8: Pulsed-Field Gel Electrophoresis of HVS-BAC-Oct colony screening 
DNA was extracted from colonies grown under kanamycin and chloramphenicol selection by low-copy number 
mini-preps. I-PpoI restriction digests were performed to remove the CMV-Oct4 insert from the HVS-BAC genome, 
thus enabling identification successful colonies. All colonies contained a 3 kb insert indicating the presence of the 
cloned CMV-Oct4 expression cassette. 
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Figure 3.9: Pulse-Field Gel Electrophoresis of the HVS-BAC-iPSC constructs 
Low-copy number maxi-preparations of DNA were performed to purify each HVS-BAC-iPSC construct. Each 
construct was digested with I-PpoI and analysed by PFG electrophoresis to demonstrate the presence of each 
cloned CMV-iPSC insert and to verify the purity and integrity of each HVS-BAC-iPSC construct. The HVS-BAC can 
be seen as a 175 kb band, while the CMV-iPSC inserts are seen as bands of sizes 3.3 kb, 3.15 kb, 2.85 kb and 3.1 
kb for CMV-Oct4, CMV-Sox2, CMV-Lin28 and CMV-Nanog respectively. 
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3.6  Generation of recombinant HVS vectors expressing 
iPSC transgenes  
Infectious HVS-iPSC virus particles were produced by transfecting each 
HVS-BAC-iPSC construct into the permissive Owl Monkey Kidney (OMK) 
cell line and culturing in DMEM with 5% foetal calf serum (FCS). Two weeks 
post-transfection, plaques started to form in the OMK cell sheet with classic 
herpesvirus comet-tail appearance. The presence of the virus in these 
plaques was confirmed by the expression of the GFP marker gene in the 
infected cells surrounding the plaque (Figure 3.10). After 3 weeks, the cell 
sheet was completely lysed and viral supernatant could then be used to 
infect more OMK cells to produce higher titre virus stocks by standard 
protocols. 
 
 
 
 
Figure 3.10: Generation of the HVS-Oct4 virus stocks in Owl Monkey Kidney Cells 
OMK cells were transfected with each HVS-BAC-iPSC construct (HVS-BAC-Oct4 is shown here) and cells were 
cultured for 2-3 week weeks in DMEM 5% foetal bovine serum. GFP positive plaques were observed after 2 weeks 
in culture indicating the production of infectious HVS-iPSC particles. Image was taken at 50x magnification. 
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3.7  Expression of iPSC transgenes in the HVS-iPSC viral 
vectors 
Once high titre viral stocks had been produced (1x 107 GFP units/ml or 
higher) it was necessary to assess if these viral vectors were capable of 
transgene delivery and expression. To assess transgene expression in 
infected cells viral supernatants were used to infect 1x106 293T cells with an 
MOI of 1, and infected cells were harvested 48 hours post-infection. Cell 
lysates were then analysed by immunoblotting with antibodies specific for 
each transgene. Figure 3.11 shows expression of the transgenes 
demonstrated by the presence of bands of sizes 39, 23 and 34 kDa for Oct4, 
Lin28 and Nanog, respectively. However, no band was detected for Sox2, 
indicating the HVS-Sox2 virus was not expressing despite the confirmation 
of the integrity of the Sox2 insert and the CMV promoter and poly 
adenylation sequences of the expression cassette. Attempts to re-clone the 
HVS-Sox2 construct were unsuccessful. Therefore, cell lines that 
endogenously expressed Sox2 were selected for reprogramming efforts, as 
it had previously been demonstrated that these cells were capable of being 
reprogrammed without exogenous Sox2 (Kim et al., 2009b). 
 
 
Figure 3.11: Expression of HVS-iPSC 
viruses in infected 293T cells 
293T cells were infected with HVS viral stocks 
and total cell lysate extracted by RIPA lysis 48 
hours post-infection. Cell lysates were 
analysed by western blot following separation 
on SDS-PAGE. Expression is demonstrated for 
HVS-Oct4, HVS-Lin28 and HVS-Nanog. 
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3.8  Discussion 
In this chapter, HVS-based vectors were developed for the delivery of the 
reprogramming factors, Oct4, Sox2, Lin28 and Nanog. Initially, these genes 
were placed under the control of the CMV promoter which was chosen as it 
provides strong expression of transgenes in a wide variety of mammalian 
cell types. Furthermore, it is already commonly used in iPSC generation, 
indicating its suitability for vectors designed for iPSC technology and has 
previously been shown to be active in HVS-based vectors in a differentiation 
model (Stevenson et al., 2000a). 
Although the CMV promoter is eventually silenced, this is a useful trait in 
iPSC vectors as it has been demonstrated that removal of iPSC gene 
expression after successful reprogramming produced colonies which more 
closely resemble ESCs in their gene expression profiles and differentiation 
potential (Kim et al., 2009c; Soldner et al., 2009). Therefore, the CMV 
promoter seems an appropriate choice for these proof-of-principle 
investigations. Future work would ideally utilise tetracycline inducible 
expression systems (Forster et al., 1999; Gossen & Bujard, 1992a) to 
provide direct, tight controlled expression of the reprogramming transgenes. 
The potential of HVS as a gene delivery system for iPSC generation has 
already been highlighted by Stevenson et al. (Stevenson et al., 2000a) 
wherein mESCs were shown to be readily infected with HVS carrying a GFP 
reporter gene. Moreover, these HVS vectors were capable of maintaining 
GFP expression throughout differentiation of the mES cells into 
macrophages, whereas transgene silencing is commonly observed in 
retroviral vectors upon differentiation (Hotta & Ellis, 2008; Laker et al., 1998). 
Therefore, if HVS is capable of maintaining transgene expression through 
differentiation, the reverse could be applicable. This will enable more reliable 
determination of the optimal stoichiometry of reprogramming factors as the 
dynamic pattern of positional silencing observed for retroviral vectors 
(Ramunas et al., 2007) would not be affected using a HVS-based episomally 
maintained vector. Dynamic positional silencing causes varying expression 
levels of the reprogramming transgenes depending on the integration site of 
the retrovirus in the genome. This therefore alters the stoichiometry of the 
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various reprogramming factors. (Hotta & Ellis, 2008) Furthermore, the ability 
of HVS to persist as a non-integrating episome enables this virus to provide 
prolonged transgene expression without disrupting normal gene expression. 
This makes HVS a safer vector for reprogramming cells and will ensure the 
iPSC and iPC cells produced have less disrupted gene expression profiles. 
This chapter details a suitable cloning technique for the quick and efficient 
generation of HVS-iPSC vectors using the HVS-BAC-GFP genome. The 
HVS-BAC contains a single I-PpoI restriction site and bacterial replication 
elements which enables fast and efficient manipulation of the HVS genome 
to incorporate the reprogramming transgenes. Furthermore, the HVS-BAC 
also contains a hygromycin resistance gene and a GFP reporter gene. The 
GFP reporter gene allows visual identification of cells carrying the HVS 
episome, and the hygromycin resistance gene allows selection of infected 
cells without the need for cell sorting. Furthermore, the hygromycin 
resistance gene will ensure that cells grown under prolonged hygromycin 
selection will not lose the HVS episomes after repeated cell divisions. 
Figures 3.4, 3.5 and 3.11 demonstrate that each pCMV-iPSC construct and 
HVS-iPSC virus highly express their respective transgenes, with the 
exception of the HVS-Sox2 virus. This could present an issue in future iPSC 
reprogramming studies as Oct4 and Sox2 are the key regulators of 
reprogramming to pluripotency and are capable of regulating their own 
expression levels as well as many other pluripotency associated genes, 
including Nanog (Masui et al., 2007; Okumura-Nakanishi et al., 2005; Ovitt & 
Schöler, 1998). Human fibroblasts have even been successfully 
reprogrammed by only using Oct4 and Sox2 (Baron et al., 1997). However, 
Kim et al demonstrated that Oct4 alone is capable of reprogramming 
neuronal stem cells as these cells endogenously express Sox2 (Episkopou, 
2005; Kim et al., 2009b). Therefore, this issue can be circumvented by 
selecting cell lines that endogenously express Sox2 for reprogramming 
attempts.  
In summary, HVS possesses many attractive qualities as a vector for iPSC 
generation. As demonstrated in this chapter, a cloning strategy has been 
devised which utilises the HVS-BAC (White et al., 2003) to enable quick and 
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efficient generation of HVS-iPSC viruses. The efficacy of this cloning 
procedure is demonstrated by the production of HVS-iPSC constructs that 
are capable of delivering three out of the four reprogramming transgenes. 
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4  Generation of Induced iPCs from the Ewings Sarcoma 
A673 Cell Line ……………………………. 
4.1  Introduction 
iPSC technology potentially holds great promise for stem-cell based 
therapies. This has been demonstrated in pre-clinical studies for a variety of 
diseases, including neurodegenerative diseases. Specifically, iPSCs have 
been used in several pre-clinical trials for cell-based replacement therapies 
to treat Parkinson‟s disease (Hargus et al., 2010; Wernig et al., 2008), 
strokes (Chen et al., 2010), and spinal chord injuries (Tsuji et al., 2010).   
Furthermore, aside from their therapeutic potential, iPSCs provide an 
excellent model for the progression of neurodegenerative diseases. 
Currently, most studies of neurodegenerative diseases are performed on 
tissue from dead patients or animal models as the availability of live brain 
tissue from humans is limited. These models are less than ideal, as tissues 
from dead patients only represent the end stages of the disease and animal 
models cannot compensate for variances caused by species, age, patient 
specificity and the complexities of the human brain.  
There have already been a number of reports detailing the generation of 
patient specific iPSCs from patients suffering from a variety of genetic 
neurodegenerative diseases including Parkinson‟s disease (Soldner et al., 
2009), Huntington‟s disease (Park et al., 2008), Alzheimer‟s disease (Israel 
et al., 2012) and Spinal Muscular Atrophy (Ebert et al., 2009) to name but a 
few. These disease-specific derived iPSCs enable further detailed study of 
the development and progression of these diseases, as well as providing 
appropriate models for drug-screens. 
Another interesting application of iPSC technology for disease modelling 
includes reprogramming somatic cancer cells to induced pluripotent cancer 
stem cells (iPCs). This has already been achieved for chronic myeloid 
leukaemia (Hu et al., 2011), colorectal cancer (Miyoshi et al., 2010),  and 
hepatocellular carcinoma (Miyoshi et al., 2010). Cancer Stem Cells (CSCs) 
are defined by their ability to seed tumours in animal hosts, to self renew and 
to produce differentiated progeny. They were originally identified in 
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leukaemia (Lapidot et al., 1994) and their presence has also been 
demonstrated in many solid tumours including breast, brain, pancreatic, 
colon, prostate, and various others (Al-Hajj et al., 2003; Collins et al., 2005; 
Li et al., 2007; O'Brien et al., 2007; Ricci-Vitiani et al., 2007; Singh et al., 
2004).These cells are more resistant to chemotherapy than other cells within 
the tumour (Dean et al., 2005). As a result, chemotherapy treatments are 
believed to remove the bulk of tumours, but leave the CSCs free to migrate 
into the lymph system. This, combined with their tumour seeding capabilities, 
has implicated cancer stem cells as having roles in metastasis and 
secondary cancers.  
Despite their important role in cancer progression and metastasis, little is 
known about CSCs due to the difficulties in their identification and isolation. 
Therefore, utilising iPSC technology to reprogram cancer cells into these 
rare cancer stem cells would provide a source of easily obtainable, pure 
cells to use for further studies. 
This chapter will focus on investigating the potential of the HVS-iPSC virus 
gene delivery vectors for reprogramming both normal somatic neural stem 
cells and somatic cancer cells to a stem cell-like state. 
4.2 Neural Stem Cells 
4.2.1  Isolation of primary mouse Neural Stem Cells 
iPSC technology was initially designed to reprogramme primary somatic 
cells to an embryonic stem-cell like state; therefore the HVS-based vectors 
generated would ideally be tested for their ability to reprogramme primary 
somatic cells, such as fibroblasts. However, as discussed in Chapter 3, the 
HVS-Sox2 virus was incapable of expressing the Sox2 transgene which 
made reprogramming these cells unfeasible. Alternatively however, Kim et 
al. demonstrated it was possible to reprogramme Neural Stem Cells (NSCs) 
to iPSC cells without the need for exogenous Sox2 expression (Kim et al., 
2009b) as these cells endogenously express Sox2 (Episkopou, 2005). 
Therefore initial attempts were made to reprogramme Neural Stem Cells 
(NSCs) using the HVS-based vectors. 
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In collaboration with Dr. Ian Wood (Faculty of Biological Sciences), murine 
brains were harvested and cultured for four weeks according to the protocol 
described by Kim et al. (Kim et al., 2009c).  Attempts were then made to 
isolate live neurospheres from other neural cells by harvesting the 
supernatant every 7 days and centrifuging at 100 rcf to pellet the 
neurospheres. The supernatant was then discarded and the neurospheres 
gently resuspended in fresh NSC medium (detailed in (Kim et al., 2009c)). 
Pictures were taken of the cells every 2-4 days (Figure 4.1). 
As Figure 4.1 demonstrates, the repeated purification stages produced fewer 
and fewer floating spheroids which did not increase in size. As such it was 
concluded that the cells were dying under prolonged culture and the floating 
spheroids were either dead cells or cellular debris. Therefore an alternative 
source of NSCs was kindly provided by Dr Ian Wood (University of Leeds) 
(see section 2.4.1). 
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Figure 4.1: Isolation of NSCs from mouse brains 
Whole murine brains were extracted and trypsinised before plating on 10 cm dishes in NSC medium. Over time 
extensive cell death was seen. Some spheroidal clumps of cells were observed, but these were poorly defined and 
resembled aggregated dead cells, and were unlike the regular, tightly formed morphology of neurospheres. All 
images were taken at 10 x magnification. 
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Figure 4.1 (continued): Isolation of NSCs from mouse brains. 
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4.2.2  Characterisation of HVS Transduction in NSCs 
Although HVS has previously been demonstrated to have a naturally broad 
tropism (Simmer et al., 1991; Smith et al., 2005; Stevenson et al., 1999), to 
date, the transduction rate of NSCs with HVS has not been assessed. 
Therefore it was first necessary to ascertain how efficiently these cells could 
be infected with HVS. To this end, NSCs were infected with varying MOIs of 
HVS-GFP and the percentage of GFP expressing cells analysed using flow 
cytometry 24 hours post-infection (Figure 4.2a). 
Results indicated that HVS-GFP was able to infect NSCs with a high 
efficiency; with 70% of cells transduced using HVS-GFP at an MOI of 0.5, 
and 85% of cells transduced using an MOI of 1. These rates of transduction 
were higher than those observed for the permissive cell line, Owl Monkey 
Kidney (OMK) cells which demonstrated transduction rates of 70% using an 
MOI of 1.  
However, as Figure 4.2b demonstrates, HVS-GFP infection appeared to be 
toxic to the cells. An increase in cytotoxicity and resulting cell death was 
observed with increased MOI. Due to the cytotoxic effects observed and 
time constraints, it was decided to focus reprogramming efforts on 
generating iPCs from somatic cancer cells.  
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Figure 4.2: Transduction rate of Neural Stem Cells 
a) NSCs displayed good transduction rates, with 85% of the cells transduced upon infection with an MOI of 1. In 
comparison, the OMK permissive cell line demonstrated lower transduction rates, with 70% GFP positive cells. b) 
Extensive cytotoxicity and cell death were observed in NSCs upon transduction with HVS-GFP. All images were 
taken at 20 x magnification. 
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4.3  Characterisation of Three Ewings Sarcoma Family 
Tumour Cell Lines …………………………….. 
The second focus of this chapter was to utilise the HVS-iPSC vectors to 
reprogramme somatic cancer cells to tumour-initiating stem cell-like cells. 
Once again, cells that endogenously expressed Sox2 were required for 
reprogramming efforts due to the lack of a functional HVS-Sox2 delivery 
vector. Ewings Sarcoma Family Tumour (ESFT) cells were selected as they 
have previously been shown to endogenously express Sox2 (Riggi et al., 
2010). Furthermore, HVS has already been demonstrated to efficiently infect 
ESFT cell lines (Smith et al., 2004). 
ESFTs are the second most frequent malignant bone tumours in 
adolescents, with a peak incidence between the ages 14 and 20 (Soldner et 
al., 2009). Prognosis for affected patients is poor with, survival rates of <50% 
at 5 years and <25% after metastasis has occurred. Recently ESFT cancer 
stem cells have been identified comprising of a small population of CD133+ 
cells within the tumour. These CSCs account for between 4%-8% of the 
ESFT cell population in primary tumours and are capable of forming 
spheroids in vitro and forming new tumours in vivo (Suvà  et al., 2009). 
However, due to their low frequency in these tumours and difficulties in their 
isolation, there is little information on the exact role of ESFT CSCs in cancer 
formation and progression. Moreover, the high mortality rates associated 
with ESFT metastasis and the implications of CSC involvement in 
metastasis, chemotherapy resistance, and radiotherapy resistance make 
ESFT CSCs of great interest, thereby requiring further study. As such, 
utilising iPSC technology to reprogramme somatic ESFT cells to induced 
Cancer Stem Cells (iPCs) would enable the generation of increased 
numbers of these rare cells, thereby allowing further study into their 
migration and differentiation potential.  
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4.3.1  ESFT Cells Endogenously Express Sox2 
To assess if the ESFT cell lines endogenously expressed Sox2, quantitative 
real-time PCR (qPCR) was performed on whole cell RNA extracted from the 
ESFT cell lines; A673, TC32 and TTC466, and Sox2 levels were analysed in 
comparison to iPSC cells which were used as a reference standard.                                                                                                                                                                                                                                                                                                                                         
Figure 4.3 demonstrates that all three ESFT cell lines endogenously express 
Sox2, with A673 and TC43 cells expressing 20% of the Sox2 levels 
observed in the iPSC controls and TTC466 cells showing 40%. Therefore 
ESFT cells were suitable for reprogramming efforts using the HVS-iPSC viral 
vectors. 
 
Figure 4.3: Endogenous Expression of Sox2 in the three ESFT cell lines relative to iPSCs 
Expression of Sox2 was measured as a percentage of iPSC control cell expression. All three ESFT cell lines 
expressed Sox2, with A673 and TC32 expressing Sox2 at 20% of the levels observed in iPSCs, and TTC466 cells 
expressing 40% of iPSC Sox2 expression levels. 
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4.3.2  Transduction rates of EWS cell lines 
HVS has previously been demonstrated to efficiently infect multicellular 
spheroids formed from two ESFT cell lines, A673 and SK-ES, supporting 
evidence that HVS can infect ESFT cell lines (Smith et al., 2005). To confirm 
efficient transduction, a range of ESFT cell lines were infected with varying 
MOIs of HVS-GFP virus and the percentage of GFP expressing cells were 
analysed using flow cytometry analysis at 24 hours post-infection. 
Figure 4.4a demonstrates that the A673 ESFT cell line exhibited the highest 
transduction rates, with 87% of the cell population becoming GFP positive 
upon infection with HVS-GFP at an MOI of 1. This transduction rate was 
much higher than the other ESFT cell lines, TC32 (32%), and TTC466 
(38%), and the permissive cell line, OMK (70%). Due to the higher rates of 
transduction observed in the A673 cell line, these cells were selected for 
further reprogramming efforts. Moreover, although a small amount of cell 
death was observed upon infecting ESFT cells with HVS-GFP at an MOI of 
1, the majority of cells appeared to be viable after HVS-GFP infection 
(Figure 4.4b). 
4.4  Reprogramming A673 using HVS-Oct4 
Kim et al. demonstrated it was possible to reprogramme somatic cells that 
endogenously expressed Sox2 using only exogenous Oct4 (Kim et al., 
2009b). Therefore, HVS-Oct4 alone was used in initial reprogramming 
attempts performed on A673 cells. Cells of passage 24 – 30 were used to 
reduce the variance between cells caused by chromosomal instability and 
aneuploidy. To this end, 1x106 cells were infected with either mock, control 
HVS-GFP or HVS-Oct4 at varying MOIs between 0.06-1.0. At 4 days post-
infection (p.i.) the cells were transferred to 10 cm dishes to allow them to 
expand and form colonies. 
Results demonstrated that the optimum MOI of HVS-Oct4 was 0.5, as lower 
MOIs resulted in fewer colonies being formed, whereas some cytotoxicity 
was observed with an MOI of 1 (data not shown). Figure 4.5 shows 
representative colonies generated upon infection with HVS-Oct4 at an MOI  
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Figure 4.4: Transduction rate of three ESFT cell lines; A673, TC32 and TTC466. 
A) TC32 and TTC466 cells displayed poor transduction rates, with a maximum of 32% and 38% of GFP positive 
cells upon infection with HVS-GFP at an MOI of 1. However, A673 cells displayed excellent transduction rates, with 
87% of cells becoming GFP-positive after infecting with the same MOI of HVS-GFP. OMK cells were used as a 
control, and displayed a 67% transduction rate with an MOI of 1. B) Some cell death was observed in cells infected 
with HVS-GFP at an MOI of 1, but most of the cells remained viable. All images were taken at 20 x magnification. 
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of 0.5. Colonies possessing a tightly packed, spheroidal morphology, clearly 
distinct from the surrounding A673 cells, were observed 18 days p.i. on 
10cm Primaria dishes. In contrast, no colonies were formed from mock or 
HVS-GFP infected cells.  
The colonies were then assessed for their ability to grow in conditions which 
allow feeder cell-independent growth of stem cells. At day 20 p.i., the 
colonies were transferred to 6 well plates, pre-coated in hESC qualified 
Matrigel, and cultured in medium consisting of ½ DMEM, ½ mTeSR and 5% 
serum to allow the cells to adjust to the mTeSR medium. At day 21 p.i. (1 
day after transferring to feeder-free stem cell culture conditions), results 
showed that the colonies were still viable and retained their densely packed 
spheroidal morphology. However, prolonged culturing in stem cell culture 
conditions (day 24 and 26 p.i., Figure 4.5) caused the colonies to deform, 
with cells growing out from the colony, and extensive cell death being 
observed. Interestingly, the uninfected and HVS-GFP infected control cells 
also failed to thrive under these culture conditions. 
4.5  Second reprogramming attempt using A673 cells 
The deformation observed in the colonies arising from HVS-Oct4 infected 
cells could indicate that HVS-Oct4 alone is not sufficient to reprogramme 
A673 cells, and that additional iPSC factors are required. Therefore, a 
second reprogramming attempt was undertaken, whereby A673 cells were 
infected with HVS-Oct4 virus in combination with either HVS-Lin28 (OL), 
HVS-Nanog (ON), or all three viruses (OLN). Cells were infected and 
cultured as described in Figure 4.6 and colonies possessing the same tightly 
packed spheroidal appearance were once again observed after 18-19 days 
p.i. (Figure 4.7). Interestingly, some of the colonies generated from the OL 
combination appeared to lose GFP expression despite being cultured under 
hygromycin selection, indicating silencing of the reporter GFP gene.  
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Figure 4.5: Generation of A673-iPC colonies upon transduction with HVS-Oct4. 
Colonies were observed on 10 cm Primaria dishes 18 days p.i. These colonies were then transferred to feeder-free 
stem cell culture conditions after 21 days p.i. However, after prolonged culture in these conditions the colonies 
deformed and extensive cell death was observed. This cell death was also observed in HVS-GFP and uninfected 
A673 cultured in these conditions. 
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Figure 4.5 (continued): Generation of A673-iPC colonies upon transduction with HVS-Oct4. 
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Figure 4.5 (continued): Generation of A673-iPC colonies upon transduction with HVS-Oct4. 
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Figure 4.5 (continued): Generation of A673-iPC colonies upon transduction with HVS-Oct4. 
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As previously, the colonies were transferred onto Matrigel coated 24 well 
dishes by gently washing off the colonies using DPBS, and cultured in 
feeder-free stem cell culture conditions. After 1 day in these culture 
conditions (day 22 p.i.), colonies derived from all three virus combinations 
were viable, with ON and OLN colonies possessing the most tightly formed 
colonies (Figure 4.8). The colonies were expanded until they were large 
enough to be picked onto individual wells of a Matrigel coated 24-well plate 
(day 24 p.i.). The OL combination produced 6 viable colonies after picking, 
with ON and OLN producing 3 and 2 colonies respectively. However, the OL 
colonies possessed poorly defined edges. In contrast, ON and OLN colonies 
displayed more densely packed spheroidal morphologies. Figure 4.9 shows 
the colonies 1 day after being picked (day 25 p.i.). 
As Figure 4.10 demonstrates, after prolonged culture in feeder-free stem cell 
culture conditions several colonies from each virus combination condition 
deformed, and extensive cell death was observed for the cells growing out 
from these colonies. This is similar to the deformation of colonies generated 
upon infection with HVS-Oct4 alone (Figure 4.5). However, the remaining 
viable colonies, after also initially shrinking in size, stabilised after 7-9 days 
on Matrigel.  
After 38 days p.i, 4 colonies remained, which were named Colony 1 (ON), 
Colony 2 (OL) Colony 3 (OL) and Colony 4 (OLN) (Figure 4.11). Colonies 2, 
3 and 4 were viable in feeder-free stem cell culture conditions, and were 
therefore expanded for further analysis. Colony 1, however, appeared much 
smaller and possessed poorly defined edges. Furthermore, certain cells 
within Colony 1 appeared to be blebbing, indicative of apoptosis, and 
attempts to expand this colony were unsuccessful.  
In contrast, Colonies 2, 3 and 4 all possessed densely packed morphologies 
and phase-bright characteristics, although Colony 3 contained a dark centre. 
Colonies 2 and 3 (OL) also possessed well defined edges, although the 
edges of Colony 4 were slightly less well defined, with cells growing out from 
the central colony mass. Interestingly, both colonies from the OL condition, 
(Colonies 2 and 3) had significantly reduced GFP expression, which was not 
observed for Colony 4 (OLN).  
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Figure 4.6: Overview of A673-iPC colony generation 
Cells were infected with an MOI of 0.5 of each virus and viral supernatants were removed after 24 hours. After 4 
days p.i., the cells were transferred to 10 cm dishes and cultured in DMEM with 10% FCS. Medium was replaced 
every 2 days until the emergence of colonies at day 18-19 p.i. After a further 2 days in DMEM 10% FCS, the cells 
were transferred to Matrigel and cultured for 1 day in medium consisting of a 1:1 mix of DMEM and mTeSR, with 
5% FCS before changing the medium to full mTeSR. When colonies were of a sufficient size, they were picked 
individually to fresh Matrigel. At day 38-40 p.i., the colonies were large enough to be split and further expanded. 
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Figure 4.7: A673-iPC Colonies at day 19 post-infection on Primaria 10 cm dishes 
After 19 days post-infection, colonies appeared which possessed densely packed morphologies with clearly 
defined edges. This morphology was distinct from that of the surrounding A673 cells. No such colonies were 
observed in uninfected and HVS-GFP transduced A673 cells. 
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Figure 4.7 (continued): A673-iPC Colonies at day 19 post-infection on Primaria 10 cm dishes. 
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Figure 4.8: A673-iPC colonies at day 22 post-infection; 1 day on Matrigel. 
Colonies were imaged 1 day after transferring onto Matrigel coated plates. Uninfected cells were trypsinised prior 
to transfer onto Matrigel coated plates. Colonies from the ON and OLN conditions appeared to have densely 
packed spheroidal morphologies, but colonies from the OL condition appeared to be have less defined edges. 
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Figure 4.8 (continued): A673-iPC colonies at day 22 post-infection; 1 day on Matrigel. 
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Figure 4.9: Individually picked A673-iPC at day 25 post-infection; 4 days on Matrigel, 1 day after picking. 
OL and OLN colonies retain their densely packed, spheroidal morphologies, with few cells growing out from the 
colony. ON colonies, however, are less well formed with more cells growing out from the colony. 
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Figure 4.9 (continued): Individually picked A673-iPC at day 25 post-infection; 4 days on Matrigel, 1 day 
after picking. 
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Figure 4.9 (continued): Individually picked A673-iPC at day 25 post-infection; 4 days on Matrigel, 1 day 
after picking. 
 
Chapter 4: Generation of A673-iPC Colonies 
132 
 
 
Figure 4.10: A673-iPC colonies at day 28; 7 days on Matrigel. 
Many of the picked A673-iPC colonies deformed after picking. The remaining colonies reduced in size after being 
picked and their edges became less defined. OL produced the largest number of viable colonies, with 6 colonies. 
ON and OLN both produced a single viable colony each. 
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Figure 4.10 (continued): A673-iPC colonies at day 28; 7 days on Matrigel. 
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Figure 4.11: Surviving colonies 38 days post-infection (17 days on Matrigel). 
Uninfected and HVS-GFP infected A673 cells did not survive after 17 days on Matrigel. Four colonies survived, 
although Colony 1 (ON) could not be expanded, and cells within this colony appeared to be apoptosing. Colonies 2, 
3 and 4 produced densely packed, phase-bright colonies, with clearly defined edges. However, Colony 4 had some 
cells outgrowing from the central cell mass. Colony 3 also appeared to have a dark centre under phase-contrast. 
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Figure 4.11 (continued): Surviving colonies 38 days post-infection (17 days on Matrigel) 
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4.6  Optimising Reprogramming Efficiency in A673 
A key interest in iPSC technology is to efficiently reprogramme cells using as 
few exogenous reprogramming factors as possible. As many of the 
pathways involved in pluripotency are also associated with oncogenesis, it is 
plausible to assume that A673 cells also express some of the genes 
associated with pluripotency. Evidence from Figure 4.3 has already 
demonstrated that A673 cells express Sox2. In addition, the clearly marked 
differences in colony morphology and survival rates observed in section 4.5 
indicate that the different stoichiometries of the pluripotency genes had 
varying effects on reprogramming efficiency of A673 cells. Therefore, the 
optimum combination of HVS-iPSC viral vectors required for efficient 
generation of A673-iPC colonies was determined by infecting A673 cells with 
various combinations of each of the HVS-iPSC viruses, as shown in Table 
4.1. HVS-GFP virus used to ensure each infection condition had the same 
total MOI of 1.5. Low MOIs were used due to the cytotoxicity issues 
observed for previous reprogramming attempts, but hygromycin selection 
ensured that all cells cultured contained HVS episome. The cells were 
cultured on Primaria 10cm dishes, and the resulting colonies were counted 
after 19 days p.i. 
 
Virus combination   MOI of individual viruses 
  HVS-GFP HVS-Oct4 HVS-Lin28 HVS-Nanog 
Uninfected 0 0 0 0 
HVS-GFP 1.5 0 0 0 
O 1 0.5 0 0 
L 1 0 0.5 0 
N 1 0 0 0.5 
OL 0.5 0.5 0.5 0 
ON 0.5 0.5 0 0.5 
LN 0.5 0 0.5 0.5 
OLN 0 0.5 0.5 0.5 
 
 
Table 4.1: MOIs of each HVS-iPSC virus used to determine the optimum reprogramming virus combination 
An MOI of 0.5 of each HVS-iPSC virus was used with cells ultimately infected with a total MOI of 1.5. HVS-iPSC 
viruses were used alone or in various combinations, with HVS-GFP co-infected to ensure the total MOI used to 
transduce the cells remained constant.  
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Figure 4.12: Morphology of counted colonies 
Colonies that possessed densely packed, spheroidal morphologies with well defined edges were counted. Cells 
that were roughly clustered, with poorly defined edges to the clusters were identified as overgrown A673 cells, and 
were not included in the colony count. The examples shown here are a counted OLN colony and a HVS-GFP 
clustered cell mass. 
 
Virus Combination No. of Colonies 
Uninfected 0 
HVS-GFP 0 
O 8 
L 6 
N 7 
OL 23 
ON 12 
LN 6 
OLN 29 
 
 
Table 4.2: Number of counted colonies for each virus combination 
Only overgrown clusters of cells were observed in the Uninfected and HVS-GFP infected cells. The greatest 
numbers of colonies were observed for the cells infected with the OLN and OL virus combinations, with 29 and 23 
colonies counted, respectively. ON produced 12 colonies, and low numbers of colonies were also observed for O, 
L, N and LN.  
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Figure 4.12 shows representative morphologies of the colonies which were 
included in the colony count. They have a tightly packed, regular spheroidal 
appearance with clearly defined edges and the cells within are small with 
scant cytoplasm. Cells infected with HVS-GFP virus also produced clusters 
of cells; however, these cells possess poorly defined edges with roughly 
clustered cells. This morphology was distinct from the colonies observed in 
A673 cells infected the HVS-iPSC viruses.  
Table 4.2 shows representative data of the number of colonies produced for 
each HVS-iPSC virus combination. The OLN and OL virus combinations 
produced the highest number of counted colonies with 29 and 23 colonies 
respectively. ON produced 12 colonies and fewer colonies were observed in 
O, L, N and LN infected cells.  
4.7  Discussion 
Due to the current limitations of iPSC-reprogramming vectors, the potential 
of HVS-based vectors was assessed. HVS is capable of providing prolonged 
transgene expression without integrating into the host genome. Therefore, 
this chapter aimed to assess the potential of HVS as a gene delivery system 
for reprogramming both NSCs to iPSCs and for the generation of ESFT 
iPCs. 
Firstly, HVS was assessed for its ability to infect NSCs, as efficient infection 
of target cells is essential for gene-delivery vectors. NSCs displayed good 
infectivity with HVS-GFP, however, extensive cell death was observed upon 
infection. This high level of cytotoxicity may be caused by the virus 
predominantly undergoing lytic replication in these cells. Although HVS 
mostly forms latent infections in human cells, Goodwin et al. demonstrated 
HVS was capable of latent persistence which could then be reactivated into 
lytic replication in the lung carcinoma cell line, A549 (Goodwin et al., 2001). 
Furthermore, HVS has been demonstrated to be capable of specific 
cytopathic infections in two pancreatic cell lines (Stevenson et al., 2000c). 
However, another, more likely explanation could be the virus-containing 
supernatant was responsible for the observed cytotoxicity. Viral 
supernatants are harvested directly from the permissive OMK cells after the 
cell sheet has been lysed and will therefore contain various cytokines 
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caused by the viral infection, which could induce apoptosis. To circumvent 
this issue, purified virus stock could be produced in the future. 
However, HVS may still have potential as a gene-delivery system in brain 
tissues as NSCs demonstrated very good infection rates with HVS-GFP. 
Furthermore, the biosafety of HVS-based vectors could be further improved 
by removing the two genes required for lytic replication, ORF50 and ORF57, 
and growing HVS particles in a permissive helper cell line stably transfected 
with constructs expressing these two genes. The resulting viruses would 
therefore only be capable of lytic replication in these stably transfected 
permissive helper cell lines. 
The second aim of this chapter was to reprogramme ESFT cells into a 
cancer stem cell-like state. to provide an abundant source of CSCs from 
various different cancers for further study. A673 cells were selected for 
reprogramming efforts in this study as they endogenously expressed Sox2, 
similarly to other ESFT cell lines (Figure 4.3) but displayed the highest rates 
of transduction (Figure 4.4a). Therefore A673 cells could be transduced 
efficiently and did not require a functional Sox2 expressing viral construct for 
successful reprogramming.  
Upon transducing cells with HVS-Oct4 alone, colonies were produced after 
19 days p.i. possessing morphologies which were distinct from the HVS-
GFP infected and uninfected control A673 cells.  These colonies possessed 
densely packed, clearly defined edges; morphologies similar to, but not 
identical, to those described for iPSCs, and had phase-bright centres. 
However, they were spheroidal, rather than flat circular colonies, which is the 
described morphology for iPSCs (data not shown). This could indicate that 
A673-iPC colonies are not true iPSCs. This is not unexpected as these cells 
were derived from cancer cell lines rather than primary somatic cells.  
Interestingly, these A673-iPC colonies failed to thrive in feeder-free stem cell 
culture conditions and deformed after 4-6 days in these culture conditions. 
This deformation and cell death may also indicate incomplete 
reprogramming, with the A673-iPC cells not sufficiently altered from their 
original somatic cell state to survive in these culture conditions. Incomplete 
reprogramming has already been observed upon Somatic Cell Nuclear 
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Transfer of nuclei from Embryonic Carcinoma cells with enucleated oocytes, 
where the resulting cells were demonstrated to be an intermediate between 
cancer cells and ESCs (Chang et al., 2010). Moreover, similar cell death 
was also reported by Miyoshi et al. during attempts to reprogramme a 
colorectal cell line, where 98% of cells transfected with reprogramming 
constructs failed to thrive (Miyoshi et al., 2010). 
Another possible explanation for the extensive cell death observed in the 
resulting A673-iPC colonies could be due to lytic replication of the HVS 
vectors. HVS was analysed for the presence of lytic replication in A673 cells 
by infecting with HVS-GFP at MOIs of 0.5 to 3 and although some cell death 
was observed at higher MOIs, HVS-GFP appeared to predominantly form 
latent stable infection in A673 cells (unpublished observation) However, it is 
possible that expression of reprogramming transgenes may be activating 
expression of lytic genes within the HVS-genome. qRT-PCR analysis to 
determine the levels of the lytic transcripts, ORF50 and ORF57, in addition 
to a late transcript such as the glycoprotein, ORF8, would indicate if lytic 
replication was occurring, and if whole, infectious virus particles were being 
produced within the A673-iPCs. 
Infection with different viral combinations produced colonies displaying 
morphologies identical to the initial reprogramming effort. Also similarly to 
the HVS-Oct4 induced A673-iPC colonies, some of these colonies deformed 
in prolonged feeder-free stem cell culture conditions. However, several 
colonies survived, indicating that combination of the HVS-iPSC viral vectors 
sufficiently increased the reprogramming efficiency to reprogramme the 
A673 cells past a critical point in the reprogramming process. Prolonged 
culture in these conditions demonstrated the colonies produced from the ON 
combination were the least stable, indicating this combination of HVS-iPSC 
viruses is not optimal for reprogramming A673 cells. In contrast, colonies 
from the OL and OLN infection combinations were viable after prolonged 
culture in mTeSR, with OL being the most efficient vector combination. From 
these data, it would be reasonable to assume that Nanog is dispensable for 
reprogramming in A673 cells. Indeed, cells reprogrammed without 
exogenous Nanog expression (OL) appeared to be the most efficiently 
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reprogrammed. Potentially, A673 cells may endogenously express Nanog; 
perhaps exogenous expression of this reprogramming factor would lead to 
unfavourable stoichiometries of the reprogramming factors, thereby reducing 
reprogramming efficiency. Because of this interesting observation, the 
optimal combination of the HVS-iPSC reprogramming vectors in A673 was 
determined by infecting cells with various combinations of all three HVS-
iPSC vectors.   
Reprogramming efficiency trials indicated that infection with all three HVS-
iPSC viruses (OLN) produced the most efficient reprogramming of A673 
cells, producing 29 colonies, with OL producing the second highest number 
of colonies. However, colonies produced from the OL vector combination 
had the highest survival rate during the second reprogramming attempt. This 
may indicate that, although the OLN combination produces the largest 
number of colonies, these colonies are less stable in feeder-free stem cell 
culture conditions, with colonies produced from the OL combination being 
reprogrammed further. Interestingly, colonies were also observed from cells 
infected with LN viruses or the L and N viruses individually. This may 
indicate a very low level of endogenous Oct4 expression in A673 cells, with 
reprogramming occurring upon the enhancement of Oct4 activity by one or 
more of the reprogramming factors.  
There are, however, certain limitations to this approach to measure 
reprogramming efficiencies. Firstly, cells were infected with low MOIs of 
each HVS-iPSC virus because of the cytotoxic effects observed upon 
transduction with HVS-GFP at an MOI of 1. This means that ultimately, a 
maximum of 70% of the cells were infected with each individual HVS-iPSC 
virus. Therefore, the proportion of cells being transduced with all viruses 
when combinations of the viruses are used is likely to be very low. For 
example, upon infection with all three viruses, if 70% of the cells are infected 
with each virus, only around 35% of the cells will receive all three viruses.  
Hygromycin selection ensures that all the cells remaining carry a copy of the 
HVS episome, but it is impossible to say if the cells are infected with one or 
many of the HVS-iPSC viruses, and if so, which ones. Ideally, if the 
cytotoxicity issues identified could be circumvented, higher MOIs of each 
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HVS-iPSC viruses would be used to ensure as close to 100% of cells as 
possible were infected with each of the viruses. This would increase the 
likelihood of each cell containing all of the viruses. Furthermore, colony 
identification was further complicated by clusters of cells which did not 
resemble the colonies observed for the previous reprogramming attempts. 
Therefore, further investigations into reprogramming efficiencies would 
require identification of the colonies using alkaline phosphatase staining.   
In summary, these data suggest that further work is required to improve the 
biosafety of HVS-iPSC viruses, and purification of virus particles is essential 
to reduce the cytotoxicity observed upon infection with HVS-GFP in NSCs 
and ESFT cells. This would eventually enable further reprogramming 
attempts on NSCs using the HVS-iPSC viruses. Furthermore, the HVS-iPSC 
viral vectors were capable of eliciting some degree of reprogramming in the 
ESFT cell line, A673, with the generation of A673-iPC colonies. However, 
these colonies are not identical to true iPSC cells. Moreover, the various 
morphologies and survival rates observed for the A673-iPC colonies indicate 
that these colonies are at different stages of the reprogramming process, 
with some being insufficiently reprogrammed to survive. 
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5  Characterisation and Differentiation of A673-iPC 
Colonies 
5.1 Introduction 
Although tumours were originally believed to be monoclonal growths of cells, 
it has since been demonstrated that they comprise a heterogeneous 
population of cells, each with their own role in tumour progression and 
survival (Heppner, 1984). The tumour microenvironment is a complex 
system of many cell types, including endothelial cells, fibroblasts, smooth-
muscle cells, lymphocytes, granulocytes, macrophages and cancer stem 
cells (CSCs). These cells all play different roles in maintaining the tumour, 
including releasing cytokines such as VEGF, FGF2 and TGF-β, which can 
cause fibroses, aberrant angiogenesis and recruitment of various cells, 
including Mesenchymal Stem Cells (MSCs) to the site of the tumour 
(Hanahan & Weinberg, 2011).  
The discovery of CSCs in tumours helps to explain why many of the current 
anti-cancer therapies fail, with large numbers of cancers developing drug 
resistance. Currently, many of the anti-cancer drugs target highly 
proliferating cells by inhibiting proliferation or by DNA damage. However, 
these highly proliferating cells tend to be more differentiated, with limited 
self-renewal and differentiation capacity, thus being unable to seed tumours. 
Therefore, most chemotherapy treatments remove the bulk of tumours, but 
are incapable of eradicating the tumour initiating CSCs, which can then 
cause metastasis and regrowth of the tumour.  
CSCs themselves possess many properties which make them more 
resistant to such forms of anti-cancer therapies. These include their more 
quiescent nature which prevents DNA damage, high expression levels of 
multi-drug resistance pumps, and the ability to reform tumours from only a 
small number of remaining CSCs. Furthermore, there is increasing evidence 
linking the process of Epithelial to Mesenchymal Transition (EMT) to drug 
resistance in cancers. Firstly, EMT produces cells more closely resembling 
MSCs, which are more resistant to drug treatments (Houthuijzen et al., 
2012). Secondly, there is increasing evidence to suggest that the EMT 
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switch may actually produce cells with properties of CSCs (Mani et al., 2008; 
Morel et al., 2008; Singh & Settleman, 2010). This further complicates the 
design of anti-cancer therapies as, if only CSCs are targeted, they may be 
replaced by de-differentiation of other cells within the tumour (Gupta et al., 
2009a). In addition, the EMT has roles in metastasis, with the resulting 
mesenchymal-like cells being able to move to other areas of the body and 
seed new tumours (Peinado et al., 2007). 
Because of their importance in drug-resistance, tumour-initiation, metastasis 
and patient relapse, there have been several drugs designed to specifically 
target CSCs. These drugs work by either targeting self-renewal signalling or 
tumour-initiating cell-surface markers  (Zhou et al., 2009a). However, 
designing drugs against CSCs is further complicated by the necessity to 
isolate or enrich CSC populations from tumours.  
CSCs have a highly unstable nature caused by the genetic and epigenetic 
perturbations which occur in cancer cells. This can confound typical methods 
of CSC identification, therefore, isolation of these cells is presently proving 
difficult. For instance, CSCs are identified by the presence of certain 
phenotypical markers originally identified in normal stem cells, such as 
CD34+/CD38low/- for lymphomas, CD133+ for brain tumours, and 
CD44+/CD24low/- for breast cancers. However, evidence suggests that certain 
cells which do not possess these markers are also capable of initiating 
cancers (Taussig et al., 2010). Furthermore, in vivo xenograft experiments to 
determine the population of tumour-initiating cells within primary tumour 
samples provide widely varying results for the same types of cancers (Kelly 
et al., 2007; Quintana et al., 2008). Transplanting human tumour samples 
into mice may alter observed CSC numbers as certain factors essential for 
tumour initiation and growth may not be cross-species reactive (Kelly et al., 
2007). In addition, many of the xenograft mice are immunodeficient, thereby 
facilitating engraftment of human cells. However, these mice will not provide 
the same cytokine-rich microenvironment which allows tumour growth 
(Nguyen et al., 2012). 
These issues could be circumvented by using iPSC technology to generate 
pure populations of CSC-like cells from the differentiated cells within the 
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tumour stroma, thereby allowing the identification of CSC specific anti-
cancer therapies. Furthermore, these cells could clarify the link between self-
renewal, pluripotency and tumourigenesis, and highlight key factors 
influencing tumour progression. 
5.2  Characterisation of Colonies 
5.2.1  A673-iPC Colonies positively stain for Alkaline 
Phosphatase 
Embryonic stem cells (ESCs) express elevated levels of alkaline 
phosphatase on their cell surface. Therefore, the putative A673-iPC colonies 
generated in Chapter 4 were screened for ESC-like characteristics initially by 
staining for alkaline phosphatase activity (Figure 5.1). iPSC cells and 
uninfected A673 cells served as positive and negative controls respectively. 
All three iPC colonies stained positive for alkaline phosphatase activity. In 
contrast, the uninfected A673 cells remained unstained. However, Colony 4 
eventually deformed after prolonged culture, and this colony had reduced 
alkaline phosphatase staining compared with Colonies 2 and 3. These data 
are a preliminary indication of some degree of reprogramming occurring in 
the A673-iPC colonies. 
 
Figure 5.1: Alkaline Phosphatase staining of  A673-iPC colonies 
Alkaline phosphatase staining was observed for all three A673-iPC colonies, although Colony 4 displayed lower 
alkaline phosphatase expression, and eventually deformed. Uninfected A673 controls did not possess alkaline 
phosphatase activity. 
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5.2.2  A673-iPC colonies demonstrate elevated levels of 
Embryonic Stem Cell Marker genes 
The expression of various genes involved in proliferation and self-renewal 
are upregulated in ESCs, and their expression is a good indication of 
successful iPSCs generation. Therefore, to ascertain if reprogramming had 
been achieved in A673 cells, the expression levels of a number of ESC 
marker genes were analysed in the generated A673-iPC colonies. To this 
end, RNA was extracted from Colonies 2 and 3, and control mock and HVS-
GFP infected A673 cells. Quantitative RT-PCR was then utilised to assess 
the expression of endogenous Oct4, Rex1, Klf4 and hTERT within these 
cells. To ensure only endogenous levels of Oct4 were measured, the 5‟ 
primer used for Oct4 transcript detection was designed within the 5‟ UTR of 
the Oct4 mRNA. This ensured no amplification of exogenous Oct4 produced 
from the HVS-based vector would occur. 
Figure 5.2 shows the results of the quantitative RT-PCR experiments. 
Results demonstrate increased levels of Oct4, Rex1 and Klf4 mRNAs in the 
two A673-iPC colonies compared to uninfected and HVS-GFP infected A673 
cells, with Colony 3 displaying the highest increase. Interestingly, hTERT 
mRNA levels in uninfected and HVS-GFP infected control cells were similar 
to those observed for the reference standard iPSC cells, with reduced 
mRNA levels seen in Colonies 2 and 3.  
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Figure 5.2: qRT-
PCR Expression 
Analysis of ESC 
marker genes in 
A673-iPC colonies 
The expression 
levels of Oct4 (A), 
Rex1, (B), Klf4 (C), 
and hTERT (D) in 
the A673-iPC 
colonies were 
compared with those 
of iPSCs. iPSCs 
were used as 
reference standards. 
Oct4, Rex1 and Klf4 
expression levels 
are increased in 
A673-iPC colonies 
compared to 
uninfected and HVS-
GFP infected A673 
cells, with Oct4 and 
Rex1 levels 
negligible in these 
two control cell lines. 
Colony 3 
consistently 
displayed higher 
expression levels of 
the ESC marker 
gene mRNAs in 
comparison to 
Colony 2. Levels of 
hTERT were higher 
than iPSCs in 
uninfected and HVS-
GFP infected A673 
cells, and were 
significantly reduced 
in both A673-iPC 
colonies. 
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5.2.3  A673-iPC colonies display differential staining for SSEA4 
A further indicator of ESC-like characteristics is the upregulation of the cell 
surface protein, SSEA4. Therefore, immunofluorescence analysis was 
performed on A673-iPC Colonies 2 and 3 using  an SSEA4 specific antibody 
provided by Dr. Christian Unger (Centre for Stem Cell Biology, University of 
Sheffield), and detected using an Invitrogen Alexa Fluor® 546 secondary 
antibody. Cells were not permeabilised prior to staining to avoid disrupting 
the cell membranes which would interfere with SSEA4 staining. iPSC cells 
were used as a positive control, and uninfected and HVS-GFP infected A673 
cells served as negative controls.  
Figure 5.3 shows SSEA4 expression in A673-iPC Colonies 2 and 3, which is 
once again higher in Colony 3. This is similar to the positive control iPSC 
cells. In contrast, SSEA4 staining was not observed in the uninfected and 
HVS-GFP transduced control cells. Interestingly however, the expression of 
SSEA4 appeared reduced in some of the colonies split from the same 
parental A673-iPC colony. This is demonstrated in Figure 5.3, whereby 
Colony 3a displayed higher SSEA4 expression than Colony 3b. In addition, 
Colony 3a maintained HVS-iPSC virus GFP reporter gene expression in the 
absence of hygromycin selection more efficiently than Colony 3b without the 
presence of hygromycin selection for the HVS-iPSC viral episomes.  
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Figure 5.3: SSEA4 staining of A673-iPC colonies 
SSEA4 expression is observed on A673-iPC colonies split from Colonies 2 and 3, with Colony 3 displaying higher 
levels of SSEA4 expression than Colony 2. However, Colony 3a displayed higher levels of SSEA4 expression and 
maintained GFP expression of the HVS-iPSC episomes better than Colony 3b and Colony 2. No SSEA4 staining 
was observed in the uninfected and HVS-GFP infected control cells. iPSC cells served as a positive control for 
SSEA4 staining. All images were taken at 20 x magnification. 
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5.3  Differentiation 
One of the defining features of CSCs is their ability to seed new tumours by 
differentiating into various types of tumour stromal cells. However, little is 
known about the exogenous signals involved in this differentiation process 
due to the difficulties in isolating CSCs. Because of this, animal models are 
commonly used to study CSC differentiation and tumour formation, but this 
makes it virtually impossible to measure the effects of the complex interplay 
of signalling pathways involved in CSC mediated tumour progression. 
However, iPCs could potentially provide an abundant source of cells, 
thereby allowing the determination of signalling systems involved in the 
various types of differentiation in both in vitro and in vivo models. Therefore, 
to assess the potential of the A673-iPC colonies generated in this study as 
models for ESFT development and progression, and to further ascertain the 
extent of their stem-like properties, differentiation trials were performed. 
5.3.1  Non-specific differentiation 
Firstly, A673-iPC Colonies 2 and 4 were non-specifically differentiated as 
described in Figure 5.4. Briefly, this process involved the formation of 
Embryoid Bodies (EBs) by culturing the A673-iPCs in either DMEM 
containing 10% FCS, or in EB medium (KO). After 8 days in suspension 
culture, the EBs were transferred onto gelatin coated dishes, and 
differentiated cells were allowed to grow out from the central colony mass for 
a further 8 days. Colony 4 was specifically selected for differentiation trials, 
as it more readily formed EBs.  
After 8 days in suspension cultures in EB medium (KO) or DMEM 
supplemented with 10% FCS, EBs formed from the control iPSC cells 
(Figure 5.5 C) and the A673-iPC colonies (Figure 5.5 D and E). Upon 
transferring the EBs to gelatin coated dishes various morphologies were 
observed in cells which expanded from the attached iPSC EBs (Figure 5.6) 
and A673-iPC EBs (Figures 5.7 and 5.8). Cells possessing neural (Figure 
5.6 B and E), epithelial (Figure 5.6 A) and cobblestone like morphologies 
(Figure 5.6 C) were observed growing from the iPSC embryoid bodies after 
8 days. However, the cells produced from the A673-iPC colonies had 
predominantly either fibroblastic, (Figures 5.7 C and 5.8 C), or neural 
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morphologies (Figures 5.7 A and  5.8 B and E), or their morphologies closely 
resembled that of the parental A673 cells (Figure 5.7 D and E). 
 
Figure 5.4: Overview of Non-specific Differentiation of iPSCs and A673-iPCs 
Adherent colonies were split, the cells transferred to low-adherence tissue culture dishes, and grown in suspension 
cultures. EBs formed after 6-8 days and were subsequently plated onto gelatin pre-coated tissue culture dishes. 
Cells were allowed to grow out from the attached EBs and after a further 6-8 days (16 days after initially forming 
the EBs) various different cell morphologies were observed. 
 
5.3.2  qRT-PCR on non-specifically differentiated Embryoid 
Bodies 
Upon differentiation of ESCs, the genes associated with pluripotency are 
rapidly downregulated and germline-specific genes are activated. Therefore, 
to determine the extent of A673-iPC colony differentiation, RNA was 
extracted from differentiated A673-iPC cells, and qRT-PCR performed to 
analyse expression of differentiation-associated marker genes were. EBs 
formed from iPSCs cultured in DMEM with 10% FCS or KO medium, were 
used as positive controls for the differentiation markers and undifferentiated 
iPSCs served as reference standards.  
Results show a downregulation of endogenous Oct4 expression in A673-iPC 
EBs formed from Colonies 2 and 4, and iPSC derived EBs. However, small 
levels of residual Oct4 expression were detected in the A673-iPC EBs 
(Figure 5.9 A) compared to iPSC derived EBs. In contrast, undifferentiated 
iPSCs control cells retained high expression of endogenous Oct4.  
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Figure 5.5: Generation of EBs during non-specific differentiation of iPSCs.  
A) Undifferentiated iPSC colony, B) Uninfected A673 cells, C) EB formed after 8 days in suspension culture from 
iPSCs; D and E) EBs formed after 8 days from A673-iPCs.   
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Figure 5.6: Non-specific differentiation of iPSCs at day 16 (8 days on gelatin). 
A, B, C, D, E; Differentiated cells growing out from the EB formed from iPSCs 16 days after the EB was formed.  
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Figure 5.7: Non-specific differentiation of A673-iPC Colony 2 at day 16 (8 days on gelatin). 
A, B, C, D, E; Morphology of differentiated cells produced from A673-iPC Colony 2-derived EBs.  
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Figure 5.8: Non-specific differentiation of A673-iPCs at day 16 (8 days on gelatin). 
A, B, C, D, E; Morphology of differentiated cells produced from A673-iPC Colony 3-derived EBs. 
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Further to Oct4 depletion, A673-iPC EBs were analysed for expression of 
lineage specific markers for each of the three germlayers. To this end, the 
expression levels of MSX1 and MAP2 (ectodermal markers), were analysed, 
in addition to the endodermal marker, Sox17, and the marker of mesodermal 
differentiation, Flk1. Figures 5.9 C, D and E show that most of the 
differentiation markers were not upregulated in the A673-iPC EBs in 
comparison to the elevated mRNA levels observed for the iPSC EB positive 
controls. However, A673-iPC EBs demonstrated increased expression of the 
ectodermal marker, MSX1 (Figure 5.9 B).  
5.3.3  Neural Lineage Directed Differentiation 
A further test of the stem-like properties of the putative A673-iPC cells is to 
differentiate the cells towards a specific lineage. Therefore, the A673-iPC 
colonies were cultured under conditions used to specifically differentiate 
ESCs down the neural lineage, as summarised in Figure 5.10. A673-iPC 
colonies were grown in suspension cultures, similar to the non-specific 
differentiation method, with the exception that the cells were cultured in 
either Neural Stem Cell Medium from Invitrogen or EB medium containing 1 
μM of all-Trans Retinoic Acid (KO RA). Retinoic acid is an inducer of 
differentiation and promotes differentiation towards a neural lineage.   
EBs were formed from iPSC control cells, and A673-iPC Colonies 2 and 4 
after 2 days (data not shown). Subsequently, the EBs were transferred to 
gelatin pre coated dishes and cultured for a further 8 days. Results in Figure 
5.11 show that cells possessed various morphologies which had grown from 
the attached EBs. Control iPSC cells grown in KO medium supplemented 
with Retinoic Acid (KO RA) or Neural Stem Cell Medium (NSC) developed 
neuroprogenitor-like morphologies (Figure 5.11 B), with some cells 
continuing to differentiate and form neuronal networks (Figure 5.11 C), and 
neurons (Figure 5.11 D). These morphologies were clearly distinct from the 
undifferentiated iPSC stem cell morphology, (Figure 5.11 A), as the cells 
were elongated and formed connecting networks. In contrast, the A673-iPC 
colony grown in KO RA medium (Figure 5.11 H) failed to display any 
changes in morphology to normal A673 cells grown in DMEM with 10% FCS 
(Figure 5.11 F).  
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Figure 5.9: Expression of marker genes specific for the three germlayers in A673-iPC Embryoid Bodies 
A) Oct4, a marker for pluripotency, is downregulated in A673-iPC EBs and EBs formed from iPSCs; B) The 
ectodermal marker MSX1 is upregulated in A673-iPC EB cells compared to uninfected A673 and HVS-GFP 
infected cells; C) Expression of MAP2, another ectodermal marker, is unaltered in A673-iPC colonies compared to 
negative control cells; D) Flk1, a mesodermal marker gene, and E) Sox17, a marker for endoderm are not 
upregulated in A673-iPC EBs compared to negative controls.  
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However, when A673-iPC EBs were grown in NSC medium, there appeared 
to be neural crests and neuronal networks forming (Figure 5.11 G). Results 
therefore suggest that the A673-iPC cells are capable of neural 
differentiation. 
5.3.4 qRT-PCR on Directed Neural Lineage Differentiated 
Embryoid Bodies 
During the differentiation of ESCs along the neuronal lineage, there are 
distinct stages marked by the changing expression levels of specific genes; 
for example, Nestin and β-III-Tubulin. Nestin is a marker for Neural 
Progenitor Cells and β-III-Tubulin is a marker for differentiated 
neurons(Abranches et al., 2006). Therefore, to determine if the 
morphologies observed in Figure 5.11 truly indicated the differentiation of 
A673-iPC colonies down a neural lineage, RNA was extracted from 
differentiated A673-iPC or iPSC cells in addition to mock and control infected 
A673 cells, and qRT-PCR performed to assess Nestin and β-III-Tubulin 
expression. 
 
 
Figure 5.10: Overview of Directed Neural Differentiation of iPSCs and A673-iPCs 
Embryoid bodies were formed by splitting the adherent colonies and transferring the cells to low-adherence tissue 
culture dishes. These suspension cultures of EBs were grown in either EB medium containing 1 µM Retinoic Acid, 
or Neural Stem Cell (NSC) medium for 2 days, before transferring the EBs to gelatin pre-coated dishes. Cells were 
cultured for a further 8 days in either EB medium without retinoic acid or NSC medium, and cells possessing neural 
morphologies were observed. 
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Figure 5.11: Directed Neural Differentiation of iPSCs and A673-iPCs 
A) Undifferentiated iPSC cells; B and D) Differentiated iPSCs cultured in NSC medium displaying neuroprogenitor 
and neural dendrite morphologies respectively; C and E) Differentiated iPSCs cultured in EB medium and retinoic 
acid (KO RA) display neural networks and neural crests respectively. F) Uninfected A673 control cells cultured in 
DMEM with 10% serum; G) A673-iPC cells cultured in NSC medium display neural networks and dendritic 
morphologies; H) A673-iPC cells cultured in KO RA possess morphologies very similar to the uninfected control 
A673 cells.  
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Figure 5.12 A shows Nestin mRNA levels are low in undifferentiated iPSCs 
or uninfected and HVS-GFP infected A673 controls. In contrast, an increase 
in Nestin expression is observed in iPSC EBs cultured in NSC or KO RA. 
Slight upregulation of Nestin mRNA levels was also observed in A673-iPC 
EBs cultured in NSC medium, but not in cells cultured in KO RA medium. β-
III-Tubulin expression in the undifferentiated and differentiated iPSC control 
cells also reflects the results observed for Nestin expression, with the 
differentiated iPSCs demonstrating elevated β-Tubulin mRNA in comparison 
to undifferentiated iPSCs (Figure 5.11 B). However, β-III-Tubulin mRNA 
levels were low in A673-iPC EB colonies cultured in NSC or KO RA medium, 
with surprisingly high levels observed in the control HVS-GFP infected A673 
cells. These results suggest some degree of neural differentiation is 
occurring in the A673-iPC embryoid bodies, but not to the extent of 
generating fully differentiated neurons.   
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Figure 5.12: Expression of the neural markers Nestin and β-Tubulin in Neural-specific differentiation of 
iPSCs and A673-iPCs  
A) Expression of Nestin is upregulated in A673-iPC EBs and iPSC EBs cultured in NSC medium; B) Slight 
upregulation of β-Tubulin is observed in iPSC EBs cultured in NSC medium, but the uninfected and HVS-GFP 
infected A673 control cells display higher levels of β-Tubulin than the A673-iPC EBs. 
 
 165 
 
5.4  Discussion 
Chapter 4 detailed the generation of ESFT iPC colonies from the A673 
ESFT cell line. However, it was apparent that although there were 
similarities between these iPCs and ESCs, they were not entirely ESC-like, 
and their failure to thrive in feeder-free stem cell culture conditions indicated 
a possible incomplete reprogramming of these cells. Therefore, this chapter 
aimed to determine the extent of reprogramming which had occurred in the 
A673-iPC cells, and to characterise their stem cell-like properties. 
Initial screening of stem cell-like characteristics was performed here, 
demonstrating elevated alkaline phosphatase activity, upregulation of ESC-
related marker genes Oct4, Rex1 and Klf4 and increased expression of the 
surface ESC-marker protein, SSEA4. All these results are indicative of 
reprogramming occurring within these cells. The results obtained for qRT-
PCR analysis of the A673-iPC gene expression (Figure 5.2 A) show Oct4 
expression was upregulated in the A673-iPC Colonies 2 and 3. Oct4 is a key 
regulator of pluripotency and binds to a 5′-ATTTGCAT consensus sequence 
in complexes with various proteins, including Sox2. These complexes allow 
Oct4 to upregulate certain pluripotency associated genes including Oct4, 
Sox2, Nanog and FGF4, and repress genes associated with differentiation 
(Cheong et al., 2011; Pardo et al., 2010; van den Berg et al., 2010). 
Therefore, upregulation of Oct4 would indicate activation of the pluripotency 
machinery in the A673-iPC colonies. The results obtained for qRT-PCR 
analysis of A673-iPC colonies show elevated mRNA levels of the 
pluripotency regulator Oct4, in addition to two other pluripotency associated 
marker genes, Rex 1 and Klf4.. These genes are both C2H2 Zinc Finger-
containing proteins involved in repressing differentiation, either by Rex 1 
mediated inhibition of Notch and STAT3 signalling (Bhandari et al., 2010), or 
by regulation of Nanog expression by Klf4 (Zhang et al., 2010).  The 
elevated mRNA levels of these two genes further confirm the activation of 
pluripotency mechanisms within the A673-iPC colonies. Interestingly, the 
expression of Oct4, Rex1 and Klf4 were consistently higher in A673-iPC 
Colony 3, despite both colonies being transduced with the same combination 
of HVS-iPSC viruses (OL). This may indicate that Colony 3 has been 
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infected with different amounts of the HVS-Oct4 and HVS-Lin28 viral vectors 
resulting in a more favourable stoichiometry of these two reprogramming 
factors.  
Interestingly, a marked decrease in hTERT mRNA levels was observed in 
the A673-iPC colonies compared to uninfected and HVS-GFP infected A673 
cells and iPSCs. hTERT is an enzyme involved in extending telomeres. 
Telomeres are gradually shortened upon repeated rounds of cellular division 
in adult stem cells or differentiated cells until they reach their Hayflick limit, 
and enter replicative senescence. Some cells may bypass this senescence 
and will continue dividing until they reach a second growth arrest stage, 
termed crisis. At this stage, chromosome ends may join together by 
chromosome bridge-break fusion; a process which usually leads to 
apoptosis. However, some cells may develop a mutation which upregulates 
their telomerase activity and enables them to produce stable telomeres and 
divide indefinitely (Shay & Wright, 2010). CSCs however, are more 
quiescent and therefore potentially express hTERT at lower levels than their 
more rapidly dividing progeny (Shay & Wright, 2010). The observed 
reduction in telomerase activity in the reprogrammed A673-iPC cells may 
indicate these cells are becoming more similar to CSCs. Furthermore, this 
observed reduction in telomerase may explain why so many of the A673-iPC 
colonies that originally formed failed to thrive. Inhibition of telomerase activity 
with the inhibitor, Imetelstat, causes CSCs to senesce (Djojosubroto et al., 
2005; Hochreiter et al., 2006), and if the reprogramming process is also 
reducing hTERT levels, this may have the same effect in these cells. 
Immunofluorescence results for SSEA4 expression showed that both the 
A673-iPC colonies were SSEA4 positive, indicating some degree of 
reprogramming occurring in these cells (Figure 5.3). However, some of the 
cells derived from the same starting colony appeared to have reduced 
SSEA4 expression. This was demonstrated for A673-iPC Colony 3, whereby 
Colony 3a expressed more SSEA4 than Colony 3b, despite both colonies 
being derived from the same original A673-iPC colony. Colony 3a also 
maintained the HVS-iPSC episomes better than Colony 3b in the absence of 
hygromycin selection, as demonstrated by GFP expression within these 
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cells. This highlights the possibility that some of the SSEA4 expression 
observed in the A673-iPC colonies may be as a result of remaining 
exogenous expression of the reprogramming factors. Because of the 
incomplete reprogramming of the A673-iPC cells, removal of exogenous 
iPSC gene expression by eliminating the HVS-iPSC viral episomes may 
cause the cells to revert back to their parental cell type, thereby losing 
SSEA4 expression.  
Interestingly, upregulation of ESC-related genes and SSEA4 was greater in 
A673-iPC Colony 3, despite both colonies being transduced with the same 
combination of HVS-iPSC viruses (OL). This may indicate that Colony 3 has 
been infected with different amounts of the HVS-Oct4 and HVS-Lin28 viral 
vectors resulting in a more favourable stoichiometry of these two 
reprogramming factors. 
Future characterisation of A673-iPCs could include bisulphate sequencing to 
analyse the methylation status of pluripotency-associated gene promoters, 
as performed by Carette and colleagues in reprogrammed Chronic Myeloid 
Leukaemia cells (Carette et al., 2010). Furthermore, it would be interesting 
to perform micro array analysis comparing A673-iPC colonies to parental 
A673 cells and ESCs, specifically looking at ESC genes, lineage-specific 
genes and cancer-associated genes. Lin et al. performed similar microarray 
analysis on iPCs generated from melanoma cells and interestingly found 
these cells possessed gene expression profiles that more closely resembled 
the ESC cell lines H1 ad H9 (89% and 86%, respectively) than their parental 
melanoma cells (53%) (Lin et al., 2008). Whole genome analysis such as 
this would also help to identify genes within CSCs which are not present in 
normal ESCs and would therefore make potential attractive anti-CSC drug 
targets. 
The second aim of this chapter was to address the differentiation potential of 
the generated A673-iPC colonies, to fully assess their potential as a model 
of ESFT development. The results of non-specific differentiation of A673-iPC 
cells (Figures 5.5 to 5.8) demonstrated firstly, that differentiation of the iPCs 
can occur and secondly, the differentiated cells predominantly displayed 
morphologies which closely resembled that of their parental somatic A673 
 168 
 
cells. This indicates these cells possess a somatic memory causing a bias in 
their differentiation, which has been reported for iPSCs (Bar-Nur et al., 2011; 
Ghosh et al., 2010; Kim et al., 2010; Marchetto et al., 2009). Furthermore, if 
the A673-iPC cells were incompletely reprogrammed, as suggested in 
Chapter 4, the loss of the HVS-iPSC viral episomes from these cells would 
allow them to revert to their parental cell type.  
Further indication of the A673-iPC somatic cell memory was shown from the 
other predominant morphologies displayed by these cells, which were 
fibroblastic and neural. ESFT cells have been shown to express many of the 
genes related to the neuro-ectodermal (Staege et al., 2004) and 
mesenchymal (Suvà  et al., 2009) lineages. Therefore the differentiation bias 
of A673-iPC cells to these lineages indicates that expression of these 
lineage-associated genes remains in the A673-iPC cells, thereby driving 
their differentiation down these specific lineages. In addition, results from the 
qRT-PCR analysis of EB marker genes in differentiated A673-iPC EBs 
provided further evidence for somatic cell memory in these cells (Figure 5.9), 
whereby only the ectodermal marker MSX1 was upregulated in non-
specifically differentiated A673 cells. Future work would involve 
immunostaining the differentiated progeny of the A673-iPC EBs with 
markers for various different lineages, particularly Vitronectin and Tuj1 which 
are specific markers for fibroblasts and neuronal cells respectively. This 
would verify that the A673-iPC cells were capable of differentiating down 
mesenchymal and neuroectodermal lineages. Furthermore, as 
mesenchymal stem cells are implicated as the cells of origin for ESFTs, it 
would be interesting to stain for the presence of the mesenchymal stem cell 
marker, CD44, in parental A673 cells and A673-iPCs to determine if 
reprogramming A673 cells to a more primitive, CSC-like state caused these 
cells to develop a mesenchymal stem cell phenotype.  
Finally, the differentiation of A673-iPC cells down a neural lineage was 
attempted, as a further assessment of their ESC-like characteristics and 
differentiation potential. Results of the neural lineage directed differentiation 
show that A673-iPC cells were capable of differentiating towards the neuro-
ectodermal lineage. Specifically, these cells developed neural networks 
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when cultured in NSC medium (Figure 5.11), and showed upregulated 
expression of Nestin which is a marker of Neural Progenitor Cells and is 
expressed in the early stages of neural differentiation (Figure 5.12). 
However, the upregulation of β-III-Tubulin in these cells was not observed. 
β-III-Tubulin is expressed in fully differentiated neurons (Abranches et al., 
2006). This is in contrast to Nestin which is present in earlier neural 
progenitors, therefore these results may indicate that the A673-iPC EBs 
maintain some degree of their primitive nature.  
Previously, Suvà and colleagues achieved directed differentiation of ESFT 
CSCs isolated from primary tumours by sorting for CD133+ cells. 
Differentiation into three mesenchymal lineages was performed; adipogenic, 
osteogenic and chondrogenic (Suvà  et al., 2009). It would therefore be 
interesting to apply these differentiation protocols to the A673-iPC cells 
generated in this study. This would determine if the A673-iPCs would also 
be capable of differentiating into these lineages, thereby demonstrating the 
extent to which these cells resemble ESFT CSCs.  
In summary, these data indicate the A673-iPC cells have acquired certain 
stem cell-like characteristics during the process of HVS-iPSC mediated 
reprogramming.  However, this effect is limited; with some ESC marker gene 
expression levels remaining unaltered in the A673-iPSC colonies, which 
further indicates incomplete reprogramming.  
Differentiation of the A673-iPC cells indicated a strong somatic cell memory, 
which appeared to limit the differentiation of these cells to ectodermal and 
mesenchymal lineages. But perhaps the somatic memory of the A673-iPC 
cells does not present a problem for the further study of tumour formation 
and progression of the ESFT CSCs, as the A673-iPC cells may still be 
capable of differentiating into the various cells found in ESFTs. Future work 
would concentrate on removing the HVS-iPSC episomes from 
reprogrammed cells, thereby removing iPSC transgene expression which 
may restrict A673-iPC differentiation. Once the viruses have been removed, 
the A673-iPC cells would represent a more accurate model of ESFT CSC 
differentiation. 
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6 Discussion 
The advent of iPSC technology generated immense scientific interest due to 
its potential to produce large quantities of pluripotent stem cell-like cells for 
therapeutic use and scientific study, including the ability to produce a variety 
of disease-in-a-dish models. However, currently retroviral gene delivery 
vectors are the predominant reprogramming technology used in iPSC 
generation. These viruses integrate into the host cell, and would therefore 
disrupt the normal gene profiles of resulting iPSCs a feature which severely 
limits the value of these cells for therapeutic use or as disease models.  
Therefore, this thesis has investigated the potential of Herpesvirus saimiri as 
a non-integrating, episomally maintained viral vector for iPSC-generation. 
Three HVS-iPSC gene delivery vectors have successfully been produced, 
expressing Oct4, Lin28 and Nanog. Their potential as iPSC-gene delivery 
vectors has been assessed through proof-of-concept experiments to 
reprogramme neural stem cells (NSCs), or somatic ESFT cancer cells to 
pluripotent cells.  
6.1 HVS as a Gene Delivery Vector for iPSC technology 
As described previously, HVS possesses a number of features which makes 
this virus an attractive gene delivery vector for iPSC generation. Firstly, it 
has a broad cell tropism, since it has been shown to infect a wide range of 
primary and cancerous tissues (Griffiths et al., 2006). Secondly, all HVS-
gene delivery vectors are based on the A11-S4 virus strain, which contains a 
natural deletion encompassing the HVS transforming protein, STP. Thirdly, 
HVS, like other herpesviruses, has a large dsDNA genome which gives it a 
large capacity for transgenes. Indeed, the generation of the HVS amplicon 
system allows up to 50kb of exogenous DNA to be inserted into the HVS 
genome (Macnab et al., 2008). This large capacity potentially enables the 
cloning of complete genomic loci into HVS-based gene delivery vectors, 
including regulatory sequences, introns and native promoter elements. 
Cloning complete genomic loci would ensure prolonged transgene 
expression without transcriptional silencing, as has been previously 
demonstrated (Wade-Martins et al., 2000). Moreover, it would also prevent 
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transgene overexpression, which is a feature often associated with cDNA 
expression constructs. These features would be particularly beneficial in 
reprogramming, where overexpression of iPSC transgenes is potentially 
oncogenic, and also reduces the efficiency of reprogramming. Furthermore, 
this large capacity would enable the creation of a single gene delivery vector 
which would encompass all the factors required for efficient iPSC 
generation. Previous attempts to generate single vectors containing multiple 
reprogramming factors have utilised polycistronic constructs which contain 
each reprogramming  gene separated by self-cleaving 2A peptides from the 
foot and mouth disease virus (FMDV) (Carey et al., 2009; Ryan & Drew, 
1994). Although these polycistronic constructs improve transduction or 
transfection efficiencies, the reprogramming efficiencies of these methods 
remain poor. This may be as a result of incomplete translation and poor 
cleavage. 
Finally, HVS possesses a further attractive feature as an iPSC-gene delivery 
vector, which is unique to the gammaherpesvirinae. It is capable of 
persisting as an episome in dividing cell populations by means of a virally 
encoded protein, ORF73 (Calderwood et al., 2005). The potential of 
episomally maintained gene delivery methods for iPSC generation has 
already been demonstrated by Yu et al. iPSC cells were successfully 
generated without disrupting the host cell genome using a plasmid vector 
containing a polycistronic construct expressing the reprogramming factors, 
Oct4, Sox2, Nanog, Lin28, Klf4, c-Myc and SV40LT, along with the EBV 
episomal maintenance elements EBNA1 and OriP (Yu et al., 2009). 
Although originally this episomal reprogramming method had poor efficiency, 
further research dramatically increased iPSC generation efficiency by 
combining this episomal vector with basic Fibroblast Growth Factor (bFGF) 
and Leukaemia Inhibitor Factor (LIF), in addition to small molecule inhibitors 
of MEK, GSK3β and TGFβ. These culture conditions enhanced 
reprogramming efficiency from 0.0001% described for the original 
reprogramming method, to 0.1% (Yu et al., 2011). Therefore, in future 
applications, the efficiency of the HVS-based episomal reprogramming 
method may also be improved by reprogramming cells in these culture 
conditions. 
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Removal of reprogramming transgenes upon iPSC generation produces 
cells which more closely resemble true ESCs in their gene expression 
profiles. This is a major advantage to future iPSC cells for therapeutic uses 
and as models of development (Soldner et al., 2009; Sommer et al., 2010). 
Therefore, reprogramming vectors are often silenced upon iPSC generation 
by incorporating inducible expression systems, such as the tetracycline 
inducible systems. These allow tight repression of iPSC transgene 
expression in the absence of tetracycline or doxycycline. However, although 
these systems remove transgene expression, the exogenous vector DNA 
remains in the reprogrammed cells. Other methods to remove the 
exogenous vector DNA and transgene expression upon reprogramming 
have included excisable gene delivery vectors such as a Cre-LoxP excisable 
retrovirus, and the PiggyBac Transposon (Kaji et al., 2009; Soldner et al., 
2009; Woltjen et al., 2009; Yusa et al., 2009). However, these systems both 
required stringent screening of the resulting iPSC cells to ensure all 
exogenous DNA was removed. Furthermore, in the case of the excisable 
retrovirus, a viral „footprint‟ remained in the cells, which could potentially 
disrupt normal host gene function.  
Once again, episomally maintained vectors have an advantage in this 
regard, as the episome could easily be removed upon reprogramming. As 
such, iPSC cells generated using episomal vectors would not require the 
stringent screening that excisable reprogramming vectors required. Indeed, 
Yu and colleagues demonstrated their episomal plasmid reprogramming 
system could be removed through repeated cellular divisions in the absence 
of selective antibiotic (Yu et al., 2009). Thus, these cells were free of any 
exogenous DNA and ectopic transgene expression. Therefore, a further 
favourable characteristic of HVS-based gene delivery vectors for iPSC 
generation would be the potential to remove the virus from reprogrammed 
cells. Because HVS episomal persistence is reliant on a single virally 
encoded protein, it would be feasible to efficiently remove the viral episome 
by regulation of ORF73 expression.  Future work would investigate three 
possible ways to achieve this; siRNAs targeted against ORF73, generation 
of a tetracycline-inducible ORF73 HVS vector or creating a virus containing 
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FLP recombination sites flanking the ORF73 gene, thereby creating an 
excisable ORF73 cassette. 
Using siRNA to knockdown ORF73 expression would require multiple 
rounds of transfection as siRNA is unstable and readily degraded within 
cells. In addition, a knockdown of nearly 100% would be required as any 
remaining episomes would be capable of expressing ORF73, and would 
therefore persist after siRNA treatment. Since most siRNAs do not achieve 
100% knockdown this may not be a feasible approach. 
A better way to control ORF73 expression may be to use a tetracycline 
inducible system (Gossen & Bujard, 1992b). These systems enable tight 
gene repression in the absence of tetracycline or doxycycline which is 
alleviated upon addition of either of these drugs. Strong expression of the 
desired transgene is provided by a CMV promoter located downstream of 
seven copies of the Tet-O operon which provide tight repression. By 
replacing the ORF73 endogenous promoter with this Tet-inducible promoter 
would enable ORF73 expression and episomal persistence upon treatment 
with tetracycline. Upon withdrawal of the drug, ORF73 expression would be 
tightly repressed and the viral episome would be lost after repeated rounds 
of cellular division. However, expression from ORFs 71 – 73 is driven by a 
common promoter located downstream of ORF73. ORF71 and ORF72 
encode vFLIP and a cyclin D homologue, respectively (Chang et al., 1996; 
Thome et al., 1997), but are not essential for HVS latency (Collins et al., 
2002). However, it was observed in ΔORF72 mutants that viral titres were 
significantly lower that wild-type HVS (unpublished observation). Therefore, 
although this strategy has significant improvements over siRNA knockdown 
of ORF73, there are still a few issues with this approach. 
Perhaps the most feasible method of producing removable HVS-based 
vectors is the generation of a HVS vector containing a Cre-excisable ORF73 
cassette.  A cassette containing ORFs 71-73 and their common promoter 
could be produced with flanking LoxP sites and recombined using site-
specific recombination within the HVS-BAC. This would produce an HVS-
based vector capable of producing viral titres similar to those of HVS-GFP, 
and upon successful reprogramming of target cells, could be removed by 
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treating the resulting iPSCs with cell-permeable Cre-recombinase. This 
would remove the ORF71-73 expression cassette from episomes, therefore 
removing their ability to persist in dividing cell populations. 
6.2 Reprogramming Neural Stem Cells 
Perhaps the most promising application of iPSC technology is the study and 
treatment of neurodegenerative disorders. This is mainly due to the 
difficulties associated with isolating adult neural stem cells from living 
patients and the limitations of animal models in neurodegenerative disease 
modelling. 
Therefore, the HVS-iPSC vectors were utilised in a proof-of-principle 
experiment to generate iPSC cells from Neural Stem Cells (NSCs). 
However, attempts to reprogramme these cells highlighted the need for 
further work to improve the biosafety of these HVS-iPSC vectors. Infection of 
NSCs with HVS-GFP caused extreme cytopathic effects in these cells, for 
which there are two possible explanations. Firstly, the virus-containing 
supernatant used to transduce cells is harvested directly from lysed cell 
sheets of the permissive cell line, OMK cells. These supernatants could 
therefore contain various cytokines and interferons which are released upon 
viral infection, leading to induction of apoptosis in subsequently infected 
cells. Purified virus stock could be produced in future applications, which 
would circumvent this issue. The second explanation for the observed 
cytotoxicity may be due to lytic expression of viral genes in NSC cells. 
Although HVS infection predominantly leads to a latent infection in human 
cells, it is capable of lytic reactivation in certain cell lines, as observed 
previously in the lung cancer cell line, A549, and in SW480 cells (Goodwin et 
al., 2001; Smith et al., 2001). Therefore HVS could potentially be capable of 
lytic replication and infectious virus production in NSCs. To further improve 
the biosafety of HVS-based reprogramming vectors, future vectors would be 
generated using the HVS-amplicon-like system (Macnab et al., 2008). The 
HVS-amplicon has improved biosafety as it lacks the majority of the HVS 
genome, which removes the ability these recombinant viruses to undergo 
lytic replication. Significantly, it does not encode the major lytic activation 
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genes, ORF50 and ORF57. Therefore, future work would involve generating 
HVS-iPSC gene delivery constructs based on the HVS-amplicon system.   
6.3 Reprogramming of ESFT A673 cells 
The presence of tumour-initiating Cancer Stem Cells (CSCs) has already 
been demonstrated for a rapidly increasing number of cancers. Due to their 
capacity for self-renewal and their ability to seed new tumours, CSCs have 
important implications in cancer progression and metastasis.  
However, the dynamic nature of these cells means they remain difficult to 
identify and isolate. The use of iPSC technology to generate induced 
pluripotent cancer stem cells (iPCs) would potentially enable vast quantities 
of pure CSC populations to be obtained for study. To this end, this thesis 
examined the potential of HVS-based iPSC gene delivery vectors to 
reprogramme cancerous cells.  
This investigation reports the generation of iPC-like colonies from the A673 
ESFT cell line using the HVS-iPSC recombinant viral vectors. Infection with 
HVS-Oct4 virus alone was capable of generating A673-iPC colonies, but 
was not sufficient to reprogramme these cells to a state whereby they were 
able to thrive in feeder-free stem cell culture conditions. The efficiency of 
reprogramming was improved by transducing the cells with HVS-Oct4 in 
conjunction with HVS-Nanog, but once again the colonies produced were 
not viable in stem cell culture conditions.  
However, transduction of A673 cells with HVS-Oct4 and HVS-Lin28 viruses, 
or a combination of all three HVS-iPSC, resulted in greater number of A673-
iPC colonies, some of which were stable upon prolonged culture in feeder-
free stem cell culture conditions. Analysis of these colonies by screening for 
alkaline phosphatase activity, qRT-PCR analysis of ESC marker genes and 
staining for SSEA4 antigen expression demonstrated that these cells 
exhibited some hallmarks of iPCs, but were probably in a state of incomplete 
reprogramming. Specifically, these cells expressed alkaline phosphatase, 
but only displayed increased mRNA levels for a limited number of ESC 
markers. Additionally, these genes were not expressed to the same levels 
observed in iPSC control cells. Moreover, significant variation in the resulting 
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A673-iPC colonies was observed, as demonstrated by the survival of some 
colonies in feeder-free stem cell culture conditions and differences in ESC-
marker gene expression. Perhaps one explanation for this variability could 
be the inherent aneuploidy and chromosome instability of the parental 
cancer cells. Aneuploidy is either duplication or removal of chromosomes 
within cells as a result of incorrect cell division. Cancer cells are frequently 
aneuploid due to high cell division rates combined with defects in cell-
division check points. Because of this, A673 cells may not have a full 
complement of genes or gene duplications which could affect the 
reprogramming efficiency, resulting in some cells achieving a more ESC-like 
state than other cells. This could explain why some of the resulting A673-iPC 
colonies deformed after prolonged culture. 
The partial reprogramming observed within the A673-iPC colonies has been 
reported previously in the generation of iPCs from cancer cell lines. 
Hochedlinger and colleagues attempted to generate iPCs from melanoma, 
leukaemia and lymphoma, by Somatic-cell Nuclear Transfer (SCNT) with 
enucleated oocytes. However, only cells containing nuclei from the 
melanoma cancer cells were successfully reprogrammed (Hochedlinger et 
al., 2004). This evidence hints at some as yet unknown road-block in the 
reprogramming of cancer cells. This is particularly surprising given the 
strong links between cancer and pluripotency which have been discussed 
previously (Bernhardt et al., 2012; Ramos-Mejia et al., 2012). Perhaps the 
similar gene expression profile of cancers to pluripotent cells makes these 
cells more difficult to reprogramme. If this is the case, then more primitive 
cancers which more closely resemble ESCs and iPSCs would be harder to 
reprogramme than cancers with a less aggressive, less primitive nature.  
Although the data presented here suggest that some degree of 
reprogramming within ESFTs is possible, this report merely details the 
reprogramming of an ESFT cancer cell line. However, cancer cell lines are 
homogenous populations of cells, and therefore not truly representative of 
the heterogeneous tumours they are derived from. Furthermore, cell lines 
are generally produced from a subpopulation of cancer cells which are better 
able to survive in prolonged in vitro culture. These cells are therefore more 
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likely to be highly proliferative and capable of unlimited self-renewal, and as 
such are likely to closely resemble ESCs and CSCs. This may make their 
reprogramming more difficult due to the endogenous expression of many of 
the pluripotency genes within these cells. Therefore, future work to 
investigate the true potential of HVS-iPSC viral vectors in iPC generation 
would involve reprogramming various cells found within primary tumour 
samples. Moreover, in addition to highlighting which cells are most 
amenable to becoming reprogrammed, this would also provide insights into 
which cells are theoretically capable of de-differentiating into new CSC 
populations. 
6.4 Differentiating A673-iPC cells 
One of the main interests of iPCs is as a model for the aberrant signalling 
pathways observed in cancer, and how these affect proliferation and 
differentiation of cells within the tumour microenvironment. Therefore, 
another aspect of this work was to determine if the A673-iPC cells generated 
in this study were capable of differentiation and thereby providing a suitable 
model for ESFT cancer progression.  
Results from the non-specific differentiation of the A673-iPC cells suggested 
that these cells were capable of differentiation, as evidenced by the altered 
cell morphologies observed growing out from the attached EBs. However, it 
results demonstrate there is an apparent strong bias towards differentiation 
along the ectodermal lineage.   
A possible explanation for the apparent differentiation bias towards the 
ectoderm could be the presence of the EWS-FLI1 fusion protein. This 
protein has been demonstrated to upregulate the expression of various 
genes involved in neural development, including neuronal pentraxin 
receptor, SMA5, and presenilin (Hu-Lieskovan et al., 2005). However, A673-
iPC cells appeared to retain their primitive nature upon differentiation down 
the neural lineage, as evidenced by their upregulated mRNA levels of 
Nestin, but low β-Tubullin expression, which is a maker of differentiated 
neurons (Abranches et al., 2006).  Again, the EWS-FLI1 fusion protein may 
explain this observation, as EWS-FLI1 upregulates expression of EZH2, a 
histone methyltransferase protein involved in suppressing genes involved in 
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differentiation. The upregulation of this protein by EWS-FLI1 is capable of 
blocking endothelial and complete neuro-ectodermal differentiation (Richter 
et al., 2009). Therefore the EWS-FLI1 protein may prevent complete 
differentiation of the A673-iPC cells to fully differentiated neurons. 
An additional factor which may reduce the A673-iPC cells capacity for 
differentiation is the residual reprogramming transgene expression from the 
HVS episomes which persist in these cells, such as Oct4. These genes are 
key regulators of pluripotency and repress differentiation of stem cells. 
Therefore residual expression of these genes within the A673-iPC cells 
would counteract their differentiation. As described previously, future 
development of the HVS-iPSC vectors would include implementing a system 
to remove the HVS episomal maintenance element, thereby allowing the 
removal of any transgenes and exogenous vector DNA from reprogrammed 
cells. This would potentially produce iPSC and iPC cells which possessed 
the same capacity for differentiation as true ESCs and CSCs. 
6.5 Conclusions 
In conclusion, this thesis has demonstrated the potential of HVS as a 
recombinant viral vector in iPSC generation. HVS-iPSC vectors were 
created, which were capable of sustained transgene delivery for Oct4, Lin28 
and Nanog. Furthermore, these vectors were able to initiate reprogramming 
in an ESFT cell line. 
The A673-iPC cells had been reprogrammed to some degree, as 
demonstrated by the elevated expression levels of certain ESC marker 
genes. However, some ESC marker genes remained unaltered or even 
reduced in the A673-iPC cells in comparison to uninfected and mock-
infected control cells, and some colonies failed to thrive in feeder-free stem 
cell culture conditions. This indicates that, although reprogramming has 
certainly been initiated in these cells, they remain incompletely 
reprogrammed. Future work would involve gene arrays to compare ESC 
maker gene expression levels between uninfected and mock-infected A673 
control cells, the A673-iPC cells, and iPSCs or ESCs. This would give a full 
genome-wide picture of the extent to which these cells are reprogrammed, 
and which genes remain unaltered. Moreover, generation of HVS-iPSC 
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vectors with inducible ORF73 expression will enable removal of exogenous 
vector DNA and transgene expression. This could produce iPCs which more 
closely resemble true CSCs in their gene expression profiles and 
differentiation capacity which will be more valuable in the study of cancer 
progression.  
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7 Appendix 
7.1 DNA ladders 
 
 
 
 
                                      
 
 
100 bp ladder (Invitrogen) 1 kb ladder (Invitrogen) 
 
 
 
 
Λ DNA-HindIII digest ladder (NEB) MidRange I Pulse-Field Gel Marker 
(NEB) 
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7.2 Constructs 
 
pCR®-Blunt II-TOPO® (Invitrogen) 
 
pEGFP-C1 (Clontech) 
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pSIN-EF2-Oct4-Pur (Addgene) 
 
pSIN-EF2-Sox2-Pur (Addgene) 
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pSIN-EF2-Lin28-Pur (Addgene) 
 
 
pSIN-EF2-Nanog-Pur (Addgene) 
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pCMV-Oct4 
 
pCMV-Sox2 
 
Chapter 7: Appendix 
 
187 
 
 
pCMV-Lin28 
 
pCMV-Nanog 
Chapter 7: Appendix 
 
188 
 
 
pShuttle-Oct4 
 
pShuttle-Sox2 
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pShuttle-Lin28 
 
pShuttle-Nanog 
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pShuttle Link 1 
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